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Abstract 
Plasminogen activator inhibitor-type 1 (PAI-1) is the main inhibitor of fibrinolysis and a 
potential risk factor for cardiovascular disease. In addition to its regulating role in fibrinolysis, 
PAI-1 may have detrimental effects in the cardiovascular system also through other 
processes, e.g. inflammation. Although PAI-1 is generally elevated in the presence of 
cardiovascular disease, it is not yet clear whether it is a causal risk factor. A polymorphism in 
the promoter region of the PAI-1 gene, the 4G/5G-polymorphism, affects the transcription of 
the PAI-1 gene, yielding higher blood levels of PAI-1 for the 4G-allele. In case of a causal 
role of PAI-1 in cardiovascular disease, an increased cardiovascular risk would be expected 
for the 4G-allele. 
The general objective of the studies in this thesis was to examine whether PAI-1 and the 
4G/5G-polymorphism are associated with cardiovascular risk. Both associations with 
markers of atherosclerosis and clinical end points were studied. Because of the acute-phase 
properties of PAI-1, we additionally examined the role of C-reactive protein (CRP), a 
sensitive marker of inflammation. 
In the Arnhem Elderly Study, comprising 641 subjects aged 65-84 years, we observed a 
strong daytime fluctuation in PAI-1 activity with peak levels in the early morning. The diurnal 
pattern was clearly present for the 4G/4G and 4G/5G-genotypes, but not for the 5G/5G-
genotype. These findings raised the hypothesis that 5G-homozygotic persons may be 
relatively protected from the early morning peak incidence in cardiovascular events. 
In a population of 208 smoking men the 4G/5G-polymorphism was not associated with two 
non-invasive markers of atherosclerosis, i.e. common carotid intima*media thickness and the 
ankle-brachial index. Neither did we observe consistent associations between the 4G/5G-
polymorphism and coronary stenosis after pooling three similar case-control studies (n = 
776) with angiographically determined coronary atherosclerosis. 
In the Arnhem Elderly Study we investigated whether PAI-1 and the 4G/5G-polymorphism 
were associated with mortality and incidence of cardiovascular events during 7.8 years of 
follow-up. We observed that the 4G/4G-genotype was protective against incident stroke and 
transient ischemic attack (relative risks of 0.4 and 0.3 respectively), which is in contrast to 
the generally accepted hypothesis that the 4G-allele would increase cardiovascular risk. For 
PAI-1 levels, an increased risk of stroke and ischemic attacks was observed in the highest 
tertile. 
In the Arnhem Elderly Study, PAI-1 and CRP were inter-related, but only in lean elderly. The 
associations between CRP and other components of the metabolic syndrome were also 
predominantly present in lean elderly. In elderly men, CRP was predictive for future 
cardiovascular events, but not in women. 
Overall, PAI-1 and the 4G/5G-polymorphism do not appear to play a major role in 
atherosclerosis, but the effects on thrombosis are still controversial. Causality of PAI-1 was 
not supported by an increased risk of cardiovascular events for the 4G/4G-genotype. In 
contrast, subjects with the 4G/4G-genotype were relatively protected against stroke. 
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General introduction 
Chapter 1 
Cardiovascular disease is the number one cause of death in Western countries. In 
the Netherlands, 36% of the deaths in 1999 were due to cardiovascular disease, with 
ischaemic heart disease and stroke as the most important causes within this 
category.1 The development of cardiovascular disease is a multifactorial process, 
with both genetic and environmental factors involved. Interactions between genetic 
and environmental factors add to the complexity of the pathogenesis of the disease. 
Two main processes can be distinguished in the development of cardiovascular 
disease, i.e. atherosclerosis and thrombosis. Established biological and lifestyle 
cardiovascular risk factors, such as hypertension, hypercholesterolemia, and 
smoking, can only explain a part of the prevalence of cardiovascular disease and 
there is an ongoing search for new risk factors. A better understanding of factors 
involved in the disease process may provide opportunities for both primary and 
secondary prevention. 
Fibrinolysis and inflammation are believed to play important roles in the 
cardiovascular disease process. Several factors from these systems are currently 
under investigation as potential risk factors for cardiovascular disease in 
epidemiological studies. Fibrinolysis is the system that breaks down a thrombus by 
degrading fibrin and is crucial in the thrombotic stage of the disease. In addition, 
fibrinolysis may also be involved in the earlier stage of atherosclerosis. The role of 
inflammation in the cardiovascular disease process is currently one of the major 
topics in the research on cardiovascular disease. Several fibrinolytic factors are also 
known as acute-phase proteins, indicating interactions between both fibrinolytic and 
inflammatory pathways at molecular level. Investigating both pathways 
simultaneously is therefore very relevant. 
In this thesis, epidemiological studies on the association between Plasminogen 
Activator Inhibitor-type 1 (PAI-1) and C-reactive protein (CRP), two newly identified 
risk factors, and cardiovascular risk are presented. PAI-1 is the main inhibitor of 
fibrinolysis and in addition an acute-phase protein. CRP is a sensitive marker of 
inflammation. 
PLASMINOGEN ACTIVATOR INHIBITOR-TYPE 1 
After vessel trauma, both the coagulation system and fibrinolysis are activated. The 
end product of the coagulation cascade is fibrin, which forms the major component of 
a thrombus. Fibrinolysis is the process by which fibrin is degraded, leading to 
dissolution of the thrombus.2 The balance between blood coagulation and fibrinolysis 
is crucial in maintaining haemostasis. A low fibrinolytic activity may lead to occlusion 
of arteries by excessive thrombus formation and thereby cardiovascular events. Over 
activation of the fibrinolytic system, on the other hand, may in rare situations lead to 
bleeding.3,4 The active component of fibrinolysis is plasmin,2 which breaks down 
fibrin into fibrin degradation products. Tissue-type plasminogen activator (t-PA) 
promotes the conversion of inactive plasminogen into the active plasmin. T-PA is in 
turn regulated by plasminogen activator inhibitor type 1 (PAI-1), which is the main 
and fast-acting inhibitor of fibrinolysis. 
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Next to its regulating function in fibrinolysis, PAI-1 is involved in various other 
mechanisms, which play a role in a range of physiological and pathophysiological 
processes.5 For instance, there is a growing body of evidence for a causal role of 
PAI-1 in tumor growth, vascularisation, and metastasis.5 PAI-1 is furthermore 
involved in the acute-phase response during inflammation,6 although its exact role in 
inflammation is not fully understood. 
In plasma, PAI-1 occurs to a major extent in its active, free form. A minor part of PAI-
1 in plasma is present in complex with t-PA. Plasma PAI-1 can be measured either 
as PAI-1 activity or as PAI-1 antigen. PAI-1 antigen comprises all PAI-1 (free or in 
complex with t-PA), while PAI-1 activity is a measurement of the amount of t-PA that 
can be inhibited.7 Both measures are highly intercorrelated7 and are more or less 
interchangeable. In this thesis we will use the term 'level' to indicate plasma PAI-1 
concentration irrespective of the method used (activity/antigen). 
PAI-1 AND CARDIOVASCULAR DISEASE 
Because of its inhibiting action on fibrinolysis, PAI-1 is considered a potential risk 
factor for cardiovascular disease. The role of PAI-1 in the thrombotic stage of 
cardiovascular disease has been studied predominantly, but evidence also exists 
that PAI-1 is involved in atherosclerosis. The evidence for a role of PAI-1 in 
cardiovascular disease will be evaluated separately for atherosclerosis and 
thrombosis. 
PAI-1 and atherosclerosis 
Atherosclerosis is a progressive disease characterized by the accumulation of lipids 
and fibrous elements in the large arteries.8 Atherosclerosis is regarded an 
inflammatory disease9 that starts already at a very early age with the subendothelial 
accumulation of lipid-laden macrophages (i.e. foam cells). More advanced lesions 
consist of a lipid-rich core covered by a fibrous cap consisting of smooth muscle cells 
and extracellular matrix. Advanced atherosclerosis of the coronary artery causes 
angina pectoris and is a strong risk factor for myocardial infarction. 
PAI-1 has been localized in the vessel wall, and shows an increased expression in 
human atherosclerotic plaques.10"13 PAI-1 might stimulate the development and/or 
progression of atherosclerosis by inhibiting the clearance of fibrin within the 
atherosclerotic plaque. However, from animal studies it is known that PAI-1 is also 
involved in mechanisms other than fibrinolysis, which might affect the atherosclerotic 
process. Mice studies have shown that PAI-1 inhibits cellular migration and 
deposition of matrix components.14 Although these mechanisms seem favorable, 
they may have adverse effects on plaque stability because decreased smooth 
muscle cell migration results in plaques with a large amount of lipid relative to 
smooth muscle cells and connective tissue, which are particularly prone to rupture.15 
Increased PAI-1 levels are observed in subjects with symptomatic atherosclerosis 
compared to healthy subjects.16,17 Two cross-sectional studies investigated the 
association between PAI-1 and markers of atherosclerosis in asymptomatic 
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populations.18'19 Both in the ARIC19 and in the NHLBI Family Heart Study18 PAI-1 
antigen was weakly positively associated with intima-media thickness, a non-
invasive marker of generalized atheroslerosis. However, the observed associations 
were explained to a large degree by other risk factors (e.g. measures of obesity and 
cholesterol). It is furthermore possible that the observed associations are due to low-
grade inflammation in response to the atherosclerotic process. 
In summary, epidemiological studies show increased levels of PAI-1 in the presence 
of atherosclerosis, but whether this is causal is still under debate. From animal 
studies we know that PAI-1 is involved in various mechanisms within the 
atheroslerotic process, which both may have favorable and unfavorable results on 
atherosclerosis. How and to what extent these mechanisms influence plaque 
progression remains poorly understood. 
PAI-1 and thrombotic outcomes 
Atherosclerotic plaque disruption activates the coagulation cascade and thrombus 
formation at the site of rupture. A thrombus can cause an acute occlusion of the 
artery, leading to massive ischemia of the target tissue, e.g. myocardial infarction or 
ischemic stroke. If the thrombus does not lead to a complete occlusion of the artery, 
it will eventually be incorporated in the plaque, resulting in narrowing of the artery. It 
is furthermore possible that the thrombus is released, after which it can cause 
obstruction of an artery somewhere else in the circulatory system, i.e. embolism. 
Because of its fibrinolysis inhibiting properties it is biologically plausible that 
increased PAI-1 levels increase thrombotic risk. In case-control studies indeed in 
patients with a history of a cardiovascular event increased PAI-1 levels were 
observed.20,21 Whether or not PAI-1 is predictive for future cardiovascular events 
may be dependent on background risk. In populations with angina pectoris, PAI-1 
levels have been shown to be predictive for future events17,22"26 and also in 
populations with a history of a myocardial infarction PAI-1 was predictive for 
recurrent events. However, in prospective studies in general (healthy) populations 
PAI-1 is not an independent risk factor for cardiovascular events.23,27"29 Only one 
prospective study specifically studied the association with future risk of stroke, in 
which PAI-1 had no predictive role. This study was performed in subjects initially free 
of cardiovascular disease.30 Prospective data in elderly is scarce. As far as we know, 
the Cardiovascular Health Study27 is the only study that investigated the relationship 
of PAI-1 with future cardiovascular risk in a population of elderly. In this population 
PAI-1 was not predictive for future cardiovascular events. 
In summary, although PAI-1 levels are increased in the presence of cardiovascular 
disease, prospective studies are inconclusive and the results seem to depend on the 
presence of cardiovascular history. The association between PAI-1 and 
cardiovascular risk in elderly has insufficiently been studied. Especially the 
association between PAI-1 and the risk of stroke deserves more attention. 
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CAUSE OR CONSEQUENCE? 
In epidemiological studies, the association between PAI-1 and cardiovascular 
disease (both atherosclerosis and thrombosis) may be confounded by many 
biological and environmental cardiovascular risk factors which are known to affect 
PAI-1 levels (e.g. obesity, cholesterol, see Chapter 2 of this thesis for a review). 
Alternatively, these risk factors may (partly) have harmful effects via PAI-1. Another 
complicating factor is the acute-phase response of PAI-1 during inflammation, which 
makes it plausible that PAI-1 levels increase in response to the ongoing 
cardiovascular disease process. PAI-1 can thus reflect the severity of the 
atherosclerotic processes in the vessel wall, which could underlie the observed 
association between PAI-1 levels and cardiovascular disease. It is therefore difficult 
to draw conclusions on the causality of PAI-1 in the cardiovascular disease process, 
based on either retrospective or prospective epidemiological studies. We studied the 
4G/5G-polymorphism in stead of PAI-1 levels, which could be useful in answering 
the question on the causal role of PAI-1 in cardiovascular disease as explained 
below. 
4G/5G-POLYMORPHISM 
The 4G/5G-polymorphism is a common single base pair insertion/deletion 
polymorphism in the promoter region of the PAI-1 gene. The 4G-allele has a 
sequence of four guanosine, whereas the 5G-allele has a fifth guanosine 
inserted.31'32 The 4G/5G polymorphism is common in the general population, with the 
two alleles having approximately equal frequencies. The 4G/5G polymorphism 
affects the binding of a nuclear protein to the PAI-1 promoter, thereby altering the 
expression of the PAI-1 gene.31 The 4G/4G-genotype has been associated with 
higher PAI-1 levels compared to the 5G/5G-genotype, with the heterozygous 
genotype having intermediate levels.33"38 Data of this polymorphism are therefore 
used as a proxy for long-term, habitual PAI-1 levels. However, it has recently 
become clear that the association between the 4G/5G-polymorphism and plasma 
PAI-1 levels may not be as strong as previously expected.39"41 Although the 4G/5G-
polymorphism may not be strongly associated with PAI-1 levels, it may be 
associated with PAI-1 responses after triggering (for example after vessel damage), 
and therefore it is still worthwhile to study the 4G/5G-polymorphism. An association 
between the 4G/5G-polymorphism and cardiovascular disease would contribute to 
evidence for a causal role of PAI-1 in cardiovascular disease. 
4G/5G-POLYMORPHISM AND CARDIOVASCULAR DISEASE 
4G/5G-polymorphism and atherosclerosis 
The association between the 4G/5G-polymorphism and atherosclerosis has only 
marginally been studied. In a large case-control study a higher frequency of the 
4G/4G-genotype was found in subjects with coronary stenosis compared to controls, 
although the 4G/5G-polymorphism was not associated with the number of affected 
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arteries.42 However, in two other case-control studies the 4G/5G-polymorphism was 
not associated with the presence37,43 or extent37 of coronary disease. The 
association between the 4G/5G-polymorphism and non-invasive markers of 
atherosclerosis has not been described. 
4G/5G-polymorphism and thrombotic outcomes 
Most studies that examined the association between the 4G/5G-polymorphism and 
cardiovascular disease focused on the relation with myocardial infarction. In a recent 
meta-analysis of 9 case-control studies of the 4G/5G-polymorphism and myocardial 
infarction, including a total of 2,813 patients and 3,358 controls,44 a small increased 
risk for the 4G/4G-genotype was observed (OR=1.20, 95%-CI: 1.04 - 1.39). 
Because of the very strict diagnostic and methodological inclusion criteria for the 
studies, 11 of 18 published studies were excluded from this meta-analysis. In two of 
the excluded studies a significantly increased risk of myocardial infarction was 
observed for the 4G/4G-genotype31,45 The authors suggested that the pooled odd 
ratio might be an overestimation of the actual risk, because of probable publication 
bias of small studies that did not observe an association. 
Prospective studies do not support an association between the 4G/5G-polymorphism 
and risk of myocardial infarction. In the Physicians' Health Study the 4G/5G-
polymorphism was not predictive for future myocardial infarction in men initially free 
of cardiovascular disease.46 In postmenopausal women47 and in elderly48 the 4G/5G-
polymorphism was not predictive for fatal myocardial infarction. 
Recently, some studies investigated the association between the 4G/5G-
polymorphism and stroke. A trend towards a protective effect of the 4G-allele was 
found in several studies,47"51 but only in one study the association was strong enough 
to reach statistical significance.47 In a case-control study in Korean subjects, on the 
contrary, the 4G-allele was associated with an increased risk of stroke.52 
C-REACTIVE PROTEIN 
C-reactive protein (CRP) is an acute-phase protein with normal values below 2 mg/L 
in general populations. Hepatic synthesis of CRP is regulated by various cytokines 
(e.g. interleukin-6, interleukin-1, tumor necrosis factor-a). CRP values above 10 
mg/L are generally used to indicate clinically relevant inflammation. The exact 
function of CRP is unclear, but it may stimulate tissue factor production and activate 
complement when aggregated. Low-grade chronic inflammation (i.e. CRP <10 mg/L) 
has been shown to predict risk of cardiovascular events in both apparently healthy 
populations and in cardiovascular patients.53,54 In the Physicians' Health Study an 
increased plasma concentration of CRP (>2.10 mg/L) was associated with a twofold 
increased risk of stroke and a threefold increased risk of myocardial infarction 
compared to low CRP values (<0.55 mg/L).55,56 In elderly populations results are less 
convincing. In the Iowa 65+ Rural Health Study, CRP was associated with mortality 
only in elderly who also had increased interleukin-6.57 In the Caerphilly Prospective 
Heart Disease Study the association between CRP and future ischemic heart 
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disease disappeared after adjusting for other risk factors such as obesity and 
smoking.58 In the Cardiovascular Health Study stronger associations were observed 
for elderly women than for elderly men, and the strongest associations for those with 
subclinical disease at baseline.59 In the Women's Health Study, CRP was the single 
strongest predictor of future coronary events.60 
A number of mechanisms by which CRP might directly promote vascular disease 
have been postulated, including activation of the classical complement system in the 
arterial wall.61,62 Alternatively, the atherosclerotic process in the vascular wall may 
increase CRP synthesis. Despite the large amount of data, the causality of the 
relationship between CRP and cardiovascular risk is still under debate. 
OUTLINE OF THE THESIS 
The main goal of the epidemiological studies in this thesis is to provide insight into 
the role of PAI-1 in both atherosclerosis and thrombotic events. An increased 
cardiovascular risk for the 4G/4G-genotype of the 4G/5G-polymorphism in the PAI-1 
gene would be in favor of a causal role of PAI-1 in the pathology of cardiovascular 
disease. Therefore, we additionally studied the association between the 4G/5G-
polymorphism and cardiovascular disease. Besides its established role in fibrinolysis, 
PAI-1 is also an acute-phase protein, providing an alternative pathway by which PAI-
1 might be associated with cardiovascular risk. We therefore studied in addition the 
role of CRP, a sensitive marker of inflammation, which enabled us to study the role 
of PAI-1 independent of inflammation. In the Arnhem Elderly Study we examined the 
relation between PAI-1 and CRP and we studied whether CRP itself was a risk factor 
for cardiovascular events. See Figure 1.1 for an overview of the associations 
studied. 
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Figure 1.1. Overview of the role of PAI-1 in cardiovascular disease and the chapters in 
which the associations are described. Dashed lines indicate associations described in this 
thesis, but which are unlikely to be directly biologically related. 
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Research questions were: 
1. Which factors influence PAI-1 levels and should be treated as potential 
confounders in epidemiological studies on the association between PAI-1 and 
cardiovascular risk? 
First, in Chapter 2 a review is given on factors that affect PAI-1 concentrations. In 
this review special emphasis is given to interactions of metabolic and lifestyle factors 
with the 4G/5G-polymorphism. In Chapter 3 the diurnal variation in PAI-1 is 
described in an elderly population, also separately for the genotypes of the 4G/5G-
polymorphism. 
2. Is the 4G/5G-polymorphism associated with atherosclerosis? 
In Chapter 4 we report on the association between the 4G/5G-polymorphism and two 
non-invasive markers of atherosclerosis, namely carotid wall thickness and ante-
brachial index, in a population of smoking men. In Chapter 5 three case-control 
studies were pooled to investigate the association of the 4G/5G-polymorphism with 
coronary stenosis, assessed by angiography. 
3. Are PAI-1 and the 4G/5G-polymorphism independent risk factors for 
cardiovascular events in the elderly, especially for stroke? 
We studied the associations between PAI-1 activity, the 4G/5G-polymorphism and 
risk of cardiovascular events in a prospective study, the Arnhem Elderly Study 
(Chapter 6). We investigated the relation between both plasma PAI-1 and the 
4G/5G-polymorphism with several end points (all-cause and cardiovascular mortality, 
incidence of stroke and incidence of myocardial infarction). 
4. Are PAI-1 and CRP intercorrelated? 
Both PAI-1 and CRP are considered as components of the metabolic syndrome en 
we used the baseline data of the Arnhem Elderly study to explore the association of 
CRP with PAI-1 and other components of the metabolic syndrome (Chapter 7). 
5. Is CRP an independent risk factor for cardiovascular disease in elderly? 
In Chapter 8 we investigated whether CRP itself is an independent risk factor for 
future cardiovascular events in the Arnhem Elderly Study. 
Finally, the main results are summarized, and implications and recommendations for 
future research are described in the General Discussion (Chapter 9). 
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INTRODUCTION 
Plasminogen activator inhibitor-type 1 (PAI-1) is the main and fast-acting inhibitor of 
activation of fibrinolysis, which plays an important role in vascular disease prevention 
by removing thrombi from the vascular system. Plasmin, the active component of 
fibrinolysis, breaks down fibrin into its degradation products. Plasminogen and 
tissue-type plasminogen activator (t-PA) bind to the surface of fibrin where t-PA 
cleaves inactive plasminogen into active plasmin. T-PA is inhibited by PAI-1, which 
inactivates t-PA by forming an irreversible 1:1 complex. 
Elevated PAI-1 is considered a potential risk factor for cardiovascular disease 
because of its regulating role in fibrinolysis. Apart from the well-documented function 
in fibrinolysis, PAI-1 is also involved in other processes, like cell migration and tissue 
remodeling. Importantly, PAI-1 is a strong reacting acute-phase reactant, reflected 
by the possibility of fast and large increase in plasma levels (up to >100 fold) during 
the acute-phase response.1 
In this review we give an overview of the determinants of plasma PAI-1. We will give 
a broader introduction on PAI-1 and the epidemiological evidence for the association 
between PAI-1 and cardiovascular disease, followed by a description of genetic, 
metabolic and lifestyle factors that affect plasma PAI-1 levels. 
PAI-1: CHARACTERISTICS AND REGULATION 
In plasma, PAI-1 is present both in an active and in low concentrations of a latent 
form, which is cleared from the circulation at a high rate. Active PAI-1 can be 
stabilized by vitronectin, a protein that binds to PAI-1 in plasma. In addition, PAI-1 in 
plasma is present in complex with t-PA. PAI-1 in plasma can be measured either as 
PAI-1 activity or as PAI-1 antigen. PAI-1 antigen comprises all PAI-1 (free or in 
complex with t-PA), while PAI-1 activity is a measurement of the amount of t-PA that 
can be inhibited. The two measures are highly intercorrelated in most situations and 
both frequently used. We will from now on refer to plasma PAI-1 levels to indicate 
either activity or antigen, unless specified otherwise. Plasma PAI-1 undergoes a 
circadian pattern with peak plasma levels observed in the early morning.2"6 
A second pool of PAI-1 is found in the a-granules of platelets, where PAI-1 is stored 
in mainly (-90%) the latent, free form.7,8 Platelet PAI-1 is released after vessel 
trauma, and substantial amounts of active PAI-1 can accumulate from activated 
platelets at sites of arterial platelet-rich thrombi, protecting a thrombus clot from 
premature lysis.7,9 
Regulation of plasma PAI-1 is a complex process, mainly occurring at the level of 
transcription of the PAI-1 gene. PAI-1 is produced by different cell types, including 
endothelial cells, hepatocytes, and adipocytes,10 and multiple regulatory factors have 
been identified that play a role in PAI-1 transcription, e.g. growth factors (TGF-p), 
inflammatory cytokines (IL-1, TNF-a), and hormones, glucose, insulin, and 
glucocorticoids (reviewed by Irigoyen11). PAI-1 is cleared from the circulation mainly 
by the liver.12 Activity of PAI-1 is in addition regulated by the spontaneous 
inactivation of PAI-1with a half-life of 1-2 hours.13 
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4G/5G-POLYMORPHISM 
The 4G/5G polymorphism is a common single base pair insertion/deletion 
polymorphism in the promoter region of the PAI-1 gene that affects the gene 
transcription.14 The 4G-allele has a sequence of four guanosines and the 5G-allele 
has a fifth guanosine inserted. The extra guanosine base creates an additional 
binding site for an inhibitor, resulting in an attenuated response to transcription 
factors for the 5G-allele.14,15 Both PAI-1 and the 4G/5G-polymorphism have been 
studied in relation to cardiovascular risk. The nature of the polymorphism can be 
described as response polymorphism. It implies that the difference between 4G and 
5G expresses more in the presence of the relevant environmental or disease factors 
and less so in healthy volunteers. 
PLASMA PAI-1 , THE 4G/5G-POLYMORPHISM AND CARDIOVASCULAR DISEASE 
PAI-1,4G/5G-polymorphism and coronary heart disease 
In most population-based prospective studies, PAI-1 was not significantly associated 
with the occurrence of a first event of coronary heart disease.16,17 In the few studies 
among healthy populations in which plasma PAI-1 was associated with risk of 
coronary events the strength of the association was strongly reduced after adjusting 
for cardiovascular risk factors.18,19 The differences reported on the prognostic value 
of PAI-1 for coronary risk in epidemiological studies has been suggested to be at 
least in part attributed to the confounding variables controlled for.20 
Furthermore, case-control and cross-sectional studies showed increased plasma 
PAI-1 levels in patients with existing coronary heart disease.21,22 Also, PAI-1 levels 
predicted future (recurrent) coronary events in populations with angina pectoris23 or a 
history of a myocardial infarction.24,25 
An association between the 4G/5G-polymorphism and cardiovascular disease would 
contribute to evidence for the hypothesis that PAI-1 is a causal risk factor for 
cardiovascular disease. In a recent meta-analysis of 9 genetic studies, mainly case-
control, a small increased risk for myocardial infarction was observed for the 4G/4G-
genotype26 (OR=1.20, 95% Cl:1.04 - 1.39). Iwai and colleagues observed that the 
4G/5G-polymorphism was associated with a faster progression to acute coronary 
syndromes after first anginal pain.27 In postmenopausal women28 and in elderly29 the 
4G/5G-polymorphism was not predictive for fatal myocardial infarction. In the 
Physicians' Health Study the 4G/5G-polymorphism was not predictive for future 
myocardial infarction in men initially free of cardiovascular disease.30 
PAI-1, 4G/5G-polymorphism and stroke 
Johansson and colleagues found that plasma PAI-1 was not significantly associated 
with incidence of (first) stroke in a population-based cohort (nested case-control 
design).31 In stroke patients, increased PAI-1 levels have been observed compared 
to healthy controls, both in the acute-phase and still several months after the 
event.21,32,33 
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Remarkably, most studies observed a protective effect for stroke of the 4G-
allele,28'29'32,34,35 although only in one study the effect was strong enough to reach 
statistical significance.28 In a Korean case-control study the 4G-allele was associated 
with an increased risk of ischemic stroke.36 The genetic background of the study 
population may possibly explain this discrepant finding. A protective role of 4G in 
stroke, opposite to an increased risk of 4G in myocardial infarction, indicates a 
difference in pathogenesis of both entities. It can be suggested that in stroke the 4G-
allele might be involved in increased PAI-1 in tissue, which might be protective. 
Many cardiovascular risk factors are known to influence plasma PAI-1 and may thus 
confound or determine the association between plasma PAI-1, its genetic variability 
and cardiovascular risk in epidemiological studies. Therefore, a good understanding 
of the factors that influence plasma PAI-1 is needed when studying the association 
between PAI-1 and cardiovascular risk. 
GENERAL CHARACTERISTICS AND PLASMA PAI-1 
PAI-1 levels tend to be higher in men than in women. This gender difference is 
known to diminish with increasing age.37 Several studies showed an age-related rise 
in PAI-1 levels in women, whilst for men a negative correlation was observed 
between PAI-1 and advanced age.38"40 
GENETIC DETERMINANTS OF PLASMA PAI -1 
Estimates on heritability of plasma PAI-1 levels range from 26% to 71 "/o39,41"44 So 
far, nine different polymorphisms have been detected in the PAI-1 gene, which have 
recently been reviewed by Nordt and colleagues.45 Three of them are located in the 
promoter region, one in intron 4, one in exon 8 and four in the 3'-untranslated region 
of the PAI-1 gene. The most extensively studied polymorphism is relation to PAI-1 
levels is the already mentioned 4G/5G-polymorphism in the promoter region of the 
gene. 
4G/5G-polymorphism and PAI-1 levels 
The 4G/4G-genotype has been associated with higher PAI-1 levels compared to the 
5G/5G-genotype, with the heterozygous genotype having intermediate levels.7,46"50 
The genotype-related differences in PAI-1 concentrations, however, were not 
present in all studies42'51 and in studies in which it did, only a small part of the 
variance in PAI-1 was explained by the 4G/5G-polymorphism.44,46 More recently, 
evidence is accumulating that, although this polymorphism may not strongly affect 
basal PAI-1 levels, it may affect PAI-1 responses. In vitro studies suggest for 
example strongest PAI-1 increases in response to interleukin-1,14,52 and VLDL53 for 
the 4G-allele. Further evidence for this hypothesis comes from clinical studies that 
showed a much stronger increase in PAI-1 in the acute-phase for patients with the 
4G-allele than for those with the 5G-allele. 
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Other polymorphisms in the PAI-1 gene 
In vitro studies in human endothelial cells showed that the Hindlll-polymorphism in 
the 3'-untranslated region of the PAI-1 gene affects PAI-1 transcription in response 
to insulin and lipoproteins.54,55 The 1/1-genotype showed the strongest response in 
PAI-1 after stimulation with insulin and the 2/2 genotype after triggering with both 
VLDL or Lp(a).55, 56 Linkage disequilibrium with small variations in the promoter 
region of the gene could possibly explain these results. No strong linkage 
disequilibrium exists between the Hindlll-polymorphism and the 4G/5G-
polymorphism.45 
The inability to account for all observed heritability of plasma PAI-1 by 
polymorphisms in the PAI-1 gene may be related to an undiscovered genetic 
variation in promotor or distant enhancers. Alternatively, the heritability may originate 
in heritability of determinants of PAI-1 levels such as lipids, insulin resistance and 
chronic inflammation. 
METABOLIC DETERMINANTS 
The metabolic syndrome comprises a cluster of cardiovascular risk factors, including 
(abdominal) obesity, glucose intolerance/type II diabetes mellitus, dyslipidaemia and 
hypertension. No uniform definition of the metabolic syndrome is used, and it has 
been argued that PAI-1 should be considered part of it.57,58 PAI-1 is associated with 
many of the components of the metabolic syndrome as will be discussed below in 
more detail. 
Obesity 
Obesity, especially central fat, is associated with increased PAI-1 levels,59 and 
weight reduction has been shown to be effective in lowering PAI-160"65 The 
relationship between PAI-1 and obesity has recently been reviewed by Mutch ef a/.66 
PAI-1 is synthesized and secreted directly by adipose tissue,67"70 but adipose tissue 
further increases plasma PAI-1 by increased hepatic PAI-1 production which is 
stimulated by adipocytes-derived cytokines (TNF-a en TGF-p).68 
In vitro studies showed higher PAI-1 production for human visceral fat than for 
subcutaneous fat.70,70"72 Recent data suggest that stromal cells, and thus not the 
adipocytes itself, are the most important source of PAI-1 within adipose tissue.72 
Visceral fat contains a higher amount of stromal cells than subcutaneous fat, which 
might thus explain the regional differences in PAI-1 production.72 However, not all 
studies showed a higher PAI-1 expression in visceral than in subcutaneous fat73 or 
even show opposite results.74 The authors of the latter study74 suggested that their 
unexpected finding might be explained by the adipose tissue in their study being 
derived from more obese subjects than in the other studies. They hypothesize that 
obesity perse may influence regional differences in PAI-1 secretion. 
In addition, adipocytes from obese subjects produced more PAI-1 than adipocytes 
from lean subjects,75,76 even after adjusting for adipocyte size.76 In contrast with 
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these findings is the observation that PAI-1 expression in human subcutaneous 
adipose tissue increased after weight reduction.65 The adipose secretion rates of 
PAI-1 in human abdominal subcutaneous adipose tissue were not different across 
the 4G/5G-genotypes.77 
Results from studies on the association between measures of obesity and PAI-1 
stratified for the 4G/5G-polymorphism do not provide consistent evidence for 
genotype-specific associations. One study showed a clear association between PAI-
1 levels and the 4G/5G-polymorphism in obese but not in lean subjects.59 In Pima 
Indians, body mass index (BMI) and PAI-1 were associated in both homozygous 
groups, but not in the 4G/5G-genotype.78 In patients with angiographically 
determined coronary disease the association between PAI-1 and BMI was strongest 
for the 5G/5G genotype.49 
Based on a study in PAI-1 knockout mice the hypothesis was raised that PAI-1 might 
also promote the evolvement of obesity.79 A recent study in 505 humans showed that 
the prevalence of obesity was twofold higher in carriers of the 4G-allele than of the 
5G-allele,80 which is in agreement with this hypothesis. The mechanism by which 
PAI-1 might promote the development of obesity is not clear yet, but might involve 
effects of PAI-1 on cell migration and angiogenesis. Further studies on the potential 
effects of PAI-1 on the progression of obesity are needed. 
In summary, it is evident that (central) obesity is an important determinant of plasma 
PAI-1 levels. The associations differ across the genotypes of the 4G/5G-
polymorphism, but further influences independent of 4G/5G are also possible and 
this should be further unraveled. The hypothesis that PAI-1 might affect the 
development of obesity is only marginally investigated. 
Blood lipids 
PAI-1 is associated with cholesterol, LDL-cholesterol, VLDL and triglyceride levels, 
and negatively with HDL-cholesterol.20 In vitro, VLDL has consistently been shown to 
induce a concentration-dependent increase in PAI-1 expression in endothelial,81,82 
and hepatic cells.81,83 It has been shown that VLDL stimulation of PAI-1 expression 
in endothelial cells is mediated through transcriptional activation of the PAI-1 gene, 
and a VLDL-response element has been identified in the promoter region of the PAI-
1 gene.53 Besides effects of VLDL on PAI-1 gene transcription, VLDL might also 
affect the stability of the PAI-1 mRNA transcripts.83 The effects of LDL-cholesterol 
are less consistent. Native-LDL generally does not induce PAI-1 synthesis in vitro, 
unless high concentrations are used or when LDL is oxidized, or glycated. 
Chronic and acute hypertriglyceridemia have been associated with changes in 
plasma PAI-1.84 However, acute hypertriglyceridemia induced by intravenous 
administration of a fat emulsion did not affect PAI-1 in healthy males.85 
The association between triglyceride levels and PAI-1 was genotype specific, with a 
steeper slope in subjects with the 4G/4G-genotype in patients with coronary artery 
disease,49 and in type 2 diabetics.86 
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Insulin resistance and diabetes 
Type 2 diabetics have higher PAI-1 plasma levels than healthy subjects.87 Bastard 
and colleagues have recently reviewed the role of plasma PAI-1 in insulin 
resistance.57 Cross-sectional studies show positive associations between fasting 
insulin levels and PAI-1 both in subjects with normal87"90 and impaired glucose 
tolerance87,88 and also in type 2 diabetics.87 Additional evidence for an association 
between PAI-1 and insulin is provided by in vitro studies, demonstrating that both 
insulin and proinsulin stimulate transcription of the PAI-1 gene in several tissues.91"93 
However, acute intravenous administration of insulin in humans did not increase PAI-
1 levels.94"97 An alternative explanation for increased levels of PAI-1 in the presence 
of diabetes could be that PAI-1 is elevated because of high serum glucose levels. 
Evidence for this hypothesis is provided by in vitro studies in which glucose 
stimulates PAI-1 expression in endothelial and vascular smooth muscle cells.98,99 In 
a prospective study of 1,047 nondiabetic subjects, PAI-1 was an independent risk 
factor for the development of type 2 diabetes.100 However, in healthy type I diabetics, 
PAI-1 is lower than in normal individuals arguing against glucose as a mediator. 
Regulation of PAI-1 by the Angiotensin-system 
The renin-angiotensin system (RAS) plays a key role in the regulation of blood 
pressure. Renin converts angiotensinogen to angiotensin 1, which in turn is 
converted to the vasoconstrictor angiotensin 2 by Angiotensin 1 converting enzyme 
(ACE). Inhibition of the RAS by ACE-inhibitors lowers blood pressure, a widely used 
therapy for hypertension. The fibrinolytic and the renin-angiotensin systems are 
linked by angiotensin II, which increased production of PAI-1 both in wVo101 and in 
wfro.102"104 Also its metabolite angiotensin IV stimulated PAI-1 production from 
human adipocytes in an in vitro study.103 Vaughan has recently reviewed the link 
between the RAS and the fibrinolytic system.105 
ACE levels have been correlated to PAI-1 concentrations and a polymorphism in the 
ACE-gene has been shown to be predictive for PAI-1 levels. Intervention studies with 
ACE-inhibitors have furthermore shown a decrease in PAI-1 levels,106 but the effects 
appear to largely depend on type of ACE-inhibitor. Further evidence for a link 
between RAS and fibrinolysis is provided by the observation that during a period of 
activation of RAS by salt depletion, the concentration of PAI-1 significantly 
increased, both in normotensive subjects106 as in subjects with essential 
hypertension.107 The latter study furthermore showed that this effect was only 
present within subjects with the 4G/4G-genotype.107 
HORMONAL INFLUENCES 
Menopausal status and Hormone Replacement Therapy 
In observational epidemiological studies it has consistently been observed that PAI-1 
levels increase after menopause.108"110 In the Framingham Offspring Study 32% 
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higher PAI-1 concentrations were observed in postmenopausal compared to 
premenopausal women.108 
Observational studies show 15-50% lower PAI-1 levels in postmenopausal women 
using hormone replacement therapy (HRT) compared to non-users111,112 In the 
Cardiovascular Health Study,111 HRT-users were thinner and had less abdominal fat 
than non-users, which largely accounted for the observed difference in PAI-1 
between users and non-users. However, estrogen dose was inversely associated 
with PAI-1 antigen but not with BMI in this study, which is in favor for a true effect of 
HRT on PAI-1. 
Several randomized controlled trials with HRT have been conducted, which 
consistently show a decline in PAI-1.113"118 In the large randomized HOPE-trial115 a 
dose response association was observed for conjugated equine estrogen (CEE), 
which was weakened by progestogen. In general smaller effects on PAI-1 are 
observed for transdermal HRT, possibly because this does not first-pass the 
liver.119120 
Estrogen may directly decrease PAI biosynthesis and secretion or may increase the 
clearance rate.121 The effect of sex hormones could furthermore be through effects 
on body composition and insulin resistance. Given the strong effects of sex 
hormones on PAI-1 these latter mechanisms may only explain a small part of the 
observed effects. 
Two small studies122,123 investigated the effects of HRT stratified by the 4G/5G-
polymorphism. A trial with transdermal HRT in 38 postmenopausal women with 
coronary artery disease showed the strongest decrease in PAI-1 for the 4G/4G-
genotype, while PAI-1 in the 5G/5G-genotype remained unchanged.122 Brown and 
colleagues,123 on the other hand, did not observe different effects of estrogen 
administration across the variants of the 4G/5G-polymorphism in a study among 19 
postmenopausal women. 
In summary, postmenopausal status and HRT are consistent determinants of plasma 
PAI-1, but data on interactions with the 4G/5G-polymorphism is limited. 
Oral contraceptives 
Use of oral contraceptives (OC) has consistently been associated with lower PAI-1 
levels in cross-sectional studies.124'125 Experimental data show that use of OC, both 
second and third generation, leads to a substantial decrease in PAI-1.126"129 Estrogen 
is generally considered the compound responsible for this decrease, but also 
administration of progesteron-only pills lowered PAI-1, although not significantly.130 
The decrease in PAI-1 is already achieved after a short period of OC-use and after 
cessation PAI-1 returns to baseline levels within 8 days.129 As far as we know, no 
studies have been reported on the effect of OC-use separately for the 4G/5G-
polymorphism. 
28 
. PAI-1: a review 
DIETARY FACTORS AND PLASMA PAI-1 
For several dietary factors, the relation with plasma PAI-1 have been examined. 
Nutrients that have most intensively been studied are n-3 fatty acids and alcohol, but 
limited data is also available on other dietary factors. 
N-3 Fatty acids 
Several interventions with polyunsaturated n-3 fatty acids have been performed, with 
conflicting results. In most studies, supplementation with n-3 fatty acids was 
associated with an increase in PAI-1.131"136 However, also interventions are known 
that lowered PAI-1 or in which PAI-1 was unaltered.137,138 Most studies were 
however rather small and differences in (control) supplements and designs of the 
studies make comparisons difficult. Hansen and colleagues estimated, based on a 
total of 17 trials, that a 17.7% increase in PAI-1 could be attributed to n-3 fatty acids 
supplementation.139 Overall, it can be concluded that n-3 fatty acids may lead to an 
increase in PAI-1 levels, but that these effects are only modest and depend on the 
type of fat. The mechanisms are still not fully understood. 
Alcohol 
In cross-sectional studies alcohol consumers consistently have higher levels of PAI-1 
than alcohol-abstainers.140"145 In the NHLBI Family Heart Study, a large population-
based study, PAI-1 was only increased in subjects consuming more than 15 grams 
of alcohol per day.142 The association between alcohol consumption and PAI-1 is 
dose-dependent (J-shaped).144,145 
Several small intervention studies in male volunteers demonstrated an acute and 
strong increase in PAI-1 after alcohol consumption.146"148 Intake of 40 grams of 
alcohol resulted in 12 times higher PAI-1 activity levels 5 hours after intake. This rise 
was independent of the type of beverage consumed (beer, wine, or spirits), 
suggesting that ethanol is the active compound.146 In women, only one intervention 
study on the short-term effects of alcohol is performed,149 showing a sharp increase 
in PAI-1 after consumption of wine at dinner in post-menopausal, but not in 
premenopausal women.149 
Apart from the acute, transient effects of alcohol on PAI-1 levels also the long-term 
effects have been studied. Most long-term interventions show higher PAI-1 levels 
after a period of alcohol intake.150"152 However, one intervention in which subjects 
were given about 20 grams of alcohol per day for a period of 30 days failed to 
increase PAI-1.153 Also in the study of McConnell151 a small increase was observed. 
The specific mechanisms, by which alcohol increases PAI-1 remain uncertain, but 
cannot be explained by a direct effect of alcohol on PAI-1 gene transcription. In 
contrast, in vitro studies demonstrated down-regulation of PAI-1 gene transcription in 
cultured human endothelial cells by ethanol.154,155 
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Other dietary factors 
Antioxidants may attenuate the response to infection, and since PAI-1 is an acute 
phase reactant, antioxidants might decrease PAI-1 levels. The association between 
vitamin C and PAI-1 has only been studied in one cross-sectional study, in which an 
inverse association between serum ascorbate and PAI-1 was observed.156 An 
experiment in obese men with administration of antioxidant vitamins did not change 
PAI-1 levels.157 Administration of a-tocopherol led to a decrease in PAI-1 in type 2 
diabetics.158 
An experimental study in a porcine model of hypercholesterolemia demonstrated that 
vitamin C and vitamin E reduced local and systemic PAI-1.159 Because the 
association between antioxidants and PAI-1 has only rarely been studied, no firm 
conclusions are allowed. Present data, however, suggest that a PAI-1 lowering effect 
of antioxidants is possible. 
SMOKING 
Data on the relationship between smoking and PAI-1 are scarce. Several cross-
sectional studies showed higher PAI-1 levels for smokers than for former and never 
smokers.160"163 However, in a study of monozygotic twins discordant for smoking no 
significant difference was observed and associations with cigarette dose were 
absent.164 In the Caerphilly Study, PAI-1 levels increased gradually with the amount 
of tobacco, but PAI-1 levels were significantly increased only for the heaviest 
smokers.144 In the Northern Sweden MONICA study no association was observed 
between smoking status and PAI-1 activity.165 Apparently, smoking is not a major 
determinant of PAI-1. Triglycerides and insulin resistance may mediate the small 
effects observed in some of the studies. In an experimental study, transdermal 
nicotine administration did not affect plasma PAI-1,166 
PHYSICAL ACTIVITY 
Cross-sectional studies suggest that individuals that regularly exercise have reduced 
PAI-1 levels compared to sedentary subjects.140,167"169 In the Northern Sweden 
MONICA study, a strong and dose-dependent association between PAI-1 and 
regular leisure time physical activity was observed both in men and women.168 Both 
intervention studies on the short- and long-term effects of physical activity on PAI-1 
have been performed, as outlined below. 
Short-term effects of exercise 
An exercise test generally results in a fall in PAI-1 levels, both in healthy populations 
and in populations with a history of cardiovascular disease.170"174 Physical activity 
has been shown to increase the release of tissue-type plasminogen activator (t-PA) 
from the vascular endothelium. As a result of this increase in t-PA-antigen, PAI-1 
activity is expected to decrease, because of the formation of complexes with t-PA. 
PAI-1 activity appears to respond faster to exercise than PAI-1 antigen,172 as 
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expected from very rapid interaction between t-PA and PAI-1. Exercise-related 
changes in liver blood flow contribute to the rapid clearance of components such as 
t-PA-PAI-1 and possibly PAI-1 and constitute another influence on blood levels in the 
acute period. No studies were done on the 4G/5G-genotype specific short-term 
effects of exercise. 
Training programs 
Training programs generally result in decreases in PAI-1.175"178 It is difficult to give an 
overall estimate of the strength of the effect on PAI-1 because of the large 
differences in populations (age, baseline condition) and exercise programs (intensity 
and duration) but the effects are notable. In men, a reduction of 80% was found after 
a 9 months training program and in women a reduction of 73%.179 A study comparing 
training effects in younger and older subjects showed a stronger decline in older 
subjects.180 In contrast, a 6-months intensive training program in elderly only led to a 
moderate decrease in PAI-1 antigen.181 In the study of De Geus et al182 the 
magnitude of effect clearly depended on baseline PAI-1 activity. It is expected that 
an effect of physical activity only lead to a fall in PAI-1 in subjects with a higher body 
weight or insulin resistance, probably by an improvement of insulin resistance. 
In contrary to other studies, the Oslo Diet and Exercise Study did not show any 
decrease in PAI-1 values after a one-year exercise program focused on endurance 
training.183 El-Sayed and colleagues184 compared the effect of 12 weeks of low 
intensity exercise with high intensity exercise and found a significant difference in 
PAI-1 activity, only in the high intensity group. The effects of training programs on 
PAI-1 are likely to be mediated by changes in body weight and blood lipids. 
We are aware of only one study that investigated the effects of physical training on 
PAI-1 levels stratified by the 4G/5G-polymorphism.185 After three years of regular 
exercise, the largest decrease in PAI-1 was observed for the 4G/4G-genotype (-36% 
versus -5% for the other genotypes).185 Baseline levels were (non-significantly) 
increased in the 4G/4G-genotype, which might partly explain the genotype-specific 
association. 
ClRCADIAN PATTERN OF PLASMA PAI-1 
PAI-1 undergoes a circadian pattern with peak plasma levels observed in the early 
morning.2"6 In the Rotterdam Study among a sub sample of 263 men and women 
aged 55 years and over, the morning/afternoon difference in PAI-1 antigen was also 
pronounced in persons with the 4G/4G-genotype than in the other genotypes.186 We 
also observed this in a population of 599 elderly (see Chapter 3). A biological 
explanation for a genotype-specific diurnal variation in PAI-1 is provided by Maemura 
and colleagues, who identified a transcription factor (CLIF: cycle-like factor) that is 
involved in the circadian pattern of PAI-1.187 The binding site of this transcription 
factor overlaps with the location of the 4G/5G-polymorphism, making an interaction 
between the 4G/5G-polymorphism and the diurnal pattern biological plausible. 
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PAI-1 AND THE ACUTE-PHASE RESPONSE 
Evidence is accumulating that PAI-1 plays a crucial role in inflammatory conditions. 
PAI-1 is an acute-phase protein,1 and proinflammatory cytokines, e.g. interleukin-1, 
TNF-a and TGF-(3, have been shown to stimulate PAI-1 production.11 The acute-
phase response of PAI-1 may be affected by the 4G/5G-polymorphism. In 
transfected HepG2 cell lines it was demonstrated that the 4G-allele produced six 
times more mRNA than the 5G-allele in response to interleukin-1.14 In severe trauma 
patients the 4G/4G-genotype showed the strongest response not only in PAI-1 but 
also in TNF-a and interleukin-1. Especially the difference in response in interleukin-1 
was remarkably, with the largest difference across the genotypes six days after 
severe trauma.188 Apparently, PAI-1 not only increases in response to 
proinflammatory cytokines, but also stimulates the synthesis of cytokines itself, 
suggesting a central role of PAI-1 in the acute-phase response. The stronger acute-
phase response for the 4G/4G-genotype may have detrimental effects on prognosis 
in acute conditions. Recent studies indeed provide evidence for genetic aspects of 
this hypothesis. The 4G-allele has been associated with the development of septic 
shock after meningococcal infection,189 a poor survival rate after severe trauma188 
and an increased mortality rate after aneurysm repair.190 
SUMMARY 
The habitual level of PAI-1 is influenced by many factors, of which obesity and 
insulin resistance are the most important. It is possible to reduce plasma PAI-1 by 
changes in life style, e.g. weight reduction and physical activity. Data on potential 
interactions between environmental and metabolic variables on one hand and the 
4G/5G-polymorphism on the other hand are still scarce. It becomes more and more 
clear that PAI-1 may possibly not be a major (causal) factor in cardiovascular 
disease, but its role in inflammation deserves further attention. In the presence of the 
4G-allele not only the PAI-1 response was more pronounced but also the response 
of other acute-phase reactants, which implies that the increases of these reactants 
are secondary to the increase in PAI-1. A myocardial infarction also provokes an 
acute phase response. It can thus be hypothesized that the 4G-allele might 
exacerbate tissue injury during the acute phase after a myocardial infarction and 
thereby negatively affect the prognosis. 
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Chapter 3 
ABSTRACT 
Background: We examined the diurnal pattern in Plasminogen Activator Inhibitor-
type 1 (PAI-1) activity and Plasminogen activator (t-PA) in relation to the 4G/5G-
polymorphism in the promoter of the PAI-1 gene. 
Methods: The analyses were performed in the Arnhem Elderly Study, a population-
based study of 598 elderly. A single blood sample was drawn and the time of blood 
sampling was recorded (between 8 a.m. and 5.30 p.m.). 
Results: Plasma PAI-1 activity was strongly associated with time of blood sampling, 
showing the highest values in the early morning. The diurnal pattern was clearly 
present in the 4G/4G (n=184) and 4G/5G (n=275) genotypes, but not in the 5G/5G-
genotype (n=139). T-PA antigen showed a weak diurnal variation, which did not 
differ across the variants of the 4G/5G-polymorphism. 
Conclusion: Our findings raise the hypothesis that 5G-homozygotic persons may 
be relatively protected from diurnal variation in the occurrence of coronary events. 
INTRODUCTION 
The occurrence of acute coronary events peaks in the early morning.1"3 This may 
partly be explained by an inability to cope with a thrombus at that time due to low 
fibrinolytic activity.4 Plasminogen activator inhibitor-typel (PAI-1) is the main inhibitor 
of fibrinolysis.5 After its initial discovery, small studies have clearly shown a strong 
diurnal variation in PAI-1 activity.6'13 Also for tissue-type plasminogen activator (t-PA) 
diurnal patterns have been observed .6,7,9,1° However, both the diurnal variations in 
PAI-1 and t-PA have not been described in larger populations. The 4G/5G-
polymorphism of the PAI-1 gene is an insertion/deletion polymorphism of the 
promoter region gene with four (4G-allele) or five guanosines (5G-allele) in a row. 
The extra guanosine base creates an additional binding site for an inhibitor, resulting 
in an attenuated response to transcription factors.14,15 A meta-analysis of studies on 
the 4G/5G-polymorphism and myocardial infarction16 indicated an increased risk for 
the 4G/4G-genotype (overall odds ratio versus 5G/5G-genotype: 1.20, 95%-
confidence interval: 1.04-1.37). 
It can be hypothesised that the diurnal variation in PAI-1 is more pronounced in the 
presence of the 4G-allele. This hypothesis is supported by the recent discovery of a 
transcription factor (CLIF), which may contribute to the diurnal PAI-1 pattern.17 In 
vitro, this transcription factor up-regulates expression of the PAI-1 gene. The binding 
site for this transcription factor overlaps with the site of the 4G/5G-polymorphism.17 
In the present study we investigated the diurnal variation in PAI-1 activity and t-PA 
antigen in a population of elderly and furthermore performed stratified analyses for 
the three variants of the 4G/5G-polymorphism. 
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METHODS 
Study population 
The Arnhem Elderly Study is a population-based cohort study. A random sample of 
non-institutionalized elderly men and women (aged 64-84 years) were invited to 
participate in a health survey, including home interviews (n=1012) and a physical 
examination (n=685). The sample was stratified for age and sex. The selection of 
participants is described elsewhere in detail.18 A single non-fasting blood sample 
was available for 641 subjects. Because of technical reasons, data on PAI-1 activity 
and/or the 4G/5G-polymorphism was missing for 43 subjects, leaving 598 subjects 
for the analysis. Written informed consent was obtained from the participants before 
the physical examination. The ethical committee of Wageningen University approved 
the study. 
Data collection 
Trained interviewers visited the participants at home. Interview topics included 
smoking habits, health status, medication and demographic data. Smoking status 
was coded as current, former and never. Packyears of cigarette smoking were 
calculated for current and former smokers as the number of cigarettes smoked times 
the number of years divided by 20. Body mass index (BMI) was calculated as weight 
divided by height squared (kg/m2). A history of cardiovascular disease was 
considered present if the participant reported a diagnosis of heart disease and/or 
stroke ever in life. Subjects were considered on medical treatment for cardiovascular 
disease if ACE-inhibitors, p-blockers, thrombolytic agents, lipid-lowering medications 
and/or salicylates had been prescribed during the 3 months prior to the interview. 
Blood sampling was performed between 8 a.m. and 5.30 p.m. and the time of blood 
sampling was recorded for every subject. Samples have been stored at -80°C. PAI-1 
activity in plasma was determined using the Chromolize® kit (Biopool, Umea, 
Sweden). T-PA antigen was measured using the Imulyse® kit (Biopool, Umea, 
Sweden). DNA was isolated with standard techniques. The 4G/5G-genotyping was 
performed according to Margaglione,19 with minor modifications. In brief, a mutated 
oligonucleotide was synthesized, which inserted a site for the BseLI enzyme within 
the product of amplification. PCR-products were digested at 55°C with the BseLI 
enzyme (MBI Fermentas, Vilnius, Lithuania). The fragments were fractionated by 
4%-agarose-gel electrophoresis. Serum total cholesterol was determined by an 
enzymatic method (CHOD-PAP). HDL-cholesterol and LDL-cholesterol were 
measured directly (Dimension®HDL method and N-geneous®LDL respectively). 
Serum insulin was determined with an immunometric assay (lmmulite®2000 insulin). 
Statistical analysis 
PAI-1 activities (lU/mL) showed a skewed distribution and were therefore log-
transformed (natural log). To enable log-transformation, PAI-1 activities of 0 lU/mL 
(n=83) were replaced by 0.01 lU/mL (i.e., lowest measured value divided by 2). 
Spearman correlation coefficients (rs) were computed to examine linear associations 
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among variables. For PAI-1 activity, geometric means and 95%-confidence intervals 
(95%-CI) were calculated per time interval by analysis of variance. For t-PA antigen, 
arithmetic mean values were calculated by time interval. Median times of blood 
sampling per time interval were included in a regression model to test for trend over 
the time intervals. Adjustments were made for potential confounders, i.e., age, sex, 
BMI, smoking status (current, former or never), packyears of smoking, alcohol 
consumption (yes/no), serum LDL and HDL-cholesterol, insulin, history of 
cardiovascular disease (yes/no) and use of cardiovascular medication (yes/no). 
Stratified analyses per genotype were performed. The relation between potential 
confounders and time of blood sampling was carefully evaluated within the three 
different genotypes. From this analysis, only smoking emerged as a potential 
confounder as the number of smokers was not equally distributed over the 
genotypes at all time intervals. Therefore, analyses were repeated after exclusion of 
smokers. Furthermore, analyses were repeated after exclusion of subjects with a 
history of cardiovascular disease. Analyses were performed with the SAS statistical 
package. A P-value of 0.05 was considered statistically significant. 
RESULTS 
The characteristics of the study population by PAI-1 genotype are shown in Table 
3.1. The frequency distribution of the 4G/4G, 4G/5G, and 5G/5G variants was 31%, 
46% and 24%, respectively. The median PAI-1 activity level in the total population 
was 1.96 lU/mL Smoking was more often present in the 4G/4G-genotype than in the 
other two genotypes (31% versus 23% and 19% respectively). 
PAI-1 activity was strongly correlated with t-PA antigen (rs=0.63, P=0.0001). PAI-1 
was furthermore associated with BMI, LDL-cholesterol and insulin (rs ranging from 
0.13-0.34). PAI-1 activity was negatively associated with age (rs=-0.12, P=0.003) and 
HDL-cholesterol (rs=-0.31, P=0.0001). Adjusting for time of blood sampling did not 
change the strength of the correlations. PAI-1 activity was higher in smokers than in 
non-smokers (geometric mean of 1.78 versus 1.01 for former smokers and 0.98 for 
never smokers, P=0.03), also after adjusting for time of blood sampling. No 
difference in PAI-1 activity was observed between men and women. T-PA antigen 
was positively associated with age, BMI, total cholesterol, LDL-cholesterol and 
insulin (rs ranging from 0.09-0.31, all P< 0.05) and negatively with HDL-cholesterol 
(rs=-0.28, P=0.0001). 
T-PA antigen was higher in men than in women (11.03 versus 9.67 ng/mL) and 
higher in smokers than in non-smokers (11.28, 10.44 and 9.62 ng/mL for smokers, 
former and never smokers respectively, P=0.001). 
Time of blood sampling was significantly associated with age (rs=0.08, P=0.046) and 
with LDL-cholesterol (rs=-0.10, P=0.02). Other characteristics were not significantly 
associated with the time of blood sampling. 
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Table 3.1. Characteristics of the study population (n=598) by the 4G/5G-polymorphism 
4G/4G 4G/5G 5G/5G 
(n=184) (n=275) (n=139) 
Age (yr) 
BMI (kg/m2) 
Men (%) 
Smoking status (%) 
Current smokers 
Former smokers 
Never smokers 
Alcohol consumers (%) 
History of cardiovascular disease (%) 
Use of cardiovascular medications (%) 
Total cholesterol (mmol/L) 
HDL-cholesterol (mmol/L) 
LDL-cholesterol (mmol/L) 
Insulin (pmol/L)* 
PAI-1 activity (IU/mL)* 
tPA antigen (ng/mL)* 
73.0 ± 5.7 
25.4 ± 3.3 
53.8 
31 
38 
32 
69 
22 
18 
6.3 ±1.2 
1.4 ±0.5 
3.8 ± 1.1 
137(97-207) 
2.1 (0.6-5.4) 
10.2 ±3.7 
74.0 ± 5.5 
26.3 
51.6 
23 
43 
34 
72 
22 
20 
6.2 ± 
1.4 ± 
3.7 ± 
t4.2 
1.2 
0.4 
1.0 
140(99-230) 
2.2 (C 
10.8: 
.8-6.0) 
t3.9 
74.0 ± 5.8 
25.9 ± 3.8 
53.2 
19 
48 
34 
79 
18 
21 
6.2 ±1.3 
1.4 ±0.3 
3.8 ±1.0 
137(91-222) 
1.4(0.3-3.9) 
9.9 ±3.7 
Values are given as mean ± SD unless indicated otherwise. 'Median with interquartile range in 
parentheses, because of skewed distribution. fT-PA levels were available for 565 subjects (4G/4G: 
n=175, 4G/5G: n=259, 5G/5G: n=131). 
In Figure 3.1 the observed PAI-1 activities (geometric means) are reported as a 
function of the time of blood sampling, showing a steady decrease in PAI-1 activity 
during the day. The test for trend over the time intervals was highly significant 
(P=0.0001). In blood samples drawn before 9 a.m. the geometric mean of PAI-1 
activity levels was about 13 times higher than in samples drawn after 4 p.m. (4.47 
versus 0.35 IU/mL). Adjustment for potential confounders (age, sex, BMI, smoking 
status (current, former or never), packyears of smoking, alcohol consumption 
(yes/no), serum LDL and HDL-cholesterol, insulin, history of cardiovascular disease 
(yes/no) and use of cardiovascular medication (yes/no)) had only negligible effects 
(P-trend = 0.0001, data not shown). Diurnal variation in PAI-1 activity was present 
both in men (n=315) and women (n=283), and also both in smokers (n=147) and 
non-smokers (n=449) (all P-trend < 0.001). 
T-PA antigen levels also varied with the time of blood sampling (P-trend=0.0001), but 
the diurnal pattern was less pronounced than that of PAI-1 (Figure 3.2). Adjusting for 
the potential confounders did not alter the pattern. 
In Figure 3.3 the diurnal variation in PAI-1 is shown separately for the three different 
genotypes using broader categories to obtain sufficient power. The percentage of 
subjects with the 5G/5G-genotype sampled before 10 a.m. was lower than for the 
other genotypes (11% versus 17% and 20%, respectively). The overall distribution of 
the 4G/5G-polymorphism over the different time intervals was however not 
statistically different (tested with %2, P=0.23). 
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Figure 3.1. PAI-1 activity (geometric mean) by time of blood sampling. The numbers above 
the bars indicate the number of subjects in each group. 
Time of blood sampling (hours) 
Figure 3.2. T-PA antigen (mean) by time of blood sampling. The numbers above the bars 
indicate the number of subjects in each group. 
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Figure 3.3. PAI-1 activity (geometric mean and 95%-confidence interval) by time of blood 
sampling separately for the 4G/5G-genotypes. The numbers below the bars indicate the 
number of subjects in each group. 
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We observed a diurnal variation in PAI-1 activity for both the 4G/4G and the 4G/5G-
genotypes (P-trend=0.0001, for both genotypes), but not for the 5G/5G-genotype (P-
trend=0.10). After adjustment for a large number of potential confounders, a 
significant trend in PAI-1 activity across the time intervals was observed for the 
5G/5G-genotype (P=0.04), but this which was considerably weaker than for the other 
two genotypes (P=0.0001, both for 4G/4G and 4G/5G). Before 10 a.m. the geometric 
mean PAI-1 differed significantly (P=0.01) among the three genotypes, with the 
lowest geometric mean for PAI-1 activity observed for the 5G/5G-genotype (0.8 
lU/mL compared to 3.5 and 5.1 lU/mL for the 4G/4G and 4G/5G-genotype 
respectively, P=0.01). This difference persisted after adjustment for potential 
confounders, i.e. age, sex, BMI, smoking status, packyears of smoking, alcohol 
consumption, serum LDL and HDL-cholesterol, insulin, history of cardiovascular 
disease and use of cardiovascular medications. The observed adjusted geometric 
means were 3.6, 4.8 and 0.7 lU/mL for the 4G/4G, 4G/5G and 5G/5G-genotypes 
respectively (P=0.008). 
No significant differences in PAI-1 concentrations were observed among the three 
genotypes at any of the other time intervals, neither in crude nor in adjusted 
analyses. Exclusion of current smokers yielded essentially similar results (Both 
4G/4G and 4G/5G: P-trend=0.0001, 5G/5G: P-trend=0.10). From this we conclude 
that the attenuated peak in PAI-1 activity before 10 a.m. in 5G/5G-subjects cannot 
be explained by smoking. Also, exclusion of subjects with a history of cardiovascular 
disease did not materially change the results (data not shown). The diurnal pattern of 
t-PA antigen was not different for the three variants of the 4G/5G-polymorphism 
(data not shown). 
DISCUSSION 
Plasma PAI-1 activity showed a strong diurnal variation in a population of elderly. We 
furthermore demonstrated this diurnal variation to be predominantly confined to the 
4G-allele. We conclude that the 4G-allele may be dominant in expressing the diurnal 
increase in the early morning, which would be in accordance with the data about the 
reduced capacity of the 4G-allele to respond to repression.14,15 
Our observation of a strong diurnal variation in PAI-1 is in agreement with the 
findings of several small studies that performed serial PAI-1 determinations, showing 
increased levels in the early morning.6"13 
Maemura et al recently discovered an endothelial derived transcription factor, CLIF 
(cycle like factor), which may contribute to the diurnal PAI-1 pattern.17 CLIF in 
complex with another transcriptional factor (CLOCK) up-regulates the PAI-1 gene in 
endothelial cells.17 The expression of the PAI-1 gene in adipose tissue also shows a 
circadian pattern, which may in part explain the diurnal variation in blood.20 
Diurnal variations in plasma t-PA have also been observed.6,7,10 In addition, circadian 
fluctuations have been reported in the efficacy of intravenous t-PA treatment in 
patients with acute myocardial infarction, with resistance to thrombolysis during the 
morning hours.21,22 In our study, the diurnal variation in PAI-1 activity was much 
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stronger than the diurnal variation in t-PA, which is in agreement with other 
studies.6,7 Therefore, the diurnal variation in PAI-1 is unlikely to be secondary to the 
variation in t-PA. 
Our finding that the diurnal in PAI-1 is predominantly confined to the 4G-allele is in 
agreement with the findings of the Rotterdam Study, which showed a more 
pronounced morning/afternoon difference in PAI-1 antigen within the 4G/4G-
genotype than in the other genotypes.23 As far as we know, no other studies were 
performed on diurnal variation in PAI-1 activity in which 4G/5G genotyping of the 
PAI-1 gene has been performed. 
The 4G/5G-polymorphism overlaps with one of the two binding sites for the CLIF-
CLOCK complex,17 which makes a differential diurnal pattern across the genotypes 
biologically plausible. It would be very informative to explore the potential differential 
binding of the CLIF-CLOCK complex to the 4G and 5G-allele, and potential 
interaction of the complex with the repressor protein that apparently binds to the 5G-
allele and suppresses gene expression. 
The Arnhem Elderly Study was not primarily designed to study the diurnal variation 
in PAI-1 activity, and therefore some limitations have to be considered. We could not 
investigate diurnal variation within subjects, because only a single blood sample per 
person was available. Differences among individuals may have contributed to the 
observed variation in PAI-1 activity. However, extensive adjustment for potential 
confounders did not alter the observed patterns. The analyses of diurnal variation in 
PAI-1 activity within strata of genotype are less prone to bias. Potential confounders 
within this respect are variables that are associated with time of blood sampling on 
one hand and the circadian pattern of PAI-1 activity (not activity itself) on the other 
hand. Few variables are likely to be related to both of these factors. We carefully 
studied the relation of potential confounders with time of blood sampling within the 
three different genotypes. From this analysis, only smoking emerged as a potential 
confounder as the number of smokers was not equally distributed at over the 
genotypes at all time intervals. Therefore, analyses were repeated after exclusion of 
smokers. This subgroup analysis yielded essentially similar results in genotype-
specific associations. The proportion of 5G/5G-subjects sampled before 10 a.m. was 
lower than for the other genotypes. Since there is no plausible biological explanation 
for this phenomenon, we consider this mainly due to chance. It is important to note, 
however, that this unequal distribution does not affect the internal validity of the 
study but only the power within that stratum. 
Small studies showed the peak in PAI-1 activity to occur between 3 and 5 a.m.6,13 It 
can be hypothesized that the differences in PAI-1 concentrations among the three 
genotypes may be larger at this time of the day, but it is not feasible to examine this 
within a population-based study. 
In a population of elderly the presence of diseases and medications may influence 
variability in PAI-1 activity, which complicates the study of genotype-specific 
associations. Nevertheless, we observed a genotype-specific diurnal variation in 
PAI-1 activity. The findings that we obtained from our population-based cohort 
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should be confirmed by clinical studies using serial blood samples, preferably in 
younger, non-smoking subjects. 
Our findings suggest that it would be worthwhile to incorporate 4G/5G-genotyping in 
studies of diurnal variation in coronary event to evaluate whether early morning 
peaks are less pronounced in homozygotes for the 5G allele. Studies on the 
determinants of PAI-1 peak levels in the early morning and the possibilities to reduce 
this rise in PAI-1, especially in carriers of the 4G-allele, are also worth further 
investigation. Interventions that affect the action of the novel transcription factor 
CLIF,17 thereby modulating diurnal variation in PAI-1. We think that our data, 
combined with the recent findings on CLIF by Maemura et al, raise the interesting 
hypothesis that the diurnal variation of PAI-1 varies among genotypes of the 4G/5G-
polymorphism. Our findings should be confirmed in a study with serial PAI-1 
determinations at different hours in three fixed groups of individuals with different 
genotypes. 
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Chapter 4 
ABSTRACT 
Background: Plasminogen activator inhibitor-1 (PAI-1) is elevated in the presence 
of atherosclerosis, but it is not yet clear if this relationship is causal. PAI-1 levels are 
partly modulated by the 4G/5G-polymorphism in the PAI-1 gene. 
Methods: We studied the association between the 4G/5G-polymorphism and 
atherosclerosis in 208 smoking men. Common carotid artery intima-media thickness 
(IMT) and the ankle-brachial index (ABI) were used as markers of atherosclerosis. 
Results: The 4G-allele was not associated with a higher prevalence of 
atherosclerosis, neither for IMT nor ABI. Although not significantly, a high IMT (>1.07 
mm) was even less frequent for the 4G/5G and 4G/4G-genotypes compared to the 
5G/5G-genotype (odds ratios of 0.6 and 0.4 respectively, p-value for trend: 0.08). 
Conclusion: Our findings cast doubt on a causal role for PAI-1 in the 
atherosclerotic process. 
INTRODUCTION 
Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of fibrinolysis and 
proteolysis in the vessel wall and it has been suggested that high PAI-1 values 
increase the risk of cardiovascular disease.1,2 The 4G/5G-polymorphism is an 
insertion/deletion polymorphism of the promoter region of the PAI-1 gene with four 
(4G-allele) or five guanosines (5G-allele) in a row. The extra guanosine base creates 
an additional binding site for an inhibitor, resulting in an attenuated response to 
transcription factors.3,4 Previous studies have shown increased PAI-1 levels in the 
presence of the 4G-allele.3"6 However, it can be hypothesized that the 4G/5G-
polymorphism influences acute PAI-1 responses rather than PAI-1 levels, which may 
explain the lack of an association between the 4G/5G-polymorphism and PAI-1 
concentrations in other studies.7,8 
A meta-analysis of studies on the 4G/5G-polymorphism and myocardial infarction9 
indicated a slightly increased risk for the 4G-allele with a pooled odds ratio of 1.20 
(95%-confidence interval: 1.04 - 1.37). Previously, it has been suggested that the 
association between the 4G/5G-polymorphism and myocardial infarction could be 
stronger in high-risk than in low-risk populations.10,11 This suggests that the impact of 
the 4G/5G-polymorphism may vary according to the presence or absence of other 
cardiovascular risk factors that affect PAI-1 concentrations (e.g. smoking). 
Increased levels of PAI-1 have been found in the presence of atherosclerosis.12,13 
Furthermore, PAI-1 has been localized in atherosclerotic arteries.14"16 However, it is 
at present not clear whether PAI-1 elevation is a cause or consequence of 
atherosclerosis. An association between the 4G/5G-polymorphism and 
atherosclerosis would favor a causal role of PAI-1 in atherosclerosis. 
In the present study among smoking men, we investigated the association between 
the 4G/5G-polymorphism and two non-invasive markers of atherosclerosis, i.e. 
carotid artery intima-media thickness (IMT) and the ankle-brachial index (ABI). 
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MATERIALS AND METHODS 
Subjects and design 
Baseline data of a trial of vitamin E supplementation and IMT in 218 male smokers 
were used. Recruitment of subjects has been described in more detail elsewhere.17 
For two persons no baseline IMT-measurement was available and for eight persons 
data on the 4G/5G-polymorphism were lacking because DNA isolation was not 
successful, leaving 208 subjects for the present study. Written informed consent had 
been obtained from all participants. The ethics committees of Wageningen University 
and Nijmegen University Hospital approved the study. 
Intima-media thickness and ankle-brachial index 
Intima-media thickness (IMT) of the distal 1.0cm of the common carotid artery was 
measured using high-resolution B-mode ultrasound with a 10 MHZ transducer. 
Details of the scanning and reading procedure have been described elsewhere.18 
The mean of the near and far wall both at the right and left side was used in the 
data-analyses. 
The systolic blood pressure at the ankle (arteria tibiallis posterior) and at the arm 
(arteria brachialis) were both measured in supine position after a 5-minute rest using 
a 8 Mhz Doppler probe (Imex, Biomedic; Colorado) and a random-zero 
sphygmomanometer. The ankle-brachial index (ABI) was calculated as the systolic 
blood pressure at the ankle divided by the systolic blood pressure at the arm. The 
lower of two measurements was used in data-analyses. 
Cardiovascular risk factors 
Data on smoking, medical history, medication and family history of cardiovascular 
disease (CVD) were obtained by questionnaire. Pack-years of smoking were 
calculated by multiplying the number of years smoked by the daily number of 
cigarettes, divided by 20. History of CVD included self-reported myocardial infarction, 
stroke, coronary bypass grafting or current use of cardiovascular medication. 
Subjects were considered to have a positive family history of CVD if they reported at 
least one first-degree family member with CVD before the age of 60 years. Plasma 
cotinin (marker of short-term smoking) was measured by packed column gas-liquid 
chromatography.19 Body mass index (BMI) was calculated as weight divided by 
height squared (kg/m2). Total plasma cholesterol was analyzed enzymatically 
(CHOD-PAP, no 237574, Boehringer Mannheim GmbH, FRG). HDL cholesterol was 
determined with the polyethylene glycol method.20 LDL cholesterol was calculated by 
the Friedewald equation.21 Plasma C-reactive protein (CRP) was measured with a 
highly sensitive ELISA procedure (Dako A/S, Glostrup, Denmark). Hypertension was 
defined as a blood pressure of 160/95 mmHg or above, or use of antihypertensive 
medication. 
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4G/5G-polymorphism 
DNA was isolated from whole blood. Polymerase chain reaction (PCR) amplification 
of genomic DNA was performed using the following allele specific primers: insertion 
allele (5G) 5'-GTC TGG ACA CGT GGG GG-3'; deletion allele (4G) 5'-GTC TGG 
ACA CGT GGG GA-3' each in a separate PCR reaction together with a common 
downstream primer and a control upstream primer to verify the occurrence of DNA 
amplification in the absence of the allele on the genomic DNA. The PCR-conditions 
were as described elsewhere.22 The amplified DNA fragments were fractionated by 
agarose gel electrophoresis and viewed under ultraviolet light after staining with 
ethidium bromide. Twenty randomly selected samples were also genotyped using a 
different method.23 The two methods yielded fully identical results. 
Statistical analyses 
Analysis of variance and x2-testing were used to test for differences in general 
characteristics between the three genotypes. Deviations of the 4G/5G-polymorphism 
distribution from that expected for a population in Hardy-Weinberg equilibrium were 
analyzed using the x2_test- Spearman correlation coefficients (rs) between markers 
of atherosclerosis and cardiovascular risk factors were calculated. Odds ratios (OR) 
for high IMT or low ABI according to 4G/5G genotype were obtained by logistic 
regression analysis. Subjects in the upper quartile of IMT (>1.07mm) or in the lower 
quartile of ABI (<1.03), respectively, were classified as cases. All other subjects were 
used as controls. Adjustments were made for age, BMI, hypertension, HDL-
cholesterol, LDL-cholesterol and smoking (cotinin and pack-years)). Tests for trends 
were performed by including genotype as a categorical variable in the logistic model 
(0, 1 and 2 for the 5G/5G, 4G/5G and 4G/4G-genotypes, respectively). Data analysis 
was repeated after exclusion of 35 subjects who reported a history of CVD. The SAS 
statistical package (version 6.11) was used. P-values below 0.05 were considered 
statistically significant. 
RESULTS 
Characteristics of the population by genotype are reported in Table 4.1. Thirty-three 
percent had the 4G/4G genotype, 54% the 4G/5G-genotype and 13% the 5G/5G-
genotype. The overall allele frequencies were 0.60 and 0.40 for the 4G and 5G 
alleles, respectively. The genotype distribution fulfilled the criteria of a Hardy-
Weinberg distribution (P>0.05). No significant differences in subject characteristics 
were observed across the genotypes. 
IMT and ABI were inversely associated (rs= -0.23, P<0.05). Age was the strongest 
predictor of both ABI (rs=-0.26, P=0.0002) and IMT (rs=0.46, P=0.0001). ABI was 
furthermore inversely correlated with systolic blood pressure (rs=-0.19, P=0.01) and 
positively with BMI (rs=0.19, P=0.01). 
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Table 4.1. Characteristics of 208 male smokers separately for the 4G/5G-polymorphism. 
General and lifestyle 
characteristics 
Age (yr) 
Body mass index (kg/m2) 
Packyears of smoking 
Hypertension* 
Plasma concentrations 
Cholesterol (mmol/L) 
HDL-cholesterol (mmol/L) 
LDL-cholesterol (mmol/L) 
Triglycerides (mmol/L) 
CRP (ng/mL) 
Cotinin (ug/mL) 
Cardiovascular history 
Family history of CVDf 
History of CVD1 
Markers of atherosclerosis 
Intima-Media Thickness (mm) 
Ankle-Brachial Index 
4G/4G 
n=69 (33%) 
59.8 ± 5.9 
26.3 ± 3.7 
40.8 ± 23.5 
13(19%) 
6.0 ±1.1 
1.2 ±0.3 
4.0 ± 0.9 
1.8 + 1.2 
2.3(1.2-4.8) 
235 ±106 
16 (23%) 
11 (16%) 
0.94 ±0.14 
1.07 + 0.06 
4G/5G 
n=113(54%) 
59.9 ± 6.2 
25.8 ± 3.2 
35.2 ± 20.6 
28 (25%) 
6.0 ±1.1 
1.2 ±0.4 
4.1 ±0.9 
1.7 + 0.9 
2.5(1.0-4.7) 
264 ±129 
21 (19%) 
21 (19%) 
0.95 ±0.18 
1.07 + 0.06 
5G/5G 
n=26(13%) 
62.4 ± 6.8 
26.3 ±3.1 
36.8 ±18.1 
2 (8%) 
5.7 ±1.2 
1.1 ±0.3 
4.1 ±1.2 
1.7+1.0 
2.8(1.7-4.6) 
250 ±107 
3(12%) 
3 (12%) 
0.98 ±0.18 
1.06 + 0.09 
Data are reported as mean (±SD) for continues variables and as n (%) for categorical variables. 
Because of a skewed distribution, CRP values are reported as median with an interquartile range. 
* Hypertension: systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 95 mmHg or 
use of antihypertensive medication. 
f
 Family history of CVD: At least 1 first-degree family member with cardiovascular disease before the 
age of 60 years. 
1
 History of CVD: history of Ml, stroke or bypass or use of medication for CVD. 
In addition, IMT was positively correlated with plasma total- and LDL-cholesterol, 
CRP, BMI, and diastolic and systolic blood pressure (rs ranging from 0.14 to 0.40, all 
P<0.05). 
The distributions of IMT and ABI are shown in Figure 4.1. Both for IMT and ABI, 
mean values were not significantly different across the genotypes. The 4G-allele was 
not associated with a higher prevalence of atherosclerosis, neither for IMT nor ABI 
(Table 4.2). Although not significantly, there was a trend towards a lower probability 
of a high IMT (>1.07mm) for both the 4G/5G and 4G/4G-genotypes compared to the 
5G/5G-group (4G/5G: OR=0.6 (95%-CI: 0.2 - 1.6), 4G/4G: OR=0.4 (95%-CI: 0.1 -
1.1), P-trend = 0.08)). For low ABI (<1.03), OR of 0.5 (95%-CI: 0.2 - 1.2) was 
observed for the 4G/5G-genotype and 0.7 (95%-CI: 0.3 - 1.9) for the 4G/4G-
genotype. Adjustments for possible confounders did not materially alter the results. 
Findings remained similar after exclusion of subjects with a history of CVD (data not 
shown). 
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[=]4G/4G 
BE—Afl/fifl 
HB5G/5G 
<0.8 [0.8; 0.9) [0.9; 1.0) [1.0; 1.1) >1.1 
IMT (mm) 
>1.1 [1.0; 1.1) [0.9; 1.0) <0.9 
ABI 
Figure 4.1. Distribution of intima-media thickness and ankle-brachial index by 4G/5G-
genotype 
Table 4.2. Association of the 4G/5G-polymorphism with indicators of atherosclerosis (IMT 
and ABI) in 208 male smokers. 
Intima-Media Thickness 
Cases/controls* (n) 
Crude OR 
Adjusted OR1 
Ankle-Brachial index 
Cases/controls* (n) 
Crude OR 
Adjusted OR1 
5G/5G* 
8/18 
1.0 
1.0 
8/18 
1.0 
1.0 
4G/5G 
24/89 
0.6 (0.2 • 
0.9 (0.3 • 
19/94 
0.5 (0.2 
0.5 (0.2 
1.6) 
2.7) 
1.2) 
1.4) 
4G/4G 
10/59 
0.4 (0.1 
0.5(0.1 
16/53 
0.7 (0.3 
0.9 (0.3 
1.1) 
1.7) 
-1.9) 
•2.9) 
P trend 
0.08 
0.18 
0.81 
0.64 
The 95%-confidence intervals are presented in parentheses. 
* Reference group 
f
 Cases: subjects in upper quartile of IMT (>1.07mm) or in the lowest quartile of ABI (<1.03) 
respectively. Controls: subjects in any of the other three quartiles. 
}
 Adjusted for age, BMI, hypertension, HDL-cholesterol, LDL-cholesterol, triglycerides and smoking 
(cotinin and packyears). 
DISCUSSION 
In the present study no association was observed between the 4G/5G-polymorphism 
and two established markers of atherosclerosis, i.e. ABI and IMT. The 4G-allele is 
generally associated with higher PAI-1 concentrations and therefore one would 
expect an increased risk of atherosclerosis if PAI-1 were causally involved. Our 
findings, howerver, do not support this hypothesis. 
The 4G/5G-polymorphism has been examined previously in relation to coronary 
atherosclerosis, as assessed by angiography.11,24 Ossei-Gerning ef al observed no 
association between the 4G/5G-polymorphism and the presence or extent of 
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coronary atherosclerosis.24 In contrast, Gardemann et al found that the 4G/5G-
polymorphism was associated both with the presence and severity of coronary 
atherosclerosis. The latter association, however, was only observed in high-risk 
subjects.11 
In the ARIC-study and the NHLBI Family Heart Study, PAI-1 levels were positively 
associated with IMT12,13 but these relationships disappeared after adjustment for 
other risk factors like age, BMI and smoking. In untreated hypertensives,25 ABI was 
significantly and inversely associated with PAI-1 antigen and this association 
persisted after adjustment for other cardiovascular risk factors. However, in the 
Rotterdam Study, no association between ABI and PAI-1 antigen was observed.26 It 
is possible that observed associations between PAI-1 and markers of atherosclerosis 
are due to PAI-1 elevations in response to the atherosclerotic process. Furthermore, 
possible confounding by cardiovascular risk factors make these results difficult to 
interpret. It has been argued that adjusting for cardiovascular risk factors should not 
be performed because of the possible intermediary role of PAI-1 in the biological 
pathway of these risk factors.13 This may be avoided by examining the 4G/5G-
polymorphism rather than PAI-1 values, as we did in the present study. 
A drawback of our study is the limited number of subjects, which makes strong 
conclusions not justified. However, with the observed genotype distribution we were 
able to detect a difference in IMT of 0.098 mm (< 1 SD) and in ABI of 0.039 (« 0.5 
SD) between the 4G/4G and 5G/5G-genotypes, which we consider clinically 
relevant. 
IMT is considered a useful marker for generalized atherosclerosis and has been 
shown to predict future cerebrovascular and coronary events.27 ABI, used for the 
diagnosis of peripheral arterial disease, has been associated with coronary and 
carotid artery disease and cardiovascular and overall mortality.27 Only a few subjects 
in our study had an ABI below the conventional cut-off value of 0.9 and therefore the 
20th percentile of the distribution in the study population (i.e. 1.03) was used as cut-
off for low ABI in our analyses. 
Evidence exists that the association of the 4G/5G-polymorphism with risk of 
cardiovascular disease is stronger in high-risk than low-risk populations.10,11 
Gardemann et al observed that the association between the 4G/5G-polymorphism 
and coronary stenosis was more pronounced in current and former smokers than in 
the population as a whole.11 The lack of an association between the 4G/5G-
polymorphism and markers of atherosclerosis in our population of male smokers 
suggests that previously reported associations might be due to PAI-1 elevation in 
response to the atherosclerotic process. 
From our findings, we hypothesize that PAI-1 plays a role in a later (thrombotic) 
rather than an earlier (atherosclerotic) stage of the cardiovascular disease process. 
Furthermore, elevated PAI-1 may predispose to formation of plaques with a high 
amount of lipid compared to smooth muscle cells as a result of decreased smooth 
muscle cell migration. These types of plaques are particularly prone to rupture.28 
Thus, although our data do not support a causal effect of PAI-1 in the atherosclerotic 
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process, it may affect the nature of the atherosclerotic plaque thereby contributing to 
risk of thrombosis. 
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ABSTRACT 
Background: PAI-1 (plasminogen activator inhibitor-type 1) is an inhibitor of 
fibrinolysis and increased levels of PAI-1 may predict cardiovascular disease. The 
4G-allele of the 4G/5G-polymorphism is associated with an increased transcription of 
the PAI-1 gene. We investigated whether the 4G-allele of the PAI-1 gene is 
associated with a higher risk of coronary stenosis and if this association is stronger 
in subgroups with a high background cardiovascular risk. 
Methods: Data were obtained from three case-control studies. Cases had 
angiographically determined coronary stenosis (n=285). Both coronary controls (i.e. 
no substantial stenosis, n=293) and population-based controls (n=198) were 
included. 
Results: A non-significant increased risk of coronary stenosis was observed for the 
4G-allele relative to the 5G/5G-genotype when compared to coronary controls 
(4G/5G: OR=1.37 (95%-CI: 0.87 - 2.14), 4G/4G: OR=1.58 (95%-CI: 0.97 - 2.57)). No 
association was observed using the population-based control group. Stratification for 
background cardiovascular risk (based on Framingham Prediction Score) showed an 
increased risk of coronary stenosis only in the low-risk group (cases versus coronary 
controls, 4G/5G: OR=2.25 (95%-CI: 1.05 - 4.85), 4G/4G: OR=2.86 (95%-CI: 1.27 -
6.47)). 
Conclusion: Our results do therefore not support the hypothesis that the effects of 
the 4G/5G-polymorphism are stronger in high-risk populations. 
INTRODUCTION 
Plasminogen activator inhibitor-type 1 (PAI-1) is a main regulator of fibrinolysis and 
proteolysis and increased levels of PAI-1 may predict cardiovascular disease.1 
Plasma PAI-1 levels are related to a common, single-base-pair guanosine insertion 
(5G)/ deletion (4G) polymorphism in the promoter region of the PAI-1 gene.2 Both 
alleles bind a transcription activator, whereas only the 5G-allele also binds a 
repressor protein to an overlapping binding site.2 The 4G-allele is associated with 
higher transcription of the gene and therefore the 4G/5G-polymorphism is an 
independent marker of increased plasma levels of PAI-1.2"4 This association was 
confirmed in several,5"10 but not all studies.11,12 
Elevated PAI-1 levels were observed in patients with a history of a myocardial 
infarction9,10 or with atherosclerotic disease.13 This does not necessarily indicate that 
PAI-1 is a causal risk factor. It is also possible that PAI-1 levels are raised as result 
of the atherosclerotic process or in response to an acute cardiovascular event. 
Furthermore, the observed associations may be due to confounding by 
cardiovascular risk factors that are known to affect PAI-1 levels and are 
simultaneously independent risk factors for cardiovascular disease.10,14 It is 
furthermore possible that some of these risk factors partly exert their effect on 
cardiovascular disease by an effect on PAI-1 concentration. 
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Genetic markers of increased PAI-1 expression are by definition not induced by 
atherosclerosis or by other external factors and therefore no discussion on the 
sequence of events exists. The meta-analysis by Boekholdt et al showed a slight 
increased risk of myocardial infarction for the 4G-allele.15 It has furthermore been 
suggested that the effect of the 4G/5G-polymorphism might be stronger in 
populations with a high background cardiovascular risk than in low-risk populations.16 
This hypothesis is supported by the observation of Gardemann et al. that the 
association between the 4G/5G-polymorphism and coronary artery disease 
predominantly existed within high-risk subgroups.17 
In the present paper, three case-control studies on angiographically defined coronary 
stenosis were combined to study whether the 4G-allele of the 4G/5G-polymorphism 
is associated with a higher risk of coronary stenosis and if this association is stronger 
in the subgroups with a higher background cardiovascular risk. The cases in this 
study were compared to two types of controls; namely coronary controls (i.e. 
showing no substantial stenosis) and population-based controls. 
METHODS 
Study population 
Data were obtained from three case-control studies among subjects that underwent 
coronary angiography. These studies were described elsewhere in detail.18"20 The 
first study was on the relation between coronary atherosclerosis and LDL oxidation.18 
The objective of study 2 was to investigate the association between plasma 
homocysteine and coronary atherosclerosis.19 The third study was conducted to 
investigate the association between oxysterols and coronary stenosis.20 These 
studies will be referred to as study 1, study 2 and study 3 respectively. 
Case-control status 
Cases and coronary controls were recruited from patients who underwent coronary 
angiography for suspected coronary atherosclerosis. Two of the three studies (study 
1 and study 2) additionally selected population-based controls. 
Cases 
Initial selection criteria for cases differed slightly between the three studies. Study 1: 
At least 85% stenosis in one and at least 50% stenosis in a second artery. Study 2: 
At least 90% stenosis in one and at least 40% stenosis in one additional coronary 
artery. Study 3: More than 80% stenosis in at least one of the three major coronary 
vessels. 
69 
Chapter 5 
Coronary controls 
Study 1: Less than 50% stenosis in no more than two of the three major coronary 
vessels. Study 2: Less than 50% stenosis in no more than one coronary artery. 
Study 3: Less than 50% stenosis in all three major coronary vessels. 
Population-based controls 
Study 1 and study 2 included population-based controls. Study 1: Controls were 
selected from participants in the Rotterdam Elderly Study21 and through an 
advertisement in a newspaper. The controls had no plaques in the carotid artery as 
assessed by ultrasound echography. Study 2: A random sample was drawn from a 
register of about 10,000 men previously recruited for participation in a trial that was 
cancelled. Spouses of participants were also invited to participate. 
Exclusion criteria 
The major exclusion criteria for all three studies were a myocardial infarction during 
2.5 (study 2) or 12 months (study 1 and 3) before the study; diabetes mellitus; 
chronic (gastro)intestinal diseases; alcohol or drug abuse. In study 1 and 3 only 
subjects who underwent their first angiography were included. Subjects under 
cardiac care for more than 2.5 years; with previous bypass surgery and subjects in 
whom more than two months had elapsed between angiography and case selection 
were excluded in study 3. Other exclusion criteria differed only slightly between the 
three studies. To improve the comparability between the studies, cases from study 3 
with less than 50% stenosis in a second vessel and coronary controls from study 3 
with stenosis in three vessels were excluded from the present analyses (n=33). 
Data were available for 790 persons (study 1: n=345, study 2: n=311, study 3: 
n=134). For 14 subjects no data were available on the 4G/5G-polymorphism due to 
an insufficient amount of DNA. Thus, the final study population consisted of 776 
subjects (cases: n=285, coronary controls: n=293, population-based controls: 
n=198). 
Data collection 
Blood concentrations of triglyceride, total cholesterol, LDL-cholesterol, HDL-
cholesterol, and blood pressure, height and weight were measured as described 
elsewhere.18"20 Hypertension was defined as systolic blood pressure above 160 
mmHg or diastolic blood pressure above 95 mmHg or use of blood pressure lowering 
medication. Hypercholesterolemia was defined as total cholesterol above 6.5 mmol/L 
or use of cholesterol lowering medication. Other data such as alcohol use, smoking 
habits and family history of cardiovascular disease were obtained by questionnaires. 
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4G/5G-polymorphism 
A 221 base-pair fragment in the promoter region of the PAI-1 gene with the 4G/5G-
polymorphism was amplified using PCR22 followed by dot blot and hybridization with 
antigen specific oligonucleotides23 The antigen specific oligonucleotide for the 4G 
allele was y32P-ACACGTGGGGAGTCAGC and for 5G was y32P-
ACACGTGGGGGAGTCAGC. A subset of 129 samples (17%) was also genotyped 
using the method described by Margaglione with some modifications.24 Both 
methods yielded complete identical results. 
Statistical analysis 
Characteristics of cases and the control groups were compared with ANOVA or the 
%2-test. The x2-test was used to test for deviation of genotype distribution from 
Hardy-Weinberg equilibrium. Odds ratios (OR's) were calculated by logistic 
regression to investigate the relation between the 4G/5G-polymorphism and 
coronary stenosis. Adjustments were made for coronary heart disease risk factors 
(family history, smoking, hypertension and hypercholesterolemia). Study was 
included as a dummy-variable in multivariate analyses to adjust for differences 
between the three studies. Stratified analysis was performed to detect potential 
effect modifiers. OR's were calculated in strata of gender, hypercholesterolemia, 
hypertension, obesity (BMI > 30 kg/m2), family history of cardiovascular diseases, 
smoking status (current/former/never), age (cut-off value: 60 years), cholesterol (cut-
off value: 6.5 mmol/L), LDL-cholesterol (cut-off value: 3.5 mmol/L), triglycerides (cut-
off value: 2.0 mmol/L) and HDL-cholesterol (cut-off value: 1.1 mmol/L). The 
Framingham Prediction Score25 was calculated as overall cardiovascular risk 
variable. The Framingham Prediction Score only considers smokers and non-
smokers. A high percentage of the cases (63.5 %) were ex-smokers. Assuming that 
many of them may have recently stopped smoking we considered ex-smokers as 
smokers when calculating the scores. Sex-specific median risk scores (men: 9; 
women: 8) were used to divide the subjects into a low-risk and a high-risk group. 
Stratified analyses were performed for these two groups. A two-sided probability of 
less than 0.05 was considered statistically significant. 
RESULTS 
The characteristics of cases and controls are shown in Table 5.1. Cases had higher 
total-cholesterol, LDL-cholesterol and triglycerides than both control groups, and 
lower HDL-cholesterol concentrations. Almost all cases were hypertensive (90.2%), 
against 65.9% of the coronary controls and 21.7% of the population-based controls. 
In cases the lowest percentage of current smokers (20.7%) and the highest 
percentage of ex-smokers (63.5%) was observed. A family history of cardiovascular 
disease was more common in cases (32.9%) than in coronary controls (24.2%), and 
population-based controls (7.6%). 
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Table 5.1. Characteristics of the study population (Mean ± SD) 
Cases 
(n=285) 
Coronary 
Controls 
(n=293) 
Population-
based 
controls 
(n=198) 
Age, years 
Sex, % male 
BMI, kg/m2 
Total cholesterol, mmol/L 
LDL-cholesterol, mmol/L 
HDL-cholesterol, mmol/L 
Hypercholesterolemia, % 
Triglycerides, mmol/L 
Systolic blood pressure, mm 
Diastolic blood pressure, mrr 
Hypertension, % 
Smokers, % 
Ex-smokers, % 
Family history of CVD*, % 
Hg 
iHg 
56.5 ± 9.3 
82.1 
26.5 ± 2.8 
6.5 ±1.3 
4.5 ±1.2 
0.98 ± 0.27 
55.8 
2.1 ±1.1 
134.5 ±16.1 
82.1 ±8.5 
90.2 
20.7 
63.5 
32.9 
53.9 ± 9.8* 
64.5* 
26.0 ± 3.3r 
6.1 ±1.3* 
4.2 ±1.2* 
1.2 ±0.38* 
35.2* 
1.7 ±0.91* 
132.3 ±16.6 
80.9 ± 8.9 
65.9* 
27.3* 
44.4* 
24.2f 
56.1 ±9.4 
78.8 
26.2 ± 3.7 
6.1 ±1.5* 
4.3 ±1.4+ 
1.1 ±0.32* 
35.4* 
1.5 ±0.87* 
134.5 ±16.0 
83.5 ± 8.8 
21.7* 
29.3* 
45.5* 
7.6* 
* P<0.01 for difference controls versus cases;+ P<.05 for difference controls versus cases 
* CVD=cardiovascular disease 
The 4G-allele frequency was 0.58 for cases, 0.53 for coronary controls and 0.57 for 
population-based controls. The difference between the 4G-allele frequency of the 
cases and the coronary controls was not significant (P=0.09). Genotype distribution 
was in Hardy-Weinberg equilibrium in both cases and coronary controls but not in 
,2 _ population-based controls (x = 6.93; 1 df, P<0.04) (Table 5.2). 
Cases versus coronary controls 
Although not significant, the 4G/4G-genotype showed an increased risk of coronary 
stenosis when cases were compared with coronary controls (Table 5.3). Relative to 
the 5G/5G-genotype the OR for the 4G/4G-genotype was 1.58 (95%-CI: 0.97 - 2.57) 
and 1.37 (95%-CI: 0.87 - 2.14) for the 4G/5G-genotype. Adjustments for possible 
confounders did not alter the results substantially. The results were not considerably 
different when the analyses were performed separately for the three studies (data 
not shown). 
Cases versus population-based controls 
No increased risk was found for carriers of the 4G-allele (Table 5.3) when comparing 
cases with population-based controls. The OR for the 4G/5G-group was 0.80 (95%-
CI: 0.47 -1.36) and for the 4G/4G-group 1.01 (95%-CI: 0.56 - 1.81) compared to the 
5G/5G-group. After adjustment for possible confounding factors similar results were 
found. The results were not different across the studies (data not shown). 
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Table 5.2. Distribution of the 4G/5G-polymorphism of the PAI-1 gene in cases and controls 
Genotype Cases 
N (%) 
5G/5G 44(15) 
4G/5G 149 (52) 
4G/4G 92 (32) 
Total 285 
Table 5.3. Univariate and multivariate odds ratios (95%-CI) for cases (n=285) compared to 
coronary controls (n=293) and population-based controls* (n=198) 
Cases versus coronary controls Cases versus population-based 
controls* 
Coronary controls 
N (%) 
61 (21) 
151 (52) 
81 (28) 
293 
Population-based 
controls 
N (%) 
27(14) 
115(58) 
56 (28) 
198 
Univariate Multivariatet Univariate Multivariate 
5G/5G 1.00 1.00 1.00 1.00 
4G/5G 1.37(0.87-2.14) 1.24(0.76-2.05) 0.80(0.47-1.36) 0.73(0.29-1.83) 
4G/4G 1.58(0.97-2.57) 1.55(0.90-2.66) 1.01(0.56-1.81) 0.79(0.30-2.09) 
* Population-based controls were only included in study 1 and 2 
1
 Adjusted for family history, smoking, hypertension, hypercholesterolemia and study 
* Reference 
Effect modification 
Cases versus coronary controls 
Analyses stratified for several cardiovascular risk factors were performed (e.g. lipid 
profile, blood pressure, age, smoking habits). No clear pattern of effect modification 
was observed for the separate risk factors except for age. For subjects younger than 
60 years an increased risk of coronary stenosis for the 4G/4G-genotype was 
observed (4G/4G: 2.09 (95%-CI: 1.15 - 3.78); 4G/5G: 1.64 (95%-CI: 0.95 - 2.81)) 
while no association was found for older persons (4G/4G: 0.75 (95%-CI: 0.30 -1.89); 
4G/5G: 0.83 (95%-CI: 0.35 -1.96)). Analyses were also performed separately for the 
low-risk and high-risk groups (based on the Framingham Prediction Score). Of the 
cases 55.1% were classified as high-risk against 36.9% of the coronary controls. The 
association between the 4G/5G-polymorphism and coronary stenosis was present in 
the low-risk group but not in the high-risk group (Table 5.4). In the low-risk group the 
OR for the 4G/5G-genotype was 2.25 (95%-CI: 1.05 - 4.83) and for the 4G/4G-
genotype 2.86 (95%-CI: 1.27 - 6.47). 
Cases versus population-based controls 
No effect modification by any of the separate cardiovascular risk factors was 
observed in the analyses with the population-based controls (data not shown). Of the 
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population-based controls 42.4% were classified as high-risk based on the 
Framingham Prediction Score. Also stratified analyses for the low-risk and the high-
risk groups did not result in different OR's (Table 4). 
Table 5.4. Multivariate* odds ratios (95%-CI) stratified over two groups based on their 
background cardiovascular risk as assessed with the Framingham risk score for the cases 
(n=285) compared to the coronary controls (n=293) and population-based controls1 (n=198) 
Cases versus Coronary Cases versus population-
controls based controlst 
Low-risk group High-risk Low-risk High-risk 
5G/5G 1.00 1.00 1.00 1.00 
4G/5G 2.25(1.05-4.83) 0.75(0.35-1.61) 0.97(0.19-4.93) 0.57(0.17-1.83) 
5G/5G 2.86(1.27-6.47) 0.96(0.42-2.22) 1.69(0.32-9.05) 0.45(0.13-1.57) 
* Adjusted for family history, smoking, hypertension, hypercholesterolemia and study 
f
 Population-based controls were only included in study 1 and 2 
* Reference 
DISCUSSION 
In this study a non-significant increased risk of coronary stenosis was found for the 
4G-allele comparing cases with coronary controls. This association was only 
observed for subjects younger than 60 years. Stratifying for overall background 
cardiovascular risk based on the Framingham Prediction Score showed only an 
association in the low-risk group. Comparing cases with population-based controls 
showed no association between the 4G/5G-polymorphism and coronary stenosis 
also not after stratification for cardiovascular risk factors. 
Results clearly depended on the type of controls. Coronary controls underwent the 
same selection procedures as the cases and one could expect them to have the 
same accuracy in reporting information. Furthermore, we do not expect 
misclassification between cases and coronary controls because of the large contrast 
between these two groups. On the other hand, coronary controls may not be 
representative of all non-diseased persons in the source population. Therefore in 
study 1 and 2 also population-based controls without clinical symptoms of coronary 
artery disease were included. Despite absence of symptoms it cannot be ruled out 
that some of the population-based controls may have had substantial coronary 
narrowing, which could have led to dilution of the association. Only in study 1 
population-based controls underwent carotid artery ultrasound echography which 
made substantial coronary atherosclerosis less likely. 
The genotype distribution within the population-based controls was not in Hardy-
Weinberg equilibrium. The 4G-allele frequency of this control group was high 
compared to other European control groups,14 which might be the reason for the 
absence of an association between the 4G/5G-polymorphism and coronary stenosis 
when using this control group. This could be caused by an unknown kind of selection 
or by differential misclassification. The latter is not very likely because the 
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investigator who performed the genotyping was blinded for case or control status. A 
subset of 129 genotypings (17%) was also repeated with a different method and no 
discrepancies were observed.17,23,26"28 The 4G-allele frequency of the coronary 
control group (0.53) was comparable to the frequency in the coronary control group 
of a comparable study (4G-allele frequency of 0.54).17 
The criteria for the case-control status were not exactly identical among the three 
studies. We improved the comparability with respect to stenosis between studies 1 
and 3, by excluding subjects from study 3 who did not fulfill the criteria of study 1. 
Other data collection methods (e.g. questionnaires, laboratory methods) also differed 
across the studies. We included "study" as explaining variable in all multivariate 
analysis to adjust for these differences. We furthermore performed analyses 
separately for the three studies, which gave essentially the same results. We 
therefore consider pooling of the three studies justified. 
Our finding of a not statistically significant increased risk of coronary stenosis for 
carriers of the 4G-allele (cases versus coronary controls) is in agreement with 
Gardemann et al,17 who found that the 4G/4G-genotype of the PAI-1 gene was 
associated with an increased risk of coronary stenosis (OR=1.31 (95%-CI: 1.04 -
1.65). The cases and the coronary controls were selected in the same way as in our 
study, but no population-based control group was included. Two studies did not 
observe an association between the 4G/5G-polymorphism and the presence9,29 or 
extent9 of coronary disease. 
Age was the only effect modifier, but only in the analysis using coronary controls. An 
increased risk for carriers of the 4G-allele on coronary stenosis was found for 
persons younger than 60 years (4G/4G: 2.09 (95%-CI: 1.15 - 3.78); 4G/5G: 1.64 
(95%-CI: 0.95 - 2.81) but not for older subjects. Eriksson et al. found an increased 
prevalence of the 4G-allele in patients with myocardial infarction under the age of 
45.2 When the polymorphism is associated with myocardial infarctions at younger 
age, one can expect a lower frequency of the 4G-allele in older case groups. This 
would imply that an effect of the 4G/5G-polymorphism in older study populations 
would be hard to detect. 
A priori we expected a stronger effect of the 4G/5G-polymorphism in high-risk groups 
than in low-risk groups. In a meta-analysis of lacoveillo et al. was found that "the risk 
of myocardial infarction for carriers of the 4G-alelle in populations at higher risk of 
myocardial infarction is almost twice that of low-risk populations".16 Similar results 
were found by Gardemann et al who observed that the association between the 
4G/5G-polymorphism and coronary artery disease predominantly existed within high-
risk subgroups.17 Our results do not support these previous findings. 
Genetic markers have the advantage of not being affected by other risk factors of 
cardiovascular disease. Since in this study no PAI-1 levels were measured there is 
no direct evidence that the 4G/5G-polymorphism was associated with PAI-1 levels. 
The 4G/5G-polymorphism has been associated with plasma PAI-1 in several 
studies,5"8 although not observed in all studies.11 In a study of Iwai et al it was 
suggested that the 4G/5G-polymorphism might have a stronger influence on the 
local production of PAI-1 at the site of plaque rupture than on plasma PAI-1 levels.30 
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In summary, we only observed a significant association between the 4G/5G-
polymorphism and coronary stenosis in a low-risk subgroup and only when 
compared to coronary controls. Our results do therefore not provide strong evidence 
for the hypothesis that the 4G-allele of the PAI-1 gene is associated with increased 
risk of coronary stenosis and do not confirm previous observations that the 
associations are stronger in high-risk populations. 
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ABSTRACT 
Background: Plasminogen Activator Inhibitor-type 1 (PAI-1) inhibits tissue-type 
Plasminogen Activator (t-PA) and is thereby the main inhibitor of fibrinolysis. At 
elevated levels, PAI-1 may increase risk of cardiovascular disease. The 4G/5G-
polymorphism affects the transcription of the PAI-1-gene and the 4G-allele has been 
associated with increased PAI-1 levels. We investigated whether plasma PAI-1, t-PA 
and the 4G/5G-polymorphism are associated with cardiovascular events at old age. 
Methods: We studied the associations of PAI-1 activity, t-PA antigen and the 
4G/5G-polymorphism with all-cause mortality, cardiovascular mortality, incident 
myocardial infarction, stroke and transient ischemic attack in a prospective study 
among 637 men and women aged 65-84 years. 
Results: The mean follow-up time was 7.8 years. The 4G/4G-genotype was 
associated with a decreased risk of stroke (relative risk (RR)=0.4 (95%-CI: 0.2 - 0.9), 
adjusted for age and sex)), transient ischemic attack (RR=0.3 (95%-CI: 0.1 - 0.8), 
and cardiovascular mortality (RR=0.5 (95%-CI: 0.1 - 1.0). The 4G/5G-polymorphism 
was not associated with risk of myocardial infarction. PAI-1 activity in the highest 
tertile gave an increased risk of stroke (RR=3.3 (95%-CI: 1.5 - 7.1), cardiovascular 
mortality (RR=2.3 (95%-CI: 1.2 - 4.4)) and all-cause mortality (RR=1.5 (95%-CI: 1.1-
2.1)), compared to the lowest tertile. 
Conclusions: Our results suggest a protective effect of the 4G-allele against stroke, 
which is notable given the direct relationship with PAI-1 level. We propose that a 
local increase in tissue PAI-1 associated with the 4G-allele may stabilize plaques, 
thereby reducing the risk of stroke. 
INTRODUCTION 
Plasminogen Activator Inhibitor-type 1 (PAI-1) is the main inhibitor of fibrinolysis and 
a potential risk factor for cardiovascular disease.1,2 PAI-1 forms a complex with 
tissue-type Plasminogen Activator (t-PA),2 thereby inhibiting formation of plasmin, 
the active component of fibrinolysis. PAI-1 levels have been shown to predict future 
coronary events in populations with angina pectoris3,4 or a history of myocardial 
infarction.5,6 However, in prospective studies in general (healthy) populations, PAI-1 
is not an independent risk factor for coronary events.7"10 
Being an acute phase reactant,11 an increased PAI-1 concentration may be a 
consequence rather than a cause of the cardiovascular disease process. 
Furthermore, many cardiovascular risk factors are associated with plasma PAI-1, 
which may confound the observed associations between PAI-1 and cardiovascular 
disease. Alternatively, it is possible that risk factors (e.g. overweight) partly exert 
their effect on cardiovascular disease through an effect on PAI-1. It is thus difficult to 
draw conclusions on the causality of PAI-1 based on observational epidemiological 
data. 
The 4G/5G-polymorphism is a common polymorphism in the promoter region of the 
PAI-1 gene.12 Both the 4G and 5G-allele have a binding site for an activator of 
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transcription. The 5G-allele has an additional binding site for a repressor, resulting in 
lower transcription rates of the PAI-1 gene compared to the 4G-allele.13,14 In general, 
higher PAI-1 levels are observed for the 4G/4G-genotype than for the 5G/5G-
genotype.15"17 An association between the 4G/5G-polymorphism and cardiovascular 
disease would provide support for a causal role of PAI-1. A recent meta-analysis of 9 
case-control studies on the association between the 4G/5G-polymorphism and risk 
of myocardial infarction showed a slightly increased risk for the 4G/4G-genotype 
(OR=1.20; (95% CI 1.04 - 1.39)).18 
The associations of PAI-1 and the 4G/5G-polymorphism with stroke received far less 
attention than the association with coronary heart disease. In the Northern Sweden 
MONICA study PAI-1 was not predictive for first stroke.19 Both case-control and 
prospective studies suggest a protective effect of the 4G-allele against stroke and 
transient ischemic attack.20'24 No prospective study in a single population has been 
performed that focused on both PAI-1 activity and the 4G/5G-polymorphism in 
relation to stroke. 
In the present longitudinal study we investigated whether PAI-1, t-PA and the 4G/5G-
polymorphism could predict for the occurrence of cardiovascular events in an elderly 
population. 
METHODS 
Study population 
The Arnhem Elderly Study is a population-based Dutch cohort study. In 1991/1992 a 
random sample of 1,793 non-institutional elderly men and women (aged 65-84 
years) was invited to participate in a health survey. The study included home 
interviews (n=1,012) and a physical examination (n=685). The sample was stratified 
for age and sex, as described in more detail elsewhere.25 A single non-fasting blood 
sample was available for 641 subjects. Because of technical reasons, data on both 
PAI-1 activity and the 4G/5G-polymorphism were missing for 4 subjects, leaving 637 
subjects for the analysis. For 31 of these subjects PAI-1 activity was missing and for 
8 subjects no 4G/5G-genotyping was available. Written informed consent was 
obtained from the participants before physical examination. The ethical committee of 
Wageningen University approved the study. 
Data collection 
Trained interviewers visited the participants at home for data collection on 
demographics, smoking habits, health status, and medication. Smoking status was 
coded as current, former or never. Body mass index (BMI) was calculated as weight 
divided by height squared (kg/m2). A history of cardiovascular disease was 
considered present if the participant reported a history of heart disease and/or 
stroke. Medication for cardiovascular disease was coded present in case of 
prescribed use of ACE-inhibitors, p-blockers, thrombolytic agents, lipid-lowering 
medications and/or salicylates during the 3 months prior to the interview. 
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Hypertension was defined as systolic blood pressures 160 mm Hg or diastolic blood 
pressure > 95 mm Hg or use of blood pressure lowering medication. 
Laboratory determinations 
Blood sampling was performed between 8.00 a.m. and 5.30 p.m. and time of blood 
sampling was recorded for every subject. Samples were stored at -80°C. Plasma 
PAI-1 activity was determined using the Chromolize™ kit (Biopool, Umea, Sweden). 
T-PA antigen was measured using the Imulyse® kit (Biopool, Umea, Sweden). DNA 
was isolated with standard techniques. The 4G/5G-genotyping was performed with 
the method described by Margaglione26 with some modifications. In brief, a mutated 
oligonucleotide was synthesized, which inserted a site for the BseLI enzyme within 
the product of amplification. PCR-products were digested at 55°C with the BseLI 
enzyme (MBI Fermentas, Vilnius, Lithuania). The fragments were fractionated by 
4%-agarose-gel electrophoresis. Serum total cholesterol was determined by an 
enzymatic method (CHOD-PAP). HDL-cholesterol and LDL-cholesterol were 
measured directly (Dimension®HDL method and N-geneous®LDL respectively). 
Serum insulin was determined with an immunometric assay (lmmulite®2000 insulin). 
C-reactive protein (CRP) was assessed using a highly sensitive ELISA procedure.27 
Follow-up 
Municipal registries provided data on mortality and migration of the study cohort at 
regular time intervals until February 2001. One person was lost to follow-up due to 
emigration. Data on morbidity and cause-specific mortality were obtained from 
general practitioners (GP), either directly or by one of the authors (T.H.) by means of 
a standard questionnaire. Follow-up data for incident cardiovascular events and 
cause-specific mortality were available for 518 subjects (81%). Reasons for missing 
data were: (1) subjects did not give permission at baseline (n=39, 6%), (2) the 
present GP could not be traced (n=31, 5%), (3) the GP refused participation (n=39, 
8%), or (4) could not provide valid data (n=10, 2%). Baseline characteristics of 
elderly for whom data from medical records were missing, were similar to those 
included in the analysis, except for serum cholesterol (6.0 versus 6.3 mmol/L, 
P=0.02). No differences were observed for age and gender distribution. 
Events were coded by a medical doctor (E.G.) according to the International 
Classification of Diseases, Tenth Revision (ICD-10). Endpoints used in the analysis 
comprised all-cause mortality, death due to major cardiovascular disease (ICD-
codes: I00-I96), incidence of myocardial infarction (121-122, both fatal and non-fatal), 
incidence of stroke (160-169, fatal and non-fatal), and incidence of transient ischemic 
attack (G45). In case of recurrent events, only the first event was considered in the 
analyses. 
Statistical analysis 
Differences in subjects characteristics among the three 4G/5G genotypes were 
tested with ANOVA (continuous variables) or x2-testing (categorical variables). A x2-
test was performed to evaluate whether the 4G/5G-polymorphism was in Hardy-
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Weinberg equilibrium. Spearman's correlation coefficients (rs) were calculated of 
PAI-1 with other cardiovascular risk factors. The Cox-proportional hazard model was 
used to calculate hazard rate ratios (subsequently referred to as relative risks, RR) 
for tertiles of PAI-1 and t-PA respectively, with the lower tertile as reference. Trend 
analyses were performed by including the median values per tertile in the model. For 
analyzing the trend across 4G/5G-genotypes the number of 4G-alleles was added to 
the model. The RRs were adjusted for age and sex ('Model 1'), and additionally for 
BMI, smoking status (current, former, never), history of cardiovascular disease, use 
of cardiovascular medication, hypertension, total cholesterol, LDL-cholesterol and 
CRP ('Model 2'). In the analyses of PAI-1 and t-PA additional adjustment for time of 
blood sampling was performed because of the known circadian variation of these 
variables. The SAS system was used for all statistical analyses. A P-value of 0.05 
was considered statistically significant. 
RESULTS 
The baseline characteristics of the study population by 4G/5G genotype are 
presented in Table 6.1. 
Table 6.1. Characteristics of the study population by the 4G/5G-polymorphism 
Men (%) 
Age (yr) 
BMI (kg/m2)* 
Smoking status (%) 
Current smokers 
Former smokers 
Never smokers 
Alcohol consumers (%)* 
Diabetes mellitus (%)** 
History of cardiovascular disease* 
Use of cardiovascular medications 
Serum total cholesterol (mmol/L) 
Serum HDL-cholesterol (mmol/L) 
Serum LDL-cholesterol (mmol/L) 
Serum CRP (ng/mL) 
Serum Insulin (pmol/L) 
Plasma PAI-1 activity (lU/mLf 
Plasma t-PA antigen (ng/mL)* 
(%) 
* (%) 
4G/4G 
(n=193) 
54 
73.0 ± 5.7 
25.4 ± 3.3 
31 
37 
33 
69 
8 
21 
18 
6.3 ±1.2 
1.4 ±0.5 
3.8 ±1.1 
2.0(1.0-4.1) 
136(95-213) 
2.2 (0.6 - 5.4) 
10.2 ±3.8 
4G/5G 
(n=287) 
52 
74.0 ± 5.4 
26.2 ±4.1 
24 
43 
33 
72 
4 
22 
20 
6.2 ±1.2 
1.4 ±0.4 
3.7 ±1.0 
2.3(1.2-4 2) 
140(97-228) 
2.2 (0.8 - 6 
10.7 ±3.9 
0) 
5G/5G 
(n=149) 
54 
74.0 ± 5.9 
25.8 ± 3.7 
21 
46 
34 
79 
3 
19 
21 
6.2 ±1.3 
1.4 ±0.3 
3.8 ±1.0 
2.0(1.0-4.0) 
135(89-218) 
1.4(0.3-3.8) 
9.9 ±3.7 
Continuous variables are presented as mean ± SD or as median (Q1-Q3) for skewed data. 
* P<0.10; fP<0.05 for difference between the genotypes. Statistical testing was performed with 
ANOVA for continuous variables and the x2 test for categorical variables. For skewed variables log-
transformed data were used; * Self-reported, see method section. 
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The frequency distribution of the 4G/4G, 4G/5G, and 5G/5G variants was 31%, 46% 
and 24%, respectively. The 4G/5G-polymorphism distribution was not in Hardy-
Weinberg equilibrium (x2=4.3; 1d/, P<0.05). Median plasma PAI-1 activity was lower 
for the 5G/5G genotype compared to both other genotypes (1.4 versus 2.2 lU/mL, 
P=0.02). Only 1% of the variance in PAI-1 activity was explained by the 4G/5G-
polymorphism. Plasma PAI-1 activity was positively associated with BMI, serum 
LDL-cholesterol, CRP and insulin (rs ranging from 0.13 to 0.34, all P< 0.05). Age and 
HDL cholesterol were negatively associated with PAI-1 (rs=-0.11, P=0.005 and rs= 
-0.31, P<0.001, respectively). PAI-1 activity was strongly correlated with t-PA antigen 
(rs=0.64, PO.001). 
Table 6.2. Relative risks (95%-CI) of fatal and non-fatal cardiovascular incidents and all-
cause mortality with PAI-1 activity in 492 Dutch elderly men and women. 
Median (lU/mL) 
Incident stroke 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
Incident TIA 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
Incident Ml 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
CVD mortality 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
All-cause mortality* 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
<0.9 
0.2 
10/1,296 
15/1,251 
8/1,294 
18/1,309 
78 /1,684 
Tertiles of PAI-1 activity (lU/mL) 
0.9-3.9 
2.0 
25/1,266 
2.8(1.4-5.9) 
4.9(2.1 -11.8) 
17/1,262 
1.1 (0.6-2.3) 
1.4(0.6-3.3) 
10/1,280 
1.3(0.5-3.3) 
1.1 (0.4-3.0) 
30/1,314 
1.9(1.1 -3.5) 
2.2(1.1 -4.4) 
87/1,662 
1.2(0.9-1.7) 
1.2(0.9-1.7) 
>3.9 
8.4 
23/1,156 
3.3(1.5-7.1) 
6.1 (2.5-14.6) 
19/1,117 
1.8(0.9-3.7) 
2.2(1.0-4.9) 
12/1,132 
2.0 (0.8 - 5.2) 
1.5(0.6-4.3) 
26/1,185 
2.3(1.2-4.4) 
3.3(1.6-6.7) 
85/1,595 
1.5(1.1 -2.1) 
1.8(1.2-2.5) 
"trend 
0.016 
0.001 
0.09 
0.06 
0.14 
0.38 
0.025 
0.003 
0.025 
0.002 
TIA = transient ischemic attack; Ml = myocardial infarction; CVD = cardiovascular disease. 
* Model 1: adjusted for sex, age and time of blood sampling. 
f
 Model 2: adjusted for sex, age, time of blood sampling, BMI, smoking status (current, former, never), 
history of cardiovascular disease, hypertension, total cholesterol, LDL-cholesterol, insulin and CRP. 
* Survival analyses for all-cause mortality included 606 elderly. 
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Table 6.3. Relative risks (95%-CI) of fatal and non-fatal cardiovascular incidents, all-cause 
mortality with the 4G/5G-polymorphism in 518 Dutch elderly men and women 
4G/5G-polymorphism 
Incident stroke 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
TIA 
Cases/Person-years 
RR, model 1* 
RR, model 2* 
Incident Ml 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
Mortality CVD 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
All-cause mortality* 
Cases/Person-years 
RR, model 1* 
RR, model 2 f 
5G/5G 
(reference) 
18/925 
16/887 
6/938 
23/952 
64/1,212 
4G/5G 
32/1,747 
0.9(0.5-1.6) 
1.0(0.5-1.8) 
26/1,716 
0.8(0.4-1.5) 
0.8(0.4-1.6) 
16/1,737 
1.4(0.6-3.6) 
1.7(0.6-4.8) 
39/1,798 
0.9(0.5-1.5) 
0.9(0.5-1.6) 
130/2,311 
1.1 (0.8-1.4) 
1.0(0.8-1.4) 
4G/4G 
9/1,177 
0.4 (0.2 - 0.9) 
0.5(0.2-1.1) 
7/1,168 
0.3(0.1 -0.8) 
0.3(0.1 -0.8) 
9/1,167 
1.1 (0.4-3.2) 
1.3(0.4-3.9) 
15/1,194 
0.5(0.3-1.0) 
0.5(0.2-1.1) 
71/1,607 
0.9(0.6-1.2) 
0.8(0.6-1.2) 
' t rend 
0.021 
0.09 
0.015 
0.011 
0.89 
0.75 
0.043 
0.07 
0.32 
0.21 
TIA = transient ischemic attack; Ml = myocardial infarction; CVD = cardiovascular disease. 
" Model 1: adjusted for sex and age. 
1
 Model 2: adjusted for sex, age, BMI, smoking status (current, former, never), hypertension, history of 
cardiovascular disease, total cholesterol, LDL-cholesterol, insulin and CRP. 
* Survival analyses for all-cause mortality included 629 elderly. 
During the follow-up period 48% of the men and 35% of the women died. Variables 
predictive for all-cause mortality were sex, smoking status, hypertension, CRP and 
history of cardiovascular disease (all P<0.05). Measures of cholesterol (total, HDL 
and LDL) were not significantly associated with all-cause mortality (data not shown). 
Data from medical records were available for 518 elderly (250 women and 268 men). 
The mortality rate of this sub-sample was 34% and 46% for women and men 
respectively. In men, 38% of the deaths were due to cardiovascular disease, and for 
women this percentage was 45%. Mean follow-up time was 7.8 years. During the 
follow-up period, 31 cases of first myocardial infarction (Ml), 59 cases of first stroke 
and 51 cases of first transient ischemic attack (TIA) were recorded. 
The results of the Cox-proportional hazard analyses on all-cause mortality, 
cardiovascular mortality, and incidence of cardiovascular events in tertiles of PAI-1 
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activity are presented in Table 6.2. PAI-1 activity in the upper tertile (> 3.9 lU/mL) 
gave an increased risk of stroke (RR=3.3 (95%-CI: 1.5 - 7.1)), cardiovascular 
mortality (RR=2.3 (95%-CI: 1.2 - 4.4)) and all-cause mortality (RR=1.5 (95%-CI: 1.1 -
2.1)). For these endpoints the trend across the tertiles was statistically significant 
(P<0.05), also after adjustment for cardiovascular risk factors (model 2, see method 
section). The significant trend across the PAI-1 tertiles persisted for incident stroke 
after exclusion of 129 subjects with a history of cardiovascular disease (data not 
shown). PAI-1 activity was also positively associated with incidence of Ml and TIA, 
but the risk estimates did not reach statistical significance (RR=2.0 (95%-CI: 0.8 -
5.2) and RR=1.8 (95%-CI: 0.9 - 3.7), respectively). 
Table 6.4. Relative risks (95%-CI) of fatal and non-fatal cardiovascular incidents, all-cause 
mortality with t-PA antigen in 464 Dutch elderly men and women. 
Tertiles of t-PA antigen (ng/mL) 
<8.5 8.5-11.7 > 11.7 
Median (ng/mL) 6.9 
Incident stroke 
Cases/Person-years 20/1,259 
RR, model 1* 
RR, model 2 f 
TIA 
Cases/Person-years 20/1,225 
RR, model 1* 
RR, model 2 f 
Incident Ml 
Cases/Person-years 4/1,281 
RR, model 1* 
RR, model 21" 
Mortality CVD 
Cases/Person-years 24/1,284 
RR, model 1* 
RR, model 2 f 
All-cause mortality* 
Cases/Person-years 63/1,641 
RR, model 1* 
RR, model 2* 
9.9 13.9 
16/1,151 
0.8(0.4-1.6) 
0.8(0.4-1.8) 
15/1,119 
0.7(0.4-1.4) 
0.7(0.3-1.5) 
19/1,109 
5.2(1.8-15.4) 
4.2(1.4-12.8) 
16/1,184 
0.7(0.4-1.3) 
0.8(0.4-1.5) 
76/1,577 
1.2(0.8-1.7) 
1.2(0.8-1.7) 
21/1,067 
1.3(0.7-2.5) 
1.4(0.7-3.0) 
15/1,040 
0.9(0.4-1.8) 
0.8(0.4-1.8) 
7/1,069 
1.9(0.6-6.7) 
1.1 (0.3-4.0) 
33/1,094 
1.8(1.0-3.1) 
1.8(1.0-3.4) 
99/1,438 
1.7(1.3-2.4) 
1.7(1.2-2.4) 
0.36 
0.28 
0.74 
0.64 
0.54 
0.56 
0.022 
0.037 
0.001 
0.003 
TIA = transient ischemic attack; Ml = myocardial infarction; CVD = cardiovascular disease. 
* Model 1: adjusted for sex, age and time of blood sampling. 
f
 Model 2: adjusted for sex, age, time of blood sampling, BMI, smoking status (current, former, never), 
history of cardiovascular disease, hypertension, total cholesterol, LDL-cholesterol, insulin and CRP. 
*.Survival analyses for all-cause mortality included 573 elderly. 
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In Table 6.3 RRs for all-cause mortality and cardiovascular events in strata of 4G/5G 
genotype are presented. After adjustment for age and sex, the 4G/4G-genotype was 
associated with a decreased risk of stroke (RR=0.4 (95%-CI: 0.2 - 0.9)), TIA (RR=0.3 
(95%-CI: 0.1 - 0.8)), and cardiovascular mortality (RR=0.5 (95%-CI: 0.3 - 1.0)). 
Further adjustments (model 2) did not weaken these associations. Restricting the 
analysis to ischemic stroke yielded a similarly decreased risk for the 4G/4G-
genotype (RR=0.2 (95%-CI: 0.04 - 1.0), model 2). No significant associations were 
observed between the 4G/5G-polymorphism and the other endpoints (Ptrend>0.05). 
Table 6.4 shows findings for t-PA antigen, which appeared to be predictive for all-
cause and cardiovascular mortality (both P-trend < 0.05). These associations 
remained statistically significant after adjusting for cardiovascular risk factors. T-PA 
was associated with an increased risk of Ml in the mid-tertile, but not in the upper 
tertile. T-PA antigen was not associated with incidence of stroke or TIA. 
DISCUSSION 
In a general population of elderly we observed a protective effect of the 4G/4G-
genotype against incident stroke and TIA. For PAI-1 activity, however, the opposite 
was observed, namely a higher risk of stroke and TIA at increasing levels. The 
associations between PAI-1 level and risk of Ml and cardiovascular mortality did not 
reach statistical significance. 
We are among the first to investigate PAI-1 activity and the 4G/5G-polymorphism 
simultaneously in relation to stroke in a prospective, population-based study. Our 
finding of a protective effect of the 4G-allele against stroke is in agreement with 
previous case-control and prospective studies20"24 (see Figure 1). One Korean study 
yielded contrasting data.28 The authors of this study suggested that this discrepancy 
might be due to racial differences. Johansson ef al. found no significant association 
between PAI-1 antigen and risk of a (first) stroke in a population-based case-control 
study, but their estimate points into the same direction as ours (odds ratio of 1.3 
(95%-CI: 0.7-2.6) for upper versus lower PAI-1 quartile).19 Stroke as considered in 
the present study is a heterogeneous entity, comprising both ischemic and 
hemorrhagic subtypes. The majority was ischemic, and restricting the analyses to 
these events yielded similar results for the 4G/5G polymorphism, PAI-1 level and t-
PA. The number of hemorrhagic strokes was too low for sub-group analyses. 
The underlying mechanism explaining the protective effect of the 4G-allele against 
stroke is probably in local tissue processes and not in fibrinolysis. PAI-1 in the 
atherosclerotic plaque might protect the fibrous cap against degradation by 
metalloproteinases, and subsequently against rupture. Alternatively, PAI-1 may 
protect against laminin degradation and brain cell death.29 Our results suggest that 
tissue proteolysis en stabilization of plaques are more important pathways in stroke 
than in acute Ml. 
High levels of PAI-1 have been shown to predict (recurrent) coronary events in 
populations with angina pectoris3,4 or a history of Ml,6 but not in healthy 
populations.8'10 In our Arnhem Elderly Study, a (non-significantly) increased risk of 
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Ml was found at increased PAI-1 levels. Only one other prospective study on PAI-1 
and cardiovascular disease in elderly has been performed, namely the 
Cardiovascular Health Study.7 In this cohort of elderly without prevalent 
cardiovascular disease, PAI-1 was not associated with the occurrence of coronary 
events. In our study, 20% of the elderly had a history of cardiovascular disease. We 
adjusted both for prevalent cardiovascular disease and of use of cardiovascular 
medication, which did not alter the results. Similar findings were also obtained after 
adjustment for CRP, an acute-phase protein strongly associated with 
atherosclerosis.30 Excluding subjects with a cardiovascular history affected our 
findings neither. 
Case-control 
Hindorff, 2002 
Endler, 2000 
Catto, 1997 
Hindorff, 2002 
Bang,2001 
Prospective 
Roest, 2000 
Heijmans, 1999 
Hoekstra, present 
Ischaemic 
Ischaemic (stroke + TIA) 
Total 
Hemorrhagic 
Ischeamic 
Total (fatal) 
Total (fatal) 
Total (fatal + non-fatal) 
0.1 10 
Relative Risk (4G/4G vs 5G/5G) 
Figure 6.1. Overview of studies investigating the association between the 4G/5G-
polymorphism and stroke. Data are presented as point estimates with corresponding 95%-
confidence intervals. For as far as possible adjusted estimates were used. 
If PAI-1 levels were causally associated with cardiovascular risk, one would expect 
to find also an increased risk for the 4G/4G-genotype. In our population, however, 
this was not the case, which is in agreement with results of previous prospective 
studies.24,31 The weak association between genotype and phenotype might explain 
the lack of consistency between the results of PAI-1 levels and the 4G/5G-
polymorphism. We could explain only 1% of the variance in PAI-1 activity by the 
4G/5G-polymorphism. The association between the 4G/5G-polymorphism and 
plasma PAI-1 levels may not be as strong as previously suggested.32"34 It is possible 
that the 4G/5G-polymorphism mainly determines the magnitude of PAI-1 response 
and does not strongly affect PAI-1 levels in resting conditions. Furthermore, plasma 
PAI-1 levels may not adequately reflect local PAI-1 levels, e.g. in vascular tissue. 
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A limitation of our study is that the study population was not in Hardy-Weinberg 
equilibrium. The reason for this is not known and unexpected for a random sample. 
The frequency of the 4G/5G-genotype is somewhat lower than expected on basis of 
allele-frequencies. The only suggestion that we have is that the restriction to non-
institutionalized individuals might have caused selection related to the 4G/5G-
polymorphism. 
Due to comorbidity, it is sometimes difficult to accurately code the underlying cause 
of death, and misclassification is thus possible. However, we consider it unlikely that 
differential misclassification across the genotypes might have occurred. Data on 
cause-specific mortality and incidence of cardiovascular events were missing for 
19% of the study population. However, loss to follow-up was on the level of the 
general practitioner rather than the individual, and it is therefore unlikely that loss to 
follow-up has largely influenced the observed associations for PAI-1 and the 4G/5G-
polymorphism. 
In conclusion, our results suggest a protective role of the 4G-allele in the 
development of stroke. Although the 4G-allele is generally associated with increased 
PAI-1 levels, we did not observe an inverse association between PAI-1 and stroke. 
More research is needed on the mechanisms that underlie the potential protective 
effect of the 4G-allele. More prospective studies on incident stroke including both 
PAI-1 level and the 4G/5G-polymorphism are needed to confirm our findings. 
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Abstract 
Background: Obesity plays a key role in the metabolic syndrome and it has 
consistently been shown that C-reactive protein (CRP) is associated with markers of 
obesity. We studied the associations of CRP with components of the metabolic 
syndrome in normal-weight and overweight elderly. 
Methods: Data analyses were performed within the Arnhem Elderly Study, a 
population-based study of 605 free-living Dutch elderly aged 65-84 years. Data 
collection included anthropometry, plasma C-reactive protein (CRP), plasma 
plasminogen activator inhibitor 1 (PAI-1), serum insulin, serum lipids, blood pressure, 
lifestyle and medical history. Overweight was defined as a body mass index (BMI) of 
25 kg/m2, or above. CRP was log-transformed (In-CRP) because of the skewed 
distribution. Associations of In-CRP with components of the metabolic syndrome 
were studied by multivariate linear regression analysis, in strata of gender and 
overweight status. Adjustments were made for age, physical activity, and smoking. 
Results: A total of 322 subjects (53%) were overweight. In normal-weight elderly 
women, In-CRP was significantly associated with BMI, PAI-1, serum insulin, and 
HDL-cholesterol after adjustment for age, physical activity and smoking. In 
overweight women, however, these relationships were weak and no longer 
statistically significant. Also in men, the associations of In-CRP with PAI-1 and serum 
insulin appeared to be modified by overweight status but interaction terms did not 
reach statistical significance. 
Conclusion: In the elderly, CRP could be a more important component of the 
metabolic syndrome in women than in men. Furthermore, our data suggest only a 
minor role of CRP in the metabolic syndrome in the presence of overweight. 
INTRODUCTION 
C-reactive protein (CRP) is an acute-phase protein that is secreted by the liver in 
response to pro-inflammatory cytokines. Concentrations above 10 mg/L are 
generally used to indicate clinically relevant or acute inflammation. Low-grade 
chronic inflammation (CRP<10 mg/L) has been shown to predict risk of 
cardiovascular events in both apparently healthy populations and in cardiovascular 
patients.1,2 In the Physicians' Health Study an increased plasma concentration of 
CRP (>2.10 mg/L) was associated with a twofold increased risk of stroke and a 
threefold increased risk of myocardial infarction compared to low CRP values (<0.55 
mg/L).3, 4 A number of mechanisms by which CRP might directly promote vascular 
disease have been postulated, including activation of the classical complement 
system in the arterial wall.5,6 Alternatively, the atherosclerotic process in the vascular 
wall may increase CRP synthesis. This hypothesis would imply that CRP is a marker 
of the extent and/or severity of the atherosclerotic process, rather than a causal 
agent. In addition, the observed association of CRP with cardiovascular disease may 
be due to confounding by smoking and other cardiovascular risk factors. 
It has been suggested that CRP is involved in the metabolic syndrome.7"9 Obesity is 
a key factor in the metabolic syndrome, with possibly a central role for cytokines 
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produced by adipose tissue.10 Body mass index (BMI) has been shown to be an 
important correlate of CRP in both elderly and younger populations.11"14 Examining 
the association of CRP with components of the metabolic syndrome by overweight 
status may provide more insight into the complex role of CRP in the development of 
cardiovascular disease. We addressed this research question in a general 
population of 605 Dutch elderly. 
METHODS 
Study population 
From October 1991 until April 1992 a random sample of 1,793 non-institutionalized 
elderly residents of Arnhem, a Dutch city of approximately 133,000 inhabitants, were 
invited to participate in a study on lifestyle and health. The selection of participants is 
described in detail elsewhere.15 A total of 1,012 elderly man and women between 65-
84 years of age were interviewed, and 685 were physically examined. From 643 
subjects a non-fasting blood sample was taken. Data from 605 participants for whom 
data on plasma CRP was available were included in the present analysis. The ethics 
committee of Wageningen University approved the study and written informed 
consent was obtained from all participants. 
Data collection 
Trained interviewers visited the participants at home and collected data on physical 
activity, food patterns, drinking and smoking habits, activities of daily living, chronic 
diseases, use of health care and medication. Physical activity was assessed by a 
validated questionnaire on household activities, sports and leisure time activities, 
developed for free-living elderly.16 Activity scores were computed from the intensity 
and duration of specific activities. Two categories of physical activity level (low and 
high) were created, based on sex-specific median activity scores of the study 
population (i.e., 9.7 for men and 5.7 for women). The presence of chronic diseases 
was assessed by a questionnaire. Subjects reported for each disease whether they 
had visited a general practitioner or medical specialist in the past 3 months. 
Cardiovascular disease was considered present if the subject reported a history of 
coronary heart disease and/or stroke. 
Non-fasting samples have been stored at -80°C. Plasma CRP was assessed using a 
highly sensitive ELISA procedure.17 Serum total cholesterol was determined by an 
enzymatic method (CHOD-PAP). HDL-cholesterol and LDL-cholesterol were 
measured directly (Dimension® HDL method and N-geneous®LDL respectively). 
Serum insulin was determined with an immunometric assay (lmmulite®2000 insulin). 
PAI-1 activity in plasma was determined using the Chromolize™ kit (Biopool, Umea, 
Sweden). Systolic and diastolic blood pressure were measured twice in supine 
position with a random-zero sphygmomanometer. The mean of the two 
measurements was used in the analyses. Mean arterial pressure (MAP) was 
calculated as 'diastolic blood pressure + 1/3 [systolic blood pressure - diastolic blood 
pressure]'. Hypertension was defined as systolic blood pressure >160 mmHg and/or 
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diastolic blood pressure >95 mmHg and/or use of antihypertensive medication. Body 
weight was measured to the nearest 0.5 kilogram on a calibrated weighing scale with 
indoor clothing and without shoes. Height was measured to the nearest 0.5 cm using 
a wall-mounted measuring tape. Body mass index (BMI) was calculated as weight 
divided by squared height (kg/m2). 
Data analysis 
Spearman correlation coefficients (rs) were calculated to examine associations 
among cardiovascular risk factors, i.e., age, plasma CRP, serum insulin, PAI-1 
activity, HDL-cholesterol, BMI and MAP. Spearman correlations were also obtained 
after stratification by gender and overweight, defined as a body mass index >25 
kg/m2. Plasma CRP values were log-transformed to improve normality (In-CRP). 
Multivariate linear regression analysis was performed with In-CRP as the dependent 
variable and cardiovascular risk factors as the independent variables, in men and 
women separately and in strata of overweight. Findings were additionally adjusted 
for age, physical activity ('high' vs. 'low') and smoking status (current, past or never). 
To test whether the observed associations differed between normal-weight and 
overweight elderly, an interaction term (overweight (0,1)*variable of interest) was 
added to the regression model. Analyses were repeated after exclusion of subjects 
with a self-reported history of cardiovascular disease and subjects with a plasma 
CRP value above 10 mg/L. Two-sided P-values below 0.05 were considered 
statistically significant. 
RESULTS 
Characteristics of the population are given in Table 7.1. Median CRP levels were 
slightly higher in men than in women (2.4 mg/L vs. 2.1 mg/L). The percentage of 
current smokers was twice as high in men (33%) than in women (16%). Among men, 
10% had never smoked compared to 59% in women. In 16 men (5%) and 4 women 
(1%) a CRP value above 10 mg/L was observed. Of the men, 50% were overweight 
(BMI > 25 kg/m2) compared to 57% of the women. The number of women using 
hormone replacement therapy was negligible (n=4,1.4%). 
BMI was the strongest correlate of CRP in women (rs=0.39, PO.001). The 
correlation between BMI and CRP in men was weak and did not reach statistical 
significance (rs=0.09, P=0.11). CRP was positively correlated both with PAI-1 (rs= 
0.21 and rs=0.24 for men and women, respectively, both PO.001) and the mean 
arterial pressure (rs= 0.12 (P=0.030) and rs=0.15 (P=0.010) for men and women, 
respectively). CRP was negatively correlated with HDL-cholesterol (rs= -0.24 and rs= 
-0.28 for men and women, respectively, both P<0.001). CRP was furthermore 
correlated with total and LDL-cholesterol in men (both rs=0.12, P=0.03) and with 
insulin in women (rs=0.15, P=0.013). CRP was not correlated with age, neither in 
men nor in women. CRP was lower in physically active than in sedentary men 
(geometric means: 1.87 vs. 2.95 mg/L, respectively, P<0.001) and women (1.57 vs. 
2.35 mg/L, respectively, P=0.008). No significant differences in CRP concentrations 
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were observed between current, former and never smokers, or between alcohol 
consumers and abstainers. 
Table 7.1. Characteristics of a general population of 605 Dutch elderly 
Men 
(n = 315) 
Women 
(n = 290) 
P-value* 
Age (yr) 
BMI (kg/m2) 
Blood pressure (mmHg) 
Systolic 
Diastolic 
MAP 
Hypertensive (%) 
History of cardiovascular disease ("/of 
Smoking status (%) 
Current 
Past 
Never 
Alcohol consumers (%) 
Physical activity score 
Serum total cholesterol (mmol/L) 
Serum HDL-cholesterol (mmol/L) 
Serum LDL-cholesterol (mmol/L) 
Serum insulin (pmol/L) 
Plasma PAI-1 activity (lU/mL) 
Plasma CRP (mg/L) 
73.2 ± 5.4 
25.4 ±3.1 
148 ±20 
81 ±11 
103 ±13 
42 
25 
10 
57 
33 
82 
9.7(4.2-13.9) 
6.0 ±1.2 
1.3 ±0.3 
3.7 ±1.0 
136(96-222) 
2.1 (0.6-5.4) 
2.4(1.2-4.7) 
74.1 ±5.9 
26.5 ±4.5 
153 ±21 
82 ±11 
106 ±12 
53 
17 
59 
26 
16 
62 
5.7(3.2-
6.5 ±1.2 
1.5 ±0.4 
3.8 ±1.0 
142(98-
1.8(0.5-
2.1 (1.0-
8.9) 
225) 
5.5) 
3.8) 
0.06 
0.001 
0.004 
0.10 
0.012 
0.18 
0.001 
0.001 
0.001 
<0.001 
<0.001 
<0.001 
0.044 
0.78 
0.59 
0.06 
MAP: mean arterial pressure; Continuous variables are given as mean + SD, and skewed data as 
median (Q1-Q3); * P-values for differences between men and women. Statistical testing was 
performed with the t-test for independent samples (continuous variables), Wilcoxon two-sample test 
(non-parametric variables) or % test (categorical variables); f Self-reported history of coronary heart 
disease and/or stroke. 
In Table 7.2 results from multivariate regression analyses with In-CRP as the 
dependent variable are presented. Age, BMI, physical activity ('high' vs. 'low'), 
smoking status (current, former and never), serum total cholesterol, serum HDL-
cholesterol, mean arterial pressure (MAP), serum insulin, and plasma PAI-1 activity 
were simultaneously included as independent variables. In men, physical activity and 
HDL-cholesterol and MAP were the variables that contributed significantly to the 
model (P<0.05). In women, only BMI and HDL-cholesterol were significantly 
associated with In-CRP. All variables together explained 1 1 % of the variance in In-
CRP in men compared to 2 1 % in women (adjusted R2). In women BMI alone 
explained 15% of the variance in In-CRP. 
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Table 7.2. Association between cardiovascular risk factors and log-transformed plasma CRP 
in elderly men and women, obtained by multivariate regression analysis 
Age (yr) 
BMI (kg/m2) 
Physical activity ('high' vs. 'low') 
Smoking status* 
Past 
Current 
Serum lipids (mmol/L) 
Total cholesterol 
HDL cholesterol 
MAP(perlOmmHg) 
Insulin (per 10 pmol/L) 
PAI-1 activity (lU/mL) 
Adjusted R2 (full model) 
0.02 
-0.003 
-0.33 
-0.26 
-0.20 
0.08 
-0.75 
0.01 
0.001 
0.01 
B (95%-^)* 
Men(n=315) 
(-0.01;0.04) 
(-0.05; 0.04) 
(-0.60; -0.07)* 
(-0.69; 0.18) 
(-0.67; 0.26) 
(-0.03; 0.20) 
(-1.20; -0.30)* 
(0.03; 0.24)* 
(-0.01;0.01) 
(-0.01:0.02) 
11% 
Women (n=290) 
0.01 
0.07 
-0.16 
0.22 
0.26 
0.05 
-0.79 
0.11 
-0.002 
0.005 
(-0.02; 0.03) 
(0.03; 0.10)* 
(-0.47; 0.16) 
(-0.13;0.57) 
(-0.14; 0.66) 
(-0.06; 0.16) 
(-1.22;-0.36)* 
(-0.02; 0.23) 
(-0.01;0.005) 
(-0.02; 0.03) 
21% 
* P<0.05 in the multivariate regression model; f Linear regression coefficient (p) denotes change in 
log-transformed plasma CRP (In-CRP) per unit change in cardiovascular risk factor, with 95%-
confidence interval in parentheses; * Dummy variables for past and current smoking were entered into 
the regression model, with never-smoking as reference. 
Stratification by BMI (<25 vs. >25 kg/m2) was performed to examine the associations 
of CRP with components of the metabolic syndrome by overweight status, both in 
men (Table 7.3) and in women (Table 4). In normal-weight women a strong 
association between BMI and In-CRP was observed, which appeared to be absent in 
overweight women (Figure 7.1). The interaction was statistically significant (P=0.005) 
also after adjustment for age, physical activity and smoking status (Table 7.5). BMI 
was not associated with In-CRP in men, neither in normal-weight nor in overweight 
subjects. Further adjustment for other potential confounders did not materially alter 
the results (data not shown). 
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Table 7.3. Spearman correlation coefficients among components of the metabolic syndrome 
in 315 elderly men, stratified by overweight 
BMI <25 kg/m2 
Plasma CRP (mg/L) 
BMI (kg/m2) 
PAI-1 activity (lU/mL) 
Serum insulin (pmol/L) 
HDL-C (mmol/L) 
MAP (mmHg) 
BMI >25 kg/m2 
Plasma CRP (mg/L) 
BMI (kg/m2) 
PAI-1 activity (lU/mL) 
Serum insulin (pmol/L) 
HDL-C (mmol/L) 
MAP (mmHg) 
CRP 
(mg/L) 
-
0.06 
0.30* 
0.18* 
-0.33* 
0.18* 
-
0.03 
0.06 
-0.03 
-0.11 
0.07 
BMI 
(kg/m2) 
-
0.23* 
0.17* 
-0.14 
0.19* 
-
0.11 
-0.03 
-0.05 
0.11 
PAI-1 
(lU/mL) 
-
0.26* 
-0.29* 
0.03 
-
0.24* 
-0.16* 
0.12 
Insulin 
(pmol/L) 
-
-0.30* 
0.03 
-
-0.09 
-0.10 
HDL-C 
(mmol/L) 
• 
-
0.08 
-
0.07 
HDL-C: serum HDL-cholesterol; MAP: mean arterial pressure; * P<0.05; * P<0.01; * P<0.001. 
Table 7.4. Spearman correlation coefficients among components of the metabolic syndrome 
in 290 elderly women, stratified by overweight 
BMI <25 kg/m2 
Plasma CRP (mg/L) 
BMI (kg/m2) 
PAI-1 activity (lU/mL) 
Serum insulin (pmol/L) 
HDL-C (mmol/L) 
MAP (mmHg) 
BMI >25 kg/m2 
Plasma CRP (mg/L) 
BMI (kg/m2) 
PAI-1 activity (lU/mL) 
Serum insulin (pmol/L) 
HDL-C (mmol/L) 
MAP (mmHg) 
CRP 
(mg/L) 
-
0.32* 
0.24* 
0.15 
-0.31* 
0.12 
-
0.13 
0.02 
0.04 
-0.10 
0.13 
BMI 
(kg/m2) 
-
0.15 
0.13 
-0.11 
0.17 
-
0.21* 
0.27* 
-0.11 
0.04 
PAI-1 
(lU/mL) 
-
0.16 
-0.29* 
0.003 
-
0.32* 
-0.30* 
0.06 
Insulin 
(pmol/L) 
-
-0.29* 
0.03 
-
-0.37* 
-0.03 
HDL-C 
(mmol/L) 
-
-0.09 
-
0.09 
HDL-C: serum HDL-cholesterol; MAP: mean arterial pressure ;* P<0.05; * P<0.01; * P<0.001. 
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Table 7.5. Associations of In-CRP with components of the metabolic syndrome in elderly 
men and women, stratified by overweight 
Men (n=315) 
BMI (kg/m2) 
PAI-1 activity (l l l /mL) 
Serum insulin (per 10 pmol/L) 
HDL-C (mmol/L) 
MAP (per 10 mmHgf 
Women (n=290) 
BMI (kg/m2) 
PAI-1 activity (l l l /mL) 
Serum insulin (per 10 pmol/L) 
HDL-C (mmol/L) 
MAP (per lOmmHg) 
B (95% CI) 
BMI <25 kg/m2 
0.07 (-0.07; 0.21) 
0.02 (-0.01; 0.04) 
0.01 (-0.003; 0.03) 
-0.55 (-1.21; 0.11) 
0.13 (-0.02; 0.28) 
0.21 (0.10; 0.33) 
0.07(0.03;0.10) 
0.02 (0.004; 0.04) 
-1.32 (-1.95;-0.68) 
0.14 (-0.07; 0.34) 
BMI >25 kg/m2 
0.02 (-0.06; 0.07) 
0.004 (-0.02; 0.03) 
0.001 (-0.01; 0.01) 
-0.53 (-1.08; 0.01) 
0.07 (-0.07; 0.21) 
0.04 (-0.009; 0.09) 
-0.01 (-0.03; 0.02) 
-0.001 (-0.01;0.01) 
-0.42 (-0.95; 0.11) 
0.08 (-0.32; 0.56) 
P-value for 
interaction* 
0.38 
0.09 
0.08 
0.95 
0.52 
0.005 
0.002 
0.020 
0.039 
0.68 
HDL-C = serum HDL-cholesterol; MAP = mean arterial pressure; Data are presented as linear 
regression coefficients (P) with 95% confidence intervals in parentheses. Adjustments were made for 
age, physical activity ('high' vs. 'low') and smoking status (never, former and current). * P-value for the 
interaction between overweight status and the variable of interest. 
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Figure 7.1. Association of In-CRP with BMI in elderly men and women, stratified by 
overweight. Findings have been obtained by linear regression analysis; Overweight: BMI >25 
kg/m2. 
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Figure 7.2. Association of In-CRP with PAI-1 activity (A) and serum insulin (B) in elderly men 
and women, stratified by overweight. Findings have been obtained by linear regression 
analysis; Overweight: BMI >25 kg/m2. 
Ln-CRP was clearly associated with PAI-1 activity in normal-weight elderly, but this 
association was absent in overweight elderly (Figure 7.2). The interaction term for 
overweight status and PAI-1 was statistically significant both in men and in women 
(both P<0.05) in crude analysis. In men, the interaction term was no longer 
statistically significant after adjusting for age, physical activity and smoking status 
(P=0.09). Also for insulin, stronger associations with In-CRP were observed in 
normal-weight than in overweight elderly (Figure 7.3), with a statistically significant 
interaction term (P=0.020) in women (Table 7.5). Furthermore, the association 
between In-CRP and HDL-cholesterol was stronger in normal-weight than in 
overweight women (P=0.039). For men, no interaction between overweight and HDL-
cholesterol was observed. The associations between In-CRP and MAP were not 
influenced by overweight status. 
Repeating the analyses after exclusion of subjects with a history of cardiovascular 
disease and subjects with CRP >10 mg/L yielded similar results (data not shown). 
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DISCUSSION 
In our study among a general population of Dutch elderly, we observed that 
overweight modified the associations between plasma CRP and major components 
of the metabolic syndrome. CRP was stronger associated with body mass index, 
PAI-1 activity and serum insulin in normal-weight than in overweight elderly. Findings 
appeared to be more pronounced in women than in men. Associations of CRP with 
MAP were not modified by overweight. To avoid confounding by the severity of the 
atherosclerotic process or other conditions that could have caused increased CRP 
levels, the analyses were repeated after exclusion of subjects with a history of 
cardiovascular disease or CRP above 10 mg/L. This did not result in alterations of 
the observed associations. 
Little is known about the underlying pathogenic mechanism of the metabolic 
syndrome, but (abdominal) obesity is believed to play a central role.10 Adipose tissue 
not only has a function as energy storage, but is also important as secretory organ. 
Adipose tissue derived products are amongst others cytokines and PAI-1, which may 
contribute to the detrimental effects of obesity on cardiovascular risk. The metabolic 
functions of adipose tissue have recently been reviewed.18 
In epidemiological studies it has consistently been shown that higher body weight is 
associated with increased levels of CRP.11"14 In addition, it has been shown that 
weight reduction lowers CRP.19'20 The observed associations between markers of 
obesity and CRP are most likely mediated by interleukin-6 (IL-6), which is produced 
by adipose tissue and is known to regulate the hepatic synthesis of CRP.21 In studies 
that stratified for gender stronger associations between CRP and BMI were observed 
for women than for men.12'22'23 Our results are consistent with these observations. 
Some possible explanations for the gender-specific associations of CRP with BMI 
can be given. First, at equal BMI, women have significantly higher amounts of total 
body fat compared to men and also a different distribution of body fat.24 Another 
explanation could be the involvement of sex steroids, which may influence the 
metabolic activity of adipose tissue.18 In line with this hypothesis, a correlation of 
CRP with estradiol has been demonstrated in overweight women.20 
We observed a strong association between CRP and BMI, but only in normal-weight 
women. The absence of an association between CRP and BMI at higher BMI 
suggests an upper limit in body weight-associated CRP levels. Because of the ability 
of the liver to produce extremely high levels of CRP during inflammation, we 
consider it unlikely that this upper limit in CRP is caused by a lower hepatic CRP 
production in response to interleukins. We hypothesize that the production of CRP 
inducing factors in adipose tissue (e.g. IL-6) may be diminished at higher body 
weight. The quantity of metabolites secreted by adipose tissue may depend on both 
total amount of fat mass and the distribution of fat over the different depots, which 
has indeed been demonstrated for PAI-1, TNF-a and other metabolites.25 This 
adipose tissue heterogeneity might explain why we observed different associations 
with CRP in normal-weight and overweight elderly. In vitro studies showed a 3-fold 
higher release of IL-6 in omental than abdominal subcutaneous adipose tissue.26 It is 
102 
. CRP and the metabolic syndrome 
not known whether IL-6 production differs between normal-weight and overweight 
elderly. 
As far as we know, previous studies have not performed stratified analyses by 
overweight status. Mean values of CRP in strata of BMI and overall associations 
between CRP and components of the metabolic syndrome have been reported, but 
these results cannot be compared to our findings. In a population of middle-aged 
obese women, CRP was associated with BMI,20 which is in contrast to our finding 
that in overweight elderly women. Possibly, the older age of our cohort provides an 
explanation for this discrepancy. 
CRP was positively associated with plasma PAI-1 activity and serum insulin in our 
study. As for BMI, these associations predominantly existed within the population of 
normal-weight elderly, both for men and women. Adipose tissue is an important 
source of circulating PAI-1.27"29 PAI-1 is directly secreted by adipose tissue and 
adipocytes-derived cytokines (TNF-a en TGF-p) furthermore stimulate hepatic PAI-1 
production.28 It has been observed that adipocytes in obese subjects could produce 
more PAI-1 than adipocytes in lean subjects30, even after adjustment for adipocyte 
size.31 
We observed no effect modification by overweight in the associations of CRP with 
MAP. Although blood pressure is also involved in the metabolic syndrome, the link 
between this variable and the metabolic syndrome may not be mediated by adipose 
tissue. 
From our data in a general elderly population, we conclude that CRP is unlikely to 
play an important, independent role in the metabolic syndrome in the presence of 
overweight. This finding, however, needs to be confirmed in prospective 
epidemiological studies, both in the elderly and in younger populations. In future 
research, it may be worthwhile to include other indicators of fat mass and body fat 
distribution, and to examine whether weight reduction alters the relationship between 
CRP and components of the metabolic syndrome. 
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ABSTRACT 
Background: C-reactive protein (CRP) is a sensitive marker of inflammation. 
Recently, there has been a growing interest in small CRP elevations since chronic 
low-grade inflammation may play a role in cardiovascular disease. 
Methods: We studied the associations of CRP with all-cause mortality, 
cardiovascular mortality, incidence of myocardial infarction, stroke and transient 
ischemic attack in a prospective study among 605 Dutch elderly men and women 
aged 65-84 years. 
Results: The mean follow-up time was 7.7 years. In men, high CRP (>2.2 mg/L) 
was associated with an increased risk of all-cause mortality (RR=1.5 (95%-CI: 1.1 -
2.1)), CVD mortality (RR=2.2 (95%-CI: 1.2 - 4.2) and incidence of stroke (RR=2.7 
(95%-CI 1.2 - 6.2)). The observed relationships remained similar after adjusting for 
potential confounders. In women, high CRP was not associated with any of the 
cardiovascular endpoints, but the number of events in women was small. 
Conclusions: We conclude that increased levels of CRP, indicating low-grade 
inflammation, may contribute to cardiovascular risk in elderly men. Our finding that 
CRP is not associated with cardiovascular risk in elderly women, however, needs 
further confirmation in larger prospective epidemiological studies. 
INTRODUCTION 
C-reactive protein (CRP), a hepatically-derived acute phase reactant protein, is a 
highly sensitive marker of inflammation. Serum CRP concentrations above 10 mg/L 
are generally considered to indicate clinical inflammation. More recently, there has 
been a growing interest in small CRP elevations since chronic low-grade 
inflammation may play a role in cardiovascular disease.1,2 CRP has been associated 
with worse prognosis in patients with coronary heart disease and stroke.3"5 
However, CRP may also have an added value in the prediction of cardiovascular and 
all-cause mortality in general healthy populations, including the elderly.6"12 We 
examined whether CRP predicted all-cause and cardiovascular mortality in the 
Arnhem Elderly Study, a prospective population-based study of Dutch elderly men 
and women with a mean follow-up of 7.7 years. 
METHODS 
Study population 
The Arnhem Elderly Study is a prospective, population-based study among older 
inhabitants of Arnhem, a city in the Netherlands. Participants were randomly 
selected from the general population after stratification for age and sex, as described 
in more detail elsewhere.13 A total of 1,012 non-institutionalized elderly men and 
women, aged 65-84 years, were enrolled in the health survey in 1991/1992. Physical 
examination was performed in 685 subjects (68%), and blood samples were 
available for 641 subjects (63%). CRP values were randomly missing for 36 
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subjects, leaving 605 subjects for the present analysis. Written informed consent for 
collection of follow-up data and approval by the ethical committee of Wageningen 
University were obtained. 
Data collection 
Trained interviewers visited the participants at home and collected data on smoking 
habits, health status, medication and demographics. Smoking status was coded as 
current, former and never. A history of cardiovascular disease was considered 
present if the participant reported a history of heart disease or stroke. Use of 
cardiovascular medication during the previous 3 months was recorded, which 
comprised use of ACE-inhibitors, beta-blockers, thrombolytic agents, lipid-lowering 
medications or salicylates. Physical examination included anthropometry, blood 
pressure measurement and blood sampling (non-fasting). Body mass index (BMI) 
was calculated as weight divided by height squared (kg/m2). Hypertension was 
defined as a systolic blood pressure >160 mmHg, or diastolic blood pressure >95 
mmHg or use of antihypertensive medication. 
Laboratory determinations 
Serum aliquots were stored at -80°C. C-reactive protein (CRP) was assessed using 
highly sensitive ELISA.14 Serum total cholesterol was determined by an enzymatic 
method (CHOD-PAP). Serum HDL and LDL cholesterol were measured directly 
(Dimension®HDL method and N-geneous®LDL respectively). Serum insulin was 
determined with an immunometric assay (lmmulite®2000 insulin). 
Follow-up 
Municipal registries provided data on mortality and migration of the study cohort at 
regular time intervals until February 2001. Information on vital status at the end of 
follow-up was complete. Data on morbidity and cause-specific mortality were 
obtained from general practitioners (GP), either directly or by one of the authors 
(T.H.) by means of a standard questionnaire. Follow-up data for incident 
cardiovascular evens and cause-specific mortality were available for 490 subjects 
(81%). Reasons for missing data were: (1) subjects gave no permission (n=39, 6%), 
(2) the GP could not be traced (n=30, 5%), (3) the GP refused participation (n=38, 
6%), or (4) could not provide valid data (n=8, 1%). Baseline characteristics of elderly, 
of whom data from medical records were missing, were comparable with those 
included in the analysis, except for serum cholesterol (6.0 versus 6.3, P=0.02). No 
differences were observed concerning age and gender distribution. 
Endpoints were coded according to the International Classification of Diseases, tenth 
revision (ICD-10). Outcomes for the present analyses comprised all-cause mortality, 
death due to major cardiovascular disease (I00-I96), incidence of myocardial 
infarction (121-122), incidence of stroke (160-169), and incidence of transient ischemic 
attack (G45). In case of recurrent cardiovascular events, only the first event was 
considered in the analysis. 
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Data analysis 
Spearman's correlation coefficients were calculated for the association between 
CRP, subject characteristics and cardiovascular risk factors. Based on the median 
CRP level of the total population (i.e., 2.2 mg/L) the study cohort was divided into a 
'low' and 'high' CRP group. Cox survival analysis was used to estimate risk of all-
cause mortality, cardiovascular mortality, incident myocardial infarction (both fatal 
and non-fatal), incident stroke (both fatal and non-fatal), and incident transient 
ischemic attacks for subjects with 'high' CRP (>2.2 mg/L) compared to subjects with 
'low' CRP (<2.2 mg/L). Hazard rate ratios (subsequently referred to as relative risk, 
RR) were adjusted for age ('Model 1'), and additionally for BMI, smoking status 
(current, former, never), history of cardiovascular disease, blood pressure (both 
systolic and diastolic), cholesterol and insulin ('Model 2'). The SAS system was used 
for all statistical analyses and P-values below 0.05 were considered statistically 
significant. 
RESULTS 
Baseline characteristics of the study population are shown in Table 8.1. CRP was 
significantly higher in men than in women (median of 2.4 vs. 2.1 mg/L, P=0.02). CRP 
levels exceeded 10 mg/L in 17 men (5%) and 4 women (1%). 
Table 8.1. Characteristics of a general population of 605 Dutch elderly 
Age (yr) 
Body mass index (kg/m2) 
Blood pressure (mmHg) 
Systolic 
Diastolic 
Smoking status (%) 
Current 
Former 
Never 
Diabetes, self reported (%) 
History of cardiovascular disease (%)* 
Use of cardiovascular medication (%)t 
Serum total cholesterol (mmol/L) 
Serum HDL-cholesterol (mmol/L) 
Serum LDL-cholesterol (mmol/L) 
Serum CRP (mg/L) 
Serum insulin (pmol/L) 
Deceased during follow-up (%) 
Men(n=315) 
73.2 ± 5.4 
25.4 ± 3.1 
148 ± 20 
81 ±11 
33 
57 
10 
3 
25 
20 
6.0±1.2 
1.3 ±0.3 
3.7 ±1.0 
2.4(1.2-4.7) 
136(96-222) 
49 
Women (n=290) 
74.1 ± 5.9 
26.5 ±4.5 
153 ±21 
82 ±11 
16 
26 
59 
6 
17 
19 
6.5 ±1.2 
1.5 ±0.4 
3.8 ±1.0 
2.1 (1.0-3.8) 
142 (98 - 225) 
34 
Continuous variables are presented as mean ± SD, or median with interquartile range (Q1-Q3) in 
case of skewed distribution. 
* Includes self-reported heart disease or stroke; * Use of ACE-inhibitors, beta-blockers, thrombolytic 
agents, lipid-lowering medication or salicylates during the 3 months prior to the interview. 
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Table 8.2. Relative risks (95%-CI) of fatal and non-fatal cardiovascular events and all-cause 
mortality with CRP in a general population of Dutch elderly men and women 
Incident stroke 
Cases/person-years 
RR, model 1* 
RR, model 2 f 
Incident Ml 
Cases/person-years 
RR, model 1* 
RR, model 2+ 
Incident TIA 
Cases/person-years 
RR, model 1* 
RR, model 21 
CVD mortality 
Cases/person-years 
RR, model 1* 
RR, model 2 f 
All-cause mortality* 
Cases/person-years 
RR, model 1* 
RR, model 2 f 
Men (r 
CRP 
<2.2 mg/L 
8/968 
9/935 
8/956 
14/975 
61/1,250 
= 250)+ 
CRP 
>2.2 mg/L 
20/867 
2.7(1.2-6.2) 
2.7(1.2-6.2) 
11/854 
1.3(0.5-3.2) 
1.3(0.5-3.2) 
16/840 
2.2 (0.9 - 5.2) 
2.5(1.0-6.2) 
30/895 
2.2(1.2-4.2) 
2.1 (1.1 -4.0) 
92/1,144 
1.5(1.1 -2.1) 
1.4(1.0-2.0) 
Women (n = 240)f 
CRP 
<2.2 mg/L 
15/1,008 
6/1,012 
14/982 
17/1,025 
50/1,310 
CRP 
>2.2 mg/L 
16/857 
1.3(0.6-2.7) 
1.0(0.4-2.4) 
4/887 
0.7(0.2-2.5) 
0.8 (0.2 - 3.4) 
13/838 
1.0(0.5-2.2) 
0.9(0.4-2.1) 
14/896 
1.0(0.5-2.0) 
0.4(0.2-1.0) 
50/1,115 
1.2(0.8-1.7) 
0.9(0.5-1.4) 
TIA = transient ischemic attack; Ml = myocardial infarction; CVD = cardiovascular disease. 
* Model 1: adjusted for age;f Model 2: adjusted for age, BMI, smoking status (current, former, never), 
history of cardiovascular disease, blood pressure, serum total cholesterol, and serum insulin. 
' Survival analyses for all-cause mortality included 315 men and 290 women respectively 
There was no significant correlation between age and serum CRP. In men, serum 
CRP was significantly correlated with LDL-cholesterol (rs=0.12, P=0.03), HDL-
cholesterol (rs=-0.24, PO.001), total cholesterol (rs=0.12, P=0.03), and systolic blood 
pressure (rs=0.13, P=0.02). BMI was a strong determinant of CRP in women 
(rs=0.39, P<0.001) but not in men (rs=0.09, P=0.11). In women, there were also 
significant associations of CRP with HDL-cholesterol (rs= -0.28, PO.001), insulin 
(rs=0.15, P=0.01), and diastolic blood pressure (rs=0.18, P=0.002). CRP was lower in 
physically active than in sedentary elderly, both in men (geometric means: 1.87 vs. 
2.95 mg/L, respectively, P<0.001) and women (1.57 vs. 2.35 mg/L, respectively, 
P=0.008). No significant differences in CRP concentrations were observed among 
current, former and never smokers, or between alcohol consumers and abstainers. 
Data from medical records were available for 490 elderly (240 women and 250 men). 
The mortality rate of this sub-sample was 34% of the women and 47% of the men. In 
men 38% of the deaths were due to cardiovascular disease and for women this 
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percentage was 45%. During the mean follow-up time of 7.7 years, 30 cases of 
myocardial infarction, 59 strokes and 51 TIA's were detected. 
History of cardiovascular disease, and systolic blood pressure were significant 
predictors for all-cause mortality in both sexes. Measures of cholesterol, smoking, 
BMI, and presence of diabetes were not significantly related to all-cause mortality. 
RR for CRP and all-cause mortality and cardiovascular endpoints are presented in 
Table 8.2. 
In men, high CRP was associated with an increased risk of all-cause mortality 
(RR=1.5 (95%-CI: 1.1 - 2.1)), CVD mortality (RR=2.2 (95%-CI: 1.2 - 4.2) and 
incidence of stroke (RR=2.7 (95%-CI: 1.2 - 6.2)). The observed relationships 
remained similar after adjusting for potential confounders (i.e., Model 2). In women, 
high CRP was not associated with any of the cardiovascular end points, but the 
number of events in women was small. 
DISCUSSION 
In this cohort of elderly Dutch men and women, highest rates of cardiovascular 
events and mortality were observed in the high CRP group in men, but not in 
women. Multivariate analyses, with adjustment for age, blood pressure, BMI, serum 
total cholesterol, serum insulin, smoking status, and history of cardiovascular 
disease, did not substantially change these results. Findings in elderly men, 
therefore, broadly reflect the findings from other prospective studies.3"8,10,11 
However, our results are not consistent with studies among elderly women that 
found a positive association between CRP and future coronary events,5,9,12 
stroke,6,10,11 and all-cause mortality.7,8 The Women's Health Study and the Women's 
Health Initiative Observational Study, two large prospective, nested case-control 
studies in postmenopausal women, showed high-sensitive CRP to be an important 
predictor of myocardial infarction or coronary heart disease mortality in healthy 
women.9,12 The women included were younger (45 years and above and 50 to 79 
years respectively) than the women of the Amhem Elderly cohort. 
A major shortcoming of the present study is the lack of power, which hampers the 
drawing of strong conclusions, especially for risk of myocardial infarction. The 
absence of an increased cardiovascular risk for high CRP in women may be due to 
chance. An alternative explanation might be that the determinants of serum CRP 
were different for men than for women, possibly resulting in a different predictive 
value. BMI is positively associated with cardiovascular risk in women, whereas CRP 
also increases with BMI. The latter may be explained by adipose tissue secreting 
interleukin-6, which subsequently may stimulate the hepatic synthesis of CRP.15 
Therefore, in the setting of obesity (especially in women), high CRP levels may not 
confer additional cardiovascular risk after adjusting for measures of obesity, because 
it is a marker of another cardiovascular risk factor. It might be that CRP in obese 
women is not a good marker for risk because it is mainly a reflection of the amount of 
adipose tissue. It is possible that in women over (roughly) 65 years of age, a 
detrimental effect of CRP would not be apparent, not only because of comorbidity 
112 
_CRP and cardiovascular risk 
(e.g., obesity), but also because of competing causes of death associated with a low-
grade inflammatory state. 
Main causes of death are different for middle aged compared to elderly populations, 
e.g., the relative incidence of congestive heart failure, cerebrovascular disease, 
chronic obstructive pulmonary disease, pneumonia, and other infections increase 
with age, while the incidence of myocardial infarction decreases.16 In line with this 
phenomenon, we observed a higher incidence of stroke compared to myocardial 
infarction in the cohort of the Arnhem Elderly Study. Furthermore, it may be 
hypothesized that an association between CRP and future coronary events and 
mortality may be stronger in elderly with a higher coronary risk. In our study the 
proportion of elderly with a history of cardiovascular disease was indeed higher in 
men than in women. 
We conclude that increased levels of CRP, indicating low-grade inflammation, may 
contribute to cardiovascular risk in elderly men. Our finding that high CRP does not 
increase risk of cardiovascular disease in elderly women, however, needs further 
confirmation in larger prospective epidemiological studies. 
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Chapter 9 
The main goal of the epidemiological studies presented in thesis was to examine the 
relationship between PAI-1 and cardiovascular disease. Interpretation of 
observational, data on these associations is complicated because of potential 
confounding by a wide range of cardiovascular risk factors and other types of bias. 
The 4G/5G polymorphism in the promotor region of the PAI-1 gene is associated 
with serum PAI-1 levels. An increased cardiovascular risk for the 4G-allele would 
add evidence for a causal role of PAI-1 in the cardiovascular disease process. 
Therefore, in most studies we investigated the association of the 4G/5G-
polymorphism with atherosclerotic and thrombotic outcomes. 
In addition to its well-known function in fibrinolysis, PAI-1 is also an acute-phase 
protein, providing an alternative pathway by which PAI-1 might be associated with 
cardiovascular risk. We therefore also examined the role of CRP, a sensitive marker 
of inflammation, which enabled us to study the role of PAI-1 independent of 
inflammation. 
This chapter provides an overview of the main findings of the studies described in 
this thesis and the consistency with existing scientific data, followed by some 
methodological considerations and suggestions for future research. 
MAIN FINDINGS 
PAI-1 showed a strong diurnal variation with an early morning peak, which appeared 
to be confined to the 4G-allele. This might lead to an increased risk of cardiovascular 
events especially in the early morning. Elderly with the 4G/4G-genotype were 
protected against stroke. The latter finding is in contrast to the generally accepted 
hypothesis that the 4G-allele (as marker for increased plasma PAI-1 levels) 
increases risk of cardiovascular events due to diminished fibrinolytic activity. 
An overview of the characteristics and the main findings of the studies described in 
this thesis are given in Table 9.1. In the following paragraphs, we will discuss our 
findings on PAI-1 and CRP in more detail and make a comparison with reported 
scientific data. 
Plasminogen activator inhibitor-type 1 
Diurnal variation in PAI-1 
In the population-based cohort of the Arnhem Elderly Study, plasma PAI-1 activity 
showed a strong diurnal variation with peak levels in the early morning. This finding 
is in agreement with the results of several small studies in which serial PAI-1 
determinations were performed.1"8 We furthermore demonstrated this diurnal 
variation to be primarily confined to the 4G-allele. In the Rotterdam Study among a 
sub sample of 263 men and women aged 55 years and over, the morning/afternoon 
difference in PAI-1 antigen was also more pronounced in persons with the 4G/4G-
genotype than in persons with the other genotypes.9 
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A biological explanation for a genotype-specific diurnal variation in PAI-1 is provided 
by Maemura et al., who identified a transcription factor (CLIF: cycle-like factor) that is 
involved in the circadian pattern of PAI-1.10 The binding site of this transcription 
factor overlaps with the location of the 4G/5G-polymorphism. The early morning 
peak in PAI-1 might partly be responsible for the high frequency of cardiovascular 
events at this time of the day and this may be different for the PAI-1 genotypes. 
4G/5G-polymorphism and atherosclerosis 
We observed no consistent association between the 4G/5G-polymorphism and 
advanced coronary stenosis in our pooled case-control study (Chapter 5, see Table). 
A non-significantly increased risk of coronary stenosis was observed for the 4G/4G-
genotype when cases were compared with coronary controls, but not when 
compared with population-based controls. In a case-control study by Gardemann et 
al. of 2,565 subjects who underwent coronary angiography, the 4G/4G-genotype was 
associated with the presence of coronary stenosis, but not with the number of 
diseased vessels.11 They observed the strongest associations between the 4G/5G-
polymorphism and coronary stenosis in high-risk sub samples (e.g. smokers, 
subjects with high BMI, and hypertensives).11 Stratification for background risk in our 
study (based on the Framingham Prediction Score), showed opposite results, i.e. a 
stronger association in low risk individuals. Two other studies did not observe any 
association between the 4G/5G-polymorphism and angiographically determined 
coronary artery disease.12,13 
Non-invasive markers of the atherosclerotic process make it possible to study 
atherosclerosis at an earlier stage, when subjects are still free of symptoms. We 
investigated the association between the 4G/5G-polymorphism and both intima-
media thickness (IMT) and ankle-brachial index (ABI) in male smokers and found no 
indication that the 4G-allele is associated with more advanced atherosclerosis than 
the 5G-allele. Although not statistically significant, a high IMT (>1.07 mm) was even 
less frequent for the 4G/5G and 4G/4G-genotypes compared to the 5G/5G-genotype 
(odds ratios of 0.6 and 0.4 respectively, P-value for trend: 0.08). Previous studies 
showed positive associations between PAI-1 antigen levels and intima-media 
thickness,14,15 but data on 4G/5G-polymorphism in relation to non-invasive markers 
of atherosclerosis are lacking. 
Plasma PAI-1, 4G/5G-polymorphism and coronary events 
In the Arnhem Elderly Study, PAI-1 activity was strongly predictive for cardiovascular 
mortality, independent of other cardiovascular risk factors (including CRP). Also for 
incident myocardial infarction an increased risk was observed for elevated PAI-1 
levels, although the association was not significant. 
In previous studies in populations with angina pectoris or a history of a myocardial 
infarction, PAI-1 levels predicted future (recurrent) coronary events. However, in 
most previous population-based prospective studies PAI-1 was not significantly 
associated with the occurrence of a first event.16,17 In the few studies among healthy 
populations in which plasma PAI-1 was associated with risk of coronary events the 
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strength of the association was strongly reduced after adjusting for cardiovascular 
risk factors.18,19 Only one other prospective study on PAI-1 and cardiovascular risk in 
the elderly has been performed, i.e. the Cardiovascular Health Study,16 in which no 
association was observed between PAI-1 and coronary risk. Elderly with known 
cardiovascular disease were excluded from this study, whereas in the Arnhem 
Elderly Study 20% of the population had a history of cardiovascular disease. Even in 
elderly without clinical evidence for cardiovascular disease, the atherosclerotic 
process is likely to be advanced, which might be the underlying reason for the 
association between PAI-1 and cardiovascular events. 
We did not observe an increased coronary risk for the 4G/4G-genotype, which is in 
agreement with previous prospective studies. In the Physicians' Health Study the 
4G/5G-polymorphism was not predictive for future myocardial infarction in men 
initially free of cardiovascular disease.20 In postmenopausal women21 and in elderly 
subjects22 the 4G/5G-polymorphism was not predictive for fatal myocardial infarction. 
In a recent meta-analysis of 9 studies, mainly case-control, a small increased risk for 
myocardial infarction was observed for the 4G/4G-genotype (OR=1.2 (95%-CI: 1.0 -
1.4)).23 
Plasma PAI-1, 4G/5G-polymorphism and risk of stroke 
In the Arnhem elderly the 4G/4G-genotype was protective for future stroke (RR= 0.4 
(95%-CI: 0.2 - 0.9). Most previous studies on stroke also showed a protective effect 
for the 4G-allele (see Chapter 6, Figure i)212224-26 but only in one study the effect 
was strong enough to reach statistical significance.21 However, in a Korean case-
control study the 4G-allele was associated with an increased risk of ischemic 
stroke.27 Despite the protective effect of the 4G-allele, we observed a higher risk of 
stroke for higher PAf-1 levels. Johansson et al. found that PAI-1 antigen was non-
significantly associated with incidence of first stroke in a population-based cohort 
(OR upper versus lower PAI-1 quartile: 1.3 (95%-CI: 0.7 - 2.6).28 The population 
studied by Johansson was younger and did not include subjects with a history of 
cardiovascular disease. In the Arnhem Elderly Study, a positive association of PAI-1 
with stroke persisted after exclusion of 20% of the subjects with a history of 
cardiovascular disease. The Arnhem Elderly Study is the first prospective study in 
which PAI-1 levels as well as the 4G/5G-polymorphism was examined in relation to 
risk of stroke within a single population. 
C-REACTIVE PROTEIN 
Role of CRP in the metabolic syndrome 
Both PAI-1 and CRP have been suggested to be part of the metabolic syndrome. In 
the Arnhem Elderly Study we examined the associations between CRP, PAI-1, and 
other components of the metabolic syndrome (i.e. BMI, insulin, HDL-cholesterol, and 
blood pressure) stratified by gender and overweight status (BMI > 25 kg/m2). In 
normal-weight women, CRP was associated with BMI, PAI-1, serum insulin and 
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HDL-cholesterol. In overweight women, however, these relationships were weak and 
not statistically significant. 
CRP and risk of thrombotic events 
In the Arnhem Elderly Study, CRP was predictive for future cardiovascular events in 
men, which is in agreement with a large number of previous epidemiological studies 
(see for review De Ferranti and Rifai29). In a meta-analysis on the association 
between CRP and coronary heart disease, including a total of 2,557 cases, an odds 
ratio of 1.9 (95%-CI: 1.5 - 2.3) was found. 
The mechanisms responsible for associations between CRP and cardiovascular risk 
are not fully understood. CRP might directly promote vascular disease. Alternatively, 
CRP might be an indicator of other cardiovascular risk factors or of the extent of pre-
existing disease. 
In contrast to previous studies in women,30,31 we did not observe a relationship 
between CRP and future cardiovascular events in elderly women. Our study may 
have had insufficient power to detect an association. An alternative explanation 
might be that the determinants of serum CRP were different for men than for women 
(see Chapter 7). 
METHODOLOGICAL CONSIDERATIONS 
Epidemiological studies like the ones reported in this thesis are prone to several 
forms of bias, which might have affected the internal validity of the results. Several 
sources of potential bias will be discussed, as well as several other methodological 
issues. 
Selection bias 
In case-control studies the selection of a proper control group is of major importance. 
The control group should be representative of those who, had they developed the 
disease, would have been selected as cases. In the pooled case-control study 
(Chapter 5), two types of controls were selected, i.e. coronary controls and 
population-based controls. Coronary controls were selected from subjects that had 
undergone coronary angiography in the same hospital as the cases. A major 
advantage of selecting coronary controls is ascertainment of the absence of 
stenosis. Furthermore, since these subjects underwent similar diagnostic procedures 
as the cases, one could expect them to have the same accuracy in reporting 
information. However, coronary controls may not be representative of the source 
population, and thus selection bias might have occurred. It is for example 
conceivable that subjects with a positive family history of cardiovascular disease are 
more likely to be referred to the hospital than subjects without such a history, which 
could have attenuated the associations. 
The second control group comprised a sample from the general population 
(population-based controls). The distribution of the 4G/5G-polymorphism in the 
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population-based controls was not in Hardy-Weinberg equilibrium, which indicates 
selection based on the 4G/5G-polymorphism. The frequency of the 4G-allele was 
high in comparison to other European control populations. The estimates based on 
the analysis with population-based controls might thus be biased, which might 
explain the absence of an association. We therefore have more confidence in the 
comparison with coronary controls. 
In prospective studies, like the Arnhem Elderly Study, two potential sources of 
selection bias have to be considered: non-response and loss to follow-up. Non-
response will only lead to biased results if it is associated both with exposure, and 
with disease outcome independently of the exposure of interest, which is unlikely. 
Loss to follow-up may cause biased results if it is related to both exposure and 
outcome. For all-cause mortality, loss to follow-up was not an issue in the Arnhem 
Elderly Study, because only one person was lost to follow-up due to emigration. Data 
on cause-specific mortality and incidence of cardiovascular events, however, were 
missing for 19% of the study population. Reasons for this were as follows: no 
permission (6%), the general practitioner could not be traced (5%), refused 
participation (8%), or could not provide valid data (2%). Thus, loss to follow-up 
occurred at the level of the general practitioner rather than of the participants and is 
therefore unlikely to be related to exposure or disease outcome. Baseline 
characteristics of elderly subjects who were lost to follow-up were similar to those 
included in the analysis, except for serum cholesterol (6.0 versus 6.3, P=0.02). No 
differences were observed with regard to age and gender distribution. It is thus not 
expected that loss to follow-up has largely influenced the associations between 
exposures (PAI-1, 4G/5G-polymorphism, CRP) and cardiovascular events. 
Information bias 
Measurement of plasma PAI-1 activity 
To minimize variance due to the circadian pattern of PAI-1, time of blood sampling 
should ideally be standardized. In the Arnhem Elderly Study blood sampling was 
performed between 8.00 a.m. and 5.30 p.m. Time of blood sampling was registered, 
making it possible to adjust for the diurnal variation in PAI-1 activity in all statistical 
analyses. We therefore do not expect this diurnal variation to have caused biased 
estimates of the risk associated with PAI-1 activity in the Arnhem Elderly Study. 
Measurement and interpretation of plasma PAI-1 activity is furthermore complicated 
by spontaneous transformation of active PAI-1 into its latent form, by complex 
forming with t-PA and by the potential release of PAI-1 from platelets.32 In the 
Arnhem Elderly Study plasma samples were cooled shortly after blood drawing and 
deep-frozen after a few hours, which will have prevented inactivation of PAI-1. We 
chose to measure PAI-1 activity and not PAI-1 antigen, because the latter is more 
affected by leakage of PAI-1 from platelets to plasma. The samples were non-
fasting, but this has probably not had a major effect on variation in PAI-132 Samples 
were stored at -80°C for a maximum of 7 years and sample degradation over this 
time period is not expected to have influenced PAI-1 to a large extent.33 
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Measurement of serum C-reactive protein 
We used a high-sensitive method to measure serum CRP concentrations at baseline 
in the Arnhem Elderly Study. The variation of CRP concentrations in a healthy 
individual over time is substantial, but it has been shown that in stable individuals 
there is a constant low level of CRP with occasional outliers.34 In order to precisely 
determine the habitual level of CRP in a healthy volunteer, one blood sample is 
regarded as sufficient.35 To avoid confounding by transient acute-phase reactions we 
repeated all analyses of CRP after exclusion of 5% of men and 1% of women with 
CRP levels above 10 ng/mL, indicating clinically relevant inflammation. 
Validation of4G/5G genotyping 
In general, quality control for genotyping methods receives insufficient consideration 
because of the assumption that errors in genotyping are unlikely to occur. However, 
as for all data collection methods, both systematic and random errors are possible. 
We used three different methods to genotype the 4G/5G-polymorphism in the study 
of male smokers (Chapter 4), the pooled case-control study (Chapter 5) and in the 
Arnhem Elderly Study (Chapters 3 and 6).21,36,37 The three methods were cross-
validated by repeating the genotyping in a random sample of male smokers and the 
case-control population, using the method of the Arnhem Elderly Study. Completely 
identical results for the 4G/5G polymorphism were obtained. Some misclassification 
might have occurred due to errors in genotyping. However, the assessment was 
blinded, which strongly reduces the likelihood of differential misclassification. 
Therefore, we are confident that misclassification of 4G/5G-genotype in our studies 
did not bias the observed associations. 
Endpoint assessment 
We present several cardiovascular endpoints in the different chapters, both 
intermediate markers of the atherosclerotic process as well as clinical cardiovascular 
events. Measurement errors in markers of intima-media thickness or ankle-brachial 
index might have led to misclassification. However, differential misclassification 
across the genotypes of the 4G/5G-polymorphism is not likely and therefore the 
results will not be biased. In the pooled case-control study (Chapter 5) the large 
contrast in the extent of coronary stenosis precludes serious misclassification of 
cases and coronary controls. Despite the absence of symptoms, it cannot be ruled 
out that some of the population-based controls may have had substantial coronary 
narrowing, which could have led to dilution of the true association. 
For the all-cause mortality data in the Arnhem Elderly Study, no large problems are 
expected, since data were obtained from municipal registries covering the total study 
population. However, the morbidity and cause-specific mortality data are more prone 
to errors. Especially in a population of elderly with a high prevalence of comorbidity, 
the true cause of death is difficult to establish. A medical doctor coded causes of 
death by the International Classification of Diseases, Tenth Revision (ICD-10). Only 
events with a high level of certainty (as judged by the treating gerteral practitioner) 
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were included in the analysis. The researchers were furthermore unaware of 
exposure at the time of collection and coding of morbidity data. Thus, some non-
differential misclassification in endpoints may have occurred, but differential 
misclassification is improbable. 
Confounding 
A wide range of cardiovascular risk factors, e.g. BMI, cholesterol, hypertension, 
insulin resistance and inflammation, have been associated with plasma PAI-1 levels 
and should be considered as potential confounders in our analyses. However, it is 
also possible that part of the harmful effects of these cardiovascular risk factors (i.e. 
body mass index, variables of the insulin resistance syndrome) may be mediated by 
effects on PAI-1 level. It is therefore debated whether or not one should adjust for 
these 'confounders' when studying the relationship between PAI-1 levels and 
cardiovascular risk in observational studies. In the Arnhem Elderly Study, the 
adjustments for confounders did not have a large effect on the estimates, indicating 
that the effects were independent of these risk factors. Potential confounders that 
were not measured in the Arnhem Elderly Study were for example blood levels of 
triglycerides and glucose. Furthermore, blood samples were drawn without an 
overnight fast, which will have led to inaccurate assessment of confounders such as 
serum cholesterol and insulin. Residual confounding can therefore not completely be 
ruled out. 
In the analysis in which we studied the diurnal variation in PAI-1 (Chapter 3), 
confounding was a potential threat to validity. We obtained a single non-fasting blood 
sample and examined the diurnal variation in PAI-1 activity by categorizing subjects 
in groups according to the time of blood sampling, after which geometric mean PAI-1 
levels between groups were compared. The observed diurnal pattern in PAI-1 might 
thus be confounded by differences between subjects. However, the circadian pattern 
was still clearly present after extensive adjustments (e.g. smoking status, 
cardiovascular history and BMI) and we therefore believe that the observed diurnal 
pattern in plasma PAI-1 is not explained by differences in characteristics between 
the groups measured at different time points. 
Confounding is less likely for the relationship between 4G/5G-polymorphism and 
cardiovascular disease. Due to 'Mendelian randomization', it is likely that variables 
are equally distributed over the genotypes and will not confound the observed 
associations.38 Only allelic variations that are in linkage disequilibrium with the 
4G/5G-polymorphism would then be unevenly distributed over the genotypes and 
potentially confound the associations (both in case-control and in prospective 
studies). 
A major disadvantage of the case-control design is the possibility that the variable of 
interest is influenced by disease status. One could argue that this is not an issue 
when studying a genetic factor, e.g. the 4G/5G-polymorphism. Because of the higher 
efficiency of the case-control design compared to prospective studies, it can even be 
argued that the case-control design is the preferred study design when the exposure 
of interest is a genetic factor.38 
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Power 
The development of cardiovascular disease is a multifactorial process with many 
genes and environmental factors involved. Large study populations are required for 
risk estimations related to a single polymorphism, and the number needed increases 
exponentially for the detection of gene-environment interactions.39 So, even if the 
4G/5G-polymorphism is truly associated with cardiovascular risk, it may be missed in 
small studies. 
In the Arnhem Elderly Study the power was sufficient to detect several significant 
associations between exposure (plasma PAI-1 activity, CRP, and the 4G/5G-
polymorphism) and cardiovascular outcomes. However, the lack of an association 
between CRP and cardiovascular risk in women in the Arnhem Elderly Study may be 
explained by limited statistical power. In particular, the interpretation of the 
associations for incident myocardial infarction is hampered by the small number of 
events in women in our study population. 
INFERENCE 
Causality of PAI-1 
The 4G/5G-polymorphism appeared not to be a strong determinant of 
atherosclerosis (Chapter 4 and 5), and these findings do thus not support a causal 
association between PAI-1 and the presence of atherosclerosis. The acute-phase 
properties of PAI-1 might be an alternative pathway by which PAI-1 could have 
detrimental effects in the cardiovascular system. Observed associations between 
atherosclerosis and PAI-1 might thus be due to increased PAI-1 synthesis, as a 
consequence of atherosclerosis. Even in elderly without clinical evidence for 
cardiovascular disease, the atherosclerotic process is likely to be advanced, which 
might be the underlying reason for the association between PAI-1 and 
cardiovascular events in the Arnhem Elderly Study. 
We tried to study the role of PAI-1 in cardiovascular disease independent of 
inflammation by adjusting for baseline CRP concentrations. However, this may be 
have been insufficient since many uncertainties exist about the exact role of CRP in 
cardiovascular disease. In addition, little is known about the link between PAI-1 and 
CRP in the acute-phase response. In the Arnhem Elderly Study the correlation 
coefficient between PAI-1 and CRP was 0.21. Based on scientific literature, it is 
known that CRP shows a stronger inflammatory response than PAI-1 activity.40 Our 
observational data, regrettably, do not allow strong conclusions on inflammatory 
properties of PAI-1 in the cardiovascular disease process. Larger studies taking into 
account both PAI-1 and CRP are therefore needed to compare their roles in the 
acute-phase response and potential interactions. 
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Level versus response 
Fibrinolysis is a system with low activity but with a large potential to respond when 
activated, i.e. when the blood vessel wall is damaged. The ability of the system to 
respond to triggers might therefore be biologically more relevant than a PAI-1 
measurement in resting conditions. Both venous occlusion of the forearm and 
exercise stress stimulate fibrinolysis and have been used to measure PAI-1 
response.41,42 However, these methods are not commonly used in large 
epidemiological studies. Before these measurements can be used on a large scale, 
their validity should be further explored and methods should be standardized.41,42 In 
addition, PAI-1 measured in plasma is a systemic marker of fibrinolysis and may not 
be a good marker of fibrinolytic status locally, which may be more relevant in the 
cardiovascular disease pathology. It is, however, not possible to assess PAI-1 at the 
site of the vascular process. 
4G/5G-polymorphism and PAI-1 levels 
Under the assumption that the 4G-allele is associated with elevated PAI-1 levels, 
comparison of cardiovascular risk in subjects with respectively none, one, or two 
copies of the 4G-allele could be interpreted as an experiment of nature in which 
individuals have randomly been allocated to high or low PAI-1 concentrations.38 An 
association between the 4G/5G-polymorphism and risk of cardiovascular disease 
would thus support the hypothesis that PAI-1 is a causal risk factor for 
cardiovascular disease. At the time the studies in this thesis were initiated it was 
believed that the 4G/5G-polymorphism and PAI-1 levels were consistently 
associated, with highest PAI-1 levels for the 4G/4G-genotype, intermediate for the 
4G/5G and lowest for the 5G/5G-genotype.12,43-46 More recently, however, a number 
of studies have failed to show an association between the 4G/5G-polymorphism and 
PAI-1 levels.47 The association between the genotype and plasma levels may thus 
not be as strong as initially expected. In the Arnhem Elderly Study only 1% of the 
variance in PAI-1 was explained by the 4G/5G-polymorphism (see Chapter 6). 
Median plasma PAI-1 activity was lower for the 5G/5G genotype compared to both 
other genotypes (1.4 versus 2.2 lU/mL). The difference between median values in 
the highest versus the lowest PAI-1 fertile was much larger (8.4 versus 0.18 lU/mL). 
Unfortunately, the association between genotype and phenotype could not be 
studied in the other populations described in this thesis. 
It is possible that the 4G/5G-polymorphism mainly determines the magnitude of PAI-
1 response and does not have a strong effect on PAI-1 level, which could explain the 
lack of a consistent association between the 4G/5G-polymorphism and PAI-1. As 
discussed earlier, the magnitude of PAI-1 response to triggers may be of larger 
interest in the cardiovascular disease process than resting PAI-1 levels. Studying the 
4G/5G-polymorphism could thus still provide valuable information in spite of the 
absence of a strong and consistent relation with plasma PAI-1. With regard to stroke, 
it is at present unclear whether plasma PAI-1 accurately represents PAI-1 cerebral 
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levels. Therefore, our findings on PAI-1 and stroke presented in Chapter 6 should be 
interpreted with caution. 
Causality of CRP 
Based on our findings we hypothesize that CRP could be a more important 
component of the metabolic syndrome in women than in men and that CRP only 
plays a minor role in the metabolic syndrome in the presence of overweight (Chapter 
7). Our findings, however, need to be confirmed in other epidemiological studies, 
both in the elderly and in younger populations. 
Possibly, a more advanced atherosclerotic process in men might explain a major 
part of the variance in CRP and, consequently, the observed association with 
cardiovascular endpoints (Chapter 8). In the Arnhem Elderly Study, no intermediate 
marker of atherosclerosis was available. It might be that CRP in women is not a 
good marker for risk because it is mainly a reflection of the amount of adipose tissue. 
OVERALL CONCLUSIONS 
Although we observed an increased risk for stroke and cardiovascular mortality for 
elevated PAI-1 levels, it is still not clear whether PAI-1 is a causal risk factor. Taking 
into account also the lack of consistency in the scientific literature, the independent 
role of PAI-1 in cardiovascular disease remains subject to debate. Our findings on 
4G/5G genotype and cardiovascular disease provide no support for a causal role of 
PAI-1. The 4G allele, generally associated with higher levels of PAI-1, was even 
associated with a lower risk of stroke. We confirmed the diurnal variation in PAI-1, 
previously observed by others, but also showed this circadian pattern to be confined 
to the 4G-allele, which may have implications for the early-morning peak in 
cardiovascular events. 
FUTURE RESEARCH 
The 4G/5G-polymorphism and diurnal PAI-1 variation 
Our finding of a genotype-specific diurnal variation in PAI-1 (Chapter 3) needs to be 
confirmed in other populations. The most appropriate approach would be to perform 
multiple blood sampling during the day in a study population pre-stratified for the 
4G/5G-polymorphism, using a standardized protocol with regard to meals and 
sleep/wake rhythm to reduce variation in PAI-1. If the diurnal variation in PAI-1 truly 
depends on the 4G/5G-polymorphism, a second research question should be 
answered, namely whether 4G-carriers have an increased risk specifically of 
cardiovascular events in the early morning. For this purpose, the 4G/5G-genotype 
distribution of patients with an acute event in the morning may be compared to that 
of patients with an event at another time of the day. 
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PAI-1 in acute inflammation: consequences for severity of a cardiovascular 
event? 
An effect of the 4G/5G-polymorphism on the prognosis of trauma and other disorders 
with a strong acute-phase response has been demonstrated.48,49 It is possible that 
PAI-1 has damaging effects itself and/or that PAI-1 launches the synthesis of other 
inflammatory reactants. The effect of PAI-1 reduction in acute conditions therefore 
deserves future investigation. 
A myocardial infarction also provokes an acute phase response.50 It can thus be 
hypothesized that the 4G/4G-genotype may result in a stronger inflammatory 
response after a myocardial infarction, thereby worsening the prognosis. It would 
therefore be worthwhile to include time of an event in clinical studies. 
4G/5G-polymorphism and risk of stroke 
We observed a protective effect of the 4G-allele against stroke, which is supported 
by several previous studies. Most studies were too small to detect significant 
differences and to examine ischemic and hemorrhagic stroke separately. A large 
case-control study with different, well-defined types of stroke would therefore be 
worthwhile. Also, more prospective studies are needed to confirm our finding that 
plasma PAI-1 levels and the 4G/5G-polymorphism have contrasting effects on risk of 
stroke. 
PAI-1 and atherosclerosis 
PAI-1 might influence both progression and vulnerability of an atherosclerotic 
plaque.51 Magnetic resonance imaging can be used specifically to determine plaque 
morphology; it displays the different components of plaque, which allows the 
identification of unstable plaques.52 Correlating both PAI-1 levels and the 4G/5G-
polymorphism with these markers would provide more insight in the role of PAI-1 in 
atherosclerosis. However, this new method is still considered experimental and 
remains a costly procedure, limiting its applicability in large epidemiological studies. 
REFERENCES 
1. Sayer JW, Gutteridge C, Syndercombe CD, Wilkinson P, Timmis AD. Orcadian activity of the 
endogenous fibrinolytic system in stable coronary artery disease: Effects of beta-adrenoreceptor 
blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1998; 32:1962-1968. 
2. Irokawa M, Nishinaga M, Funayama H, Ikeda U, Shimada K. Effect of a change in the sleep/wake 
cycle on the diurnal variation of fibrinolytic parameters. J Thromb Thrombolysis 1998;5:165-168. 
3. Andreotti F, Prevost R, Lupi A, Hamilton J, de Bart AW, Huisman LM, Maseri A, Kluft C. Circadian 
patterns of plasma t-PA and PAI-1 antigen levels in patients with severe peripheral 
atherosclerosis. Fibrinolysis 1996; 10 Suppl. 2:159-160. 
4. Masuda T, Ogawa H, Miyao Y, Yu Q, Misumi I, Sakamoto T, Okubo H, Okumura K, Yasue H. 
Circadian variation in fibrinolytic activity in patients with variant angina. Br Heart J 1994;71:156-
161. 
127 
Chapter 9 
5. Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch JJ. Circadian variation of tissue 
plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating 
factor in men with ischaemic heart disease. Br Heart J 1993;69:121-124. 
6. Chandler WL, Mornin D, Whitten RO, Angleton P, Farin FM, Fritsche TR, Veith RC, Stratton JR. 
Insulin, Cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. 
Thromb Res 1990;58:1-12. 
7. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and 
its rapid inhibitor (PAI-1). Circulation 1989;79:101-106. 
8. Andreotti F, Davies GJ, Hackett DR, Khan Ml, De Bart AC, Aber VR, Maseri A, Kluft C. Major 
circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial 
infarction, sudden cardiac death and stroke. Am J Cardiol 1988;62:635-637. 
9. Van der Bom JG, Bots ML, Haverkate F, Kluft C, Grobbee DE. The 4G5G polymorphism in the 
gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood Prepublished October 24, 
2002; DOI 10.1182/blood-2002-07-2151. 
10. Maemura K, de La Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, Lee ME. 
CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator 
inhibitor-1 gene expression. J Biol Chem 2000;275:36847-36851. 
11. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype 
of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary 
atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999;82:1121-1126. 
12. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator 
inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial 
infarction in patients characterized by coronary angiography. Arterioscler Thromb Vase Biol 
1997;17:33-37. 
13. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, Davis BP. Lack of 
association of a common polymorphism of the plasminogen activator inhibitor-1 gene with 
coronary artery disease and myocardial infarction. J Am Coll Cardiol 1999;34:1778-1783. 
14. Folsom AR, Pankow JS, Williams RR, Evans GW, Province MA, Eckfeldt JH. Fibrinogen, 
plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family 
Heart Study. Thromb Haemost 1998;79:400-404. 
15. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic 
parameters with early atherosclerosis. The ARIC Study. Circulation 1995;91:284-290. 
16. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, Tracy RP. Fibrinolytic 
activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. 
Arterioscler Thromb Vase Biol 1999;19:493-498. 
17. Lowe GO, Yarnell JG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue 
plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart 
disease in the Caerphilly Study. Thromb Haemost 1998;79:129-133. 
18. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High 
plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first 
acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an 
independent primary risk factor. Circulation 1998;98:2241-2247. 
19. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of 
hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in 
Communities (ARIC) Study. Circulation 1997; 96:1102-1108. 
128 
.General discussion 
20. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous 
thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen 
activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62. 
21. Roest M, van-der-Schouw YT, Banga JD, Tempelman MJ, de-Groot PG, Sixma JJ, Grobbee DE. 
Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of 
cerebrovascular mortality in older women. Circulation 2000;101:67-70. 
22. Heijmans BT, Westendorp RGJ, Knook DL, Kluft C, Slagboom PE. Angiotensin l-converting 
enzyme and plasminogen activator inhibitor-1 gene variants: Risk of mortality and fatal 
cardiovascular disease in an elderly population-based cohort. J Am Coll Cardiol 1999;34:1176-
1183. 
23. Boekholdt SM, Bijsterveld NR, Moons AHM, Levi M, Buller HR, Peters RJG. Genetic variation in 
coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulation 
2001;104:3063-3068. 
24. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT, Reiner AP. The association 
of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in 
young women. J Cardiovasc Risk 2002;9:131 -137. 
25. Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype 
at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) 
gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 
2000;110:469-471. 
26. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator 
inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular 
disease. Thromb Haemost 1997;77:730-734. 
27. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the 
plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type 
plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001 ;11 :294-299. 
28. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen 
activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen 
activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 
2000;31:26-32. 
29. De Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction 
and interventions. Clin Chim Acta 2002;317:1-15. 
30. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of 
inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-
843. 
31. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson 
RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and 
incident coronary heart disease - Prospective analysis from the Women's Health Initiative 
observational study. JAMA 2002;288:980-987. 
32. Kluft C, Meijer P. Update 1996: Blood collection and handling procedures for assessment of 
plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis 1996; 10 Suppl. 
2:171-179. 
33. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and 
inflammation factors in stored plasma samples. Thromb Haemost 2001;86:1495-1500. 
34. de Maat MM, de Bart AW, Hennis BC, Meijer P, Havelaar AC, Mulder PH, Kluft C. Interindividual 
and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, 
young volunteers and patients with angina pectoris. Arterioscler Thromb Vase Biol 1996; 16:1156-
1162. 
129 
Chapter 9_ 
35. Kluft C, de Maat MP. Determination of the habitual low blood level of C-reactive protein in 
individuals. Ital Heart J 2001 ;2:172-180. 
36. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, dAddedda M, 
DiMinno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb 
Haemost 1997;77:605-606. 
37. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter 
polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 
1995;74:1032-1034. 
38. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors 
in complex diseases. Lancet 2001;358:1356-1360. 
39. Merlini PA, Ardissino D. Genetic polymorphisms to evaluate the risk of myocardial infarction: a 
long way away. Thromb Haemost 2001 ;86:1136-1138. 
40. Gabay C. Mechanisms of disease - Acute-phase proteins and other systemic responses to 
inflammation . N Engl J Med 1999;340:448-454. 
41. Kempter B, Peinemann A, Biniasch O, Haberl RL. Decreased fibrinolytic stimulation by a short-
term venous occlusion test in patients with cerebrovascular disease. Thromb Res 1995;79:363-
368. 
42. Nikfardjam M, Graf S, Beckmann R, Hornykewycz S, Koller-Strametz J, Binder BR, Huber K. 
Fibrinolytic response to venous occlusion compared to physical stress test in young patients with 
coronary artery disease. Thromb Haemost 1999;82 Suppl 1:80-84. 
43. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, JuhanVague I. 
Metabolic determinants are much more important than genetic polymorphisms in determining the 
PAI-1 activity and antigen plasma concentrations - A family study with part of the Stanislas 
Cohort. Arterioscler Thromb Vase Biol 1998;18:84-91. 
44. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Di Bitondo R, Donati MB, lacoviello L. 4G/5G 
promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: A model 
of gene-environment interaction. Thromb Haemost 1998;79:354-358. 
45. Nordenhem A, Wiman B. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from 
healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene. Scand J Clin Lab 
Invest 1997;57:453^61. 
46. Margaglione M, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, Celentano E, 
Panico S, DiMinno G. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects 
attending a metabolic ward: Relation to polymorphisms of PAI-1 and angiotensin converting 
enzyme (ACE) genes. Arterioscler Thromb Vase Biol 1997;17:2082-2087. 
47. Cesari M, Sartori MT, Patrassi GM, Vettore S, Rossi GP. Determinants of plasma levels of 
plasminogen activator inhibitor-1 - A study of normotensive twins. Arterioscler Thromb Vase Biol 
1999;19:316-320. 
48. Westendorp RGJ, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene 
and risk of meningococcal septic shock. Lancet 1999;354:561-563. 
49. Menges T, Hermans PWM, Little SG, Langefeld T, Boning O, Engel J, Sluijter M, de-Groot R, 
Hempelmann G. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis 
of severely injured patients. Lancet 2001 ;357:1096-1097. 
50. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive 
protein and complement are important mediators of tissue damage in acute myocardial infarction. 
J Exp Med 1999;190:1733-1739. 
130 
.General discussion 
51. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. 
Circulation 1999;99:2496-2498. 
52. Feinstein SB, Voci P, Pizzuto F. Noninvasive surrogate markers of atherosclerosis. Am J Cardiol 
2002;89:31 C-44C. 
131 
Summary 
Plasminogen activator inhibitor-type 1 (PAI-1) is the main inhibitor of fibrinolysis and 
thereby a potential risk factor of cardiovascular disease. In addition to its regulating 
role in fibrinolysis, PAI-1 is also involved in other processes by which PAI-1 may 
have detrimental effects on the cardiovascular disease process. For example, PAI-1 
is involved in inflammation and in processes like cell proliferation and cell migration. 
Many biological and lifestyle factors are known that influence PAI-1 levels, which 
make it difficult to estimate whether PAI-1 is a causal and independent risk factor for 
cardiovascular disease. 
A polymorphism in the promoter region of the PAI-1 gene, the 4G/5G-polymorphism, 
has also extensively been studied in relation to cardiovascular risk. This 
polymorphism affects the transcription of the PAI-1 gene in response to several 
triggers, for example proinflammatory cytokines. The 4G-allele results in higher 
transcription rates than the 5G-allele and has been associated with higher plasma 
PAI-1 levels. The 4G/4G-genotype has been studied as potential risk factor for 
cardiovascular disease, but the results are not yet conclusive. 
The general objective of the studies described in this thesis was to evaluate whether 
PAI-1 and the 4G/5G-polymorphism are associated with risk of cardiovascular 
disease. PAI-1 is potentially involved in atherosclerosis and in the thrombotic stage 
of the cardiovascular disease process. We therefore studied the associations both 
with markers of atherosclerosis and with clinical end points. PAI-1 is furthermore an 
acute-phase reactant and we therefore additionally studied C-reactive protein, a 
sensitive marker of inflammation. 
DETERMINANTS OF PLASMA PAI-1 
In Chapter 2 the scientific literature on determinants of plasma PAI-1 is reviewed. 
There is strong evidence for a substantial influence of obesity and the metabolic 
syndrome on plasma PAI-1. PAI-1 can be reduced by lifestyle interventions such as 
weight reduction and physical activity. Interactions between metabolic and lifestyle 
factors and the 4G/5G-polymorphism have only rarely been studied. 
PAI-1 is known to follow a diurnal pattern with highest levels in the early morning. It 
has been suggested that this early morning peak in PAI-1 may partly be responsible 
for the increased number of cardiovascular events at this time of the day. In Chapter 
3 we studied this diurnal variation in plasma PAI-1 and we examined whether the 
patterns were different for the genotypes of the 4G/5G-polymorphism. The analyses 
were performed in the Arnhem Elderly Study, a population-based study of 598 
elderly. A single blood sample was drawn and the time of blood sampling was 
recorded (between 8 a.m. and 5.30 p.m.). We observed a strong diurnal pattern in 
PAI-1 activity, with the highest values observed in the early morning, The diurnal 
pattern was clearly present in the 4G/4G (n=184) and 4G/5G (n=275) genotypes, but 
not in the 5G/5G-genotype (n=139). These findings raised the hypothesis that 5G-
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homozygotic persons may be relatively protected from the early morning peak 
incidence in cardiovascular events. 
PAI-1, THE 4G/5G-POLYMORPHISM AND CARDIOVASCULAR DISEASE 
The association between the 4G/5G-polymorphism and markers of atherosclerosis is 
described in Chapter 4 and 5. In Chapter 6 findings are presented on PAI-1 activity, 
the 4G/5G-polymorphism and incidence of cardiovascular events in elderly. 
4G/5G-polymorphism and atherosclerosis 
We observed no association between the 4G/5G-polymorphism and two non-
invasive markers of atherosclerosis, i.e. common carotid artery intima-media 
thickness (IMT) and the ankle-brachial index (ABI) in a population of 208 male 
smokers (Chapter 4). The 4G-allele was not associated with a higher prevalence of 
atherosclerosis, neither for IMT nor ABI. Although not statistically significant, a high 
IMT (>1.07 mm) was even less frequent for the 4G/5G and 4G/4G-genotypes 
compared to the 5G/5G-genotype (odds ratios (ORs) of 0.6 and 0.4 respectively, P-
value for trend: 0.08). In Chapter 5 we investigated the association between the 
4G/5G-polymorphism and coronary stenosis by pooling the data of three similar 
case-control studies. In these studies the distribution of the 4G/5G-polymorphism in 
285 cases with angiographically determined coronary stenosis was compared with 
the distributions in two control groups: a coronary control group (n=293) and a 
population-based control group (198). The coronary controls were selected by the 
same procedure as the cases, but did not have advanced coronary stenosis. A non-
significantly increased risk of coronary stenosis was observed for the 4G-allele 
relative to the 5G/5G-genotype when compared to coronary controls (4G/4G-
genotype: OR=1.58 (95%-CI: 0.97 - 2.57)). No association was observed in 
comparison to the population-based control group. Stratification for background 
cardiovascular risk (based on Framingham Prediction Score) showed an increased 
risk of coronary stenosis only in the low-risk group (cases versus coronary controls, 
4G/4G-genotype: OR=2.86 (95%-CI: 1.27 - 6.47)). 
PAI-1, the 4G/5G-polymorphism and coronary events 
In Chapter 6 a longitudinal study is described (Arnhem Elderly study) in which the 
predictive value of PAI-1 activity, t-PA antigen and the 4G/5G-polymorphism for 
cardiovascular events was studied. The most important finding was that the 4G/4G-
genotype protected against incident stroke and transient ischemic attack. This 
observation is in contrast to the generally accepted hypothesis that the 4G-allele 
would increase cardiovascular risk. However, these results are in agreement with 
some other studies. The mechanism is probably not part of the fibrinolytic system. 
For PAI-1 levels, an increased risk of stroke and transient ischemic attack was 
observed in the highest tertile. 
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C-REACTIVE PROTEIN 
In Chapter 7 the role of C-reactive protein (CRP) in the metabolic syndrome is cross-
sectionally examined in a population of 605 elderly men and women (Arnhem Elderly 
Study). CRP was strongly associated with components of the metabolic syndrome 
(BMI, PAI-1, HDL-cholesterol and blood pressure), but these associations were 
predominantly present in lean elderly (BMI < 25 kg/m2). The data suggest that in 
elderly CRP may not be an important component of the metabolic syndrome in the 
presence of overweight. PAI-1 and CRP were inter-related, but only in lean subjects. 
In Chapter 8 the predictive value of CRP for future cardiovascular events in the 
elderly was studied, showing that CRP does have an added value in this population 
for men but not for women. Including CRP in cardiovascular risk algorithms for older 
men may thus improve their predictive value. 
DISCUSSION AND CONCLUDING REMARKS 
In Chapter 9, our results are methodologically considered and placed in the context 
of other scientific literature in this field. Overall, PAI-1 and the 4G/4G-genotype do 
not appear to be associated with the presence of atherosclerosis, but the effects on 
thrombosis are still controversial. Although we observed an increased risk for several 
cardiovascular events for elevated PAI-1 levels, it is still not clear whether PAI-1 is a 
causal risk factor. Causality of PAI-1 was not supported by an increased risk of 
cardiovascular events for the 4G/4G-genotype. In contrast, the 4G/4G-genotype was 
associated with a lower risk of stroke. More research is needed on the mechanisms 
responsible for the protective effect for the 4G/4G-genotype against stroke and 
ischemic attack. 
The role of PAI-1 and the 4G/5G-polymorphism in acute inflammatory situations may 
be of clinical relevance. This should be further studied, also in relation to the acute-
phase response in myocardial and cerebrovascular infarction. In addition, our finding 
of a genotype-specific diurnal variation in PAI-1 might have clinical implications and 
should be further elucidated. 
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De vertaling van de titel van het proefschrift in het Nederlands: 
Fibrinolyse, ontsteking en hart- en vaatziekten. Epidemiologisch onderzoek 
naar plasminogen activator inhibitor-type 1 en C-reactief proteTne 
ACHTERGROND VAN HET ONDERZOEK 
Hart- en vaatziekten 
In westerse landen zijn hart- en vaatziekten nog steeds de belangrijkste 
doodsoorzaak. In Nederland was in 2000 het aandeel van de hart- en vaatziekten in 
de totale sterfte 36%. Onder de verzamelnaam hart- en vaatziekten vallen onder 
meer hartinfarct en beroerte. Van veel verschillende factoren is inmiddels bekend dat 
ze het risico op hart- en vaatziekten verhogen, bijvoorbeeld roken en een verhoogd 
cholesterol gehalte in het bloed. Daamaast spelen waarschijnlijk ook andere factoren 
een rol waar we nog minder van af weten. In de studies die beschreven zijn in dit 
proefschrift heb ik twee minder bekende risicofactoren onderzocht, namelijk 
Plasminogen Activator Inhibitor-type 1 (PAI-1) en C-reactief ProteTne (CRP). 
Hartinfarct 
Een hartinfarct is het gevolg van een afsluiting van de kransslagader(s). Dit begint 
met een kleine beschadiging van de gladde binnenwand van het bloedvat. Het 
lichaam probeert die beschadiging te herstellen; er klonteren bloedplaatjes samen 
op de beschadigde plaats en witte bloedcellen dringen de vaatwand binnen. Die 
witte bloedcellen nemen cholesterol op, wat een brijachtige massa geeft waar zich 
later ook kalk op afzet. Hierdoor worden de kransslagaders steeds nauwer en kan 
het zuurstofrijke bloed de hartspier moeilijker bereiken. Dit noemen we 
slagaderverkalking of atherosclerose. Wanneer een bloedstolsel een vernauwde 
kransslagader plotseling helemaal afsluit, ontstaat een hartinfarct. Door die 
afgesloten kransslagader krijgt het bijbehorende gedeelte van de hartspier geen 
zuurstof meer en sterft af. De ernst van een hartinfarct hangt af van de grootte van 
de beschadiging en welk deel van de hartspier is aangedaan. 
Cerebrovasculair accident 
Als de bloedvoorziening naar de hersenen plotseling ergens onderbroken wordt, 
spreken we van een cerebrovasculair accident (afgekort tot CVA, ook wel beroerte 
genoemd). Meestal gaat het bij een CVA om een herseninfarct (bij 80% van de 
getroffenen). Dit is vergelijkbaar met een hartinfarct, maar dan in het hoofd. Een 
herseninfarct ontstaat doordat een bloedstolsel een slagader in het hoofd afsluit. Een 
deel van de hersencellen krijgt daardoor geen zuurstof meer en sterft af. De 
vernauwing in de slagader is vaak het gevolg van slagaderverkalking of 
atherosclerose. Een hersenbloeding ontstaat doordat een zwakke plek in het 
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bloedvat openbarst waardoor er hersenweefsel beschadigd raakt. De verschijnselen 
die optreden zijn vergelijkbaar als bij een herseninfarct. 
Fibrinolyse 
Als een bloedvat beschadigd raakt, wordt er een bloedstolsel gevormd om de 
bloeding te stoppen. Een bloedstolsel bestaat voor een belangrijk deel uit fibrine, dat 
later weer wordt afgebroken (fibrinolyse). Plasmine is de werkzame stof van de 
fibrinolyse. De hoeveelheid actief plasmine dat in het bloed voorkomt, wordt bepaald 
door diverse eiwitten die elkaar bei'nvloeden (remmen of activeren). Zie figuur 1 voor 
een overzicht van de fibrinolyse. Het eiwit Plasminogen Activator Inhibitor-type 1 
(afgekort tot PAI-1) is de belangrijkste remmer. Het evenwicht tussen enerzijds de 
bloedstolling en anderzijds de fibrinolyse is van cruciaal belang. Een hoge 
concentratie PAI-1 in het bloed zorgt ervoor dat bloedstolsels minder efficient 
worden opgeruimd en zou daarom mogelijk een risicofactor kunnen zijn voor het 
ontstaan van hart- en vaatziekten. 
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Figuur 1. Schema van de bloedstolling en de fibrinolyse. 
De regulerende rol in de fibrinolyse is de meest bekende functie van PAI-1, maar 
daarnaast is PAI-1 ook betrokken bij andere processen, waaronder ontsteking. Dit 
heeft mogelijk een bijkomende ongunstige invloed op het proces van hart- en 
vaatziekten. De concentratie van PAI-1 in het bloed wordt bepaald door veel 
verschillende factoren. In hoofdstuk 2 wordt een overzicht gegeven van de meest 
belangrijke genetische, biologische en leefstijlfactoren. Hieruit blijkt dat met name 
lichaamsgewicht en het insulineresistentiesyndroom een belangrijke invloed hebben 
op PAI-1. 
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Het 4G/5G-polymorfisme 
Het genetisch materiaal (DNA) is opgebouwd uit een grote hoeveelheid bouwstenen. 
Een gen is een stuk genetisch materiaal dat codeert voor een eiwit. In het PAI-1 gen 
komt een kleine genetische variatie (polymorfisme) voor met twee verschillende 
vormen. De ene vorm (de 4G-vorm) heeft een bouwsteen minder heeft dan de 
andere vorm (5G-vorm). Deze kleine variatie heeft een effect op de hoeveelheid PAI-
1 die het lichaam produceert. Beide vormen komen ongeveer evenveel voor in de 
algemene bevolking. Aangezien iedereen van elk gen twee copien heeft (van beide 
ouders een), komen er drie combinaties (genotypes) voor, namelijk het 4G/4G-
genotype, het 4G/5G-genotype en het 5G/5G-genotype. Over het algemeen worden 
de hoogste bloed PAI-1 waarden gevonden voor het 4G/4G-genotype en de laagste 
voor het 5G/5G-genotype. 
DOEL VAN HET ONDERZOEK 
Met ons onderzoek beoogden we na te gaan of bij ouderen de hoeveelheid PAI-1 in 
het bloed en het 4G/5G-polymorfisme voorspellend is voor het ontstaan van hart- en 
vaatziekten. Hiervoor hebben we gebruik gemaakt van de gegevens van het 
Arnhemse Ouderen Onderzoek. Bovendien hebben we in een tweetal andere 
populaties onderzocht of het 4G/5G-polymorfisme iets te maken heeft met de 
aanwezigheid van atherosclerose (aderverkalking). Ook hebben we gekeken naar de 
rol van ontsteking 
Eerst zullen de opzet en de belangrijkste resultaten van het Arnhemse Ouderen 
Onderzoek besproken worden, waarna de resultaten van de onderzoeken naar de 
relatie tussen het 4G/5G-polymorfisme en atherosclerose aan bod zullen komen. 
OPZET VAN HET ARNHEMSE OUDEREN ONDERZOEK 
In 1991/1992 is er in Arnhem een onderzoek gedaan naar lichamelijke activiteit in 
relatie tot diverse gezondheidskenmerken bij 1012 zelfstandig wonende ouderen van 
65 tot en met 84 jaar. Er zijn gegevens verzameld over leefwijze (zoals lichamelijke 
activiteit, voedingsgewoonten, roken) en gezondheid. Bij 641 personen is verder 
lichamelijk onderzoek uitgevoerd en bloed afgenomen. In het bloed zijn onder 
andere het cholesterolgehalte en de hoeveelheid PAI-1 bepaald. Ook is het 
polymorfisme in het PAI-1 gen bepaald. 
We hebben de personen uit het onderzoek gevolgd in de tijd. Gegevens over 
verhuizingen en sterfte tot 1 februari 2001 zijn verkregen via de 
bevolkingsadministraties van de gemeente Arnhem en andere gemeenten in 
Nederland. Verder zijn we met hulp van huisartsen en verpleeghuizen nagegaan 
welke personen hart- en vaatziekten hebben gekregen. We hebben het risico op 
totale sterfte, sterfte ten gevolge van hart- en vaatziekten, hartinfarcten en beroertes 
bestudeerd in relatie tot PAI-1 en het 4G/5G-polymorfisme. 
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RESULTATEN 
4G/5G-polymorfisme en dagvariatie in PAI-1 activiteit 
Veel van de hartinfarcten vinden vroeg in de ochtend plaats. De redenen hiervoor 
zijn nog onbekend, maar er wordt gedacht dat de variatie over de dag heen van 
factoren uit de fibrinolyse hier mogelijk iets mee te maken hebben. Uit kleinschalig 
onderzoek was al bekend dat de concentratie PAI-1 in het bloed sterk afhankelijk is 
van het moment op de dag, met de hoogste waarden vroeg in de ochtend. Deze 
dagvariatie in PAI-1 was nog niet bestudeerd in grotere (epidemiologische) 
onderzoeken. In het Arnhemse Ouderen Onderzoek vonden we een duidelijk 
dagritme (zie figuur 2). De gemeten PAI-1 activiteit in bloedmonsters die voor 9 uur 
's ochtends waren afgenomen was ongeveer 13 maal zo hoog als in monsters 
afgenomen na 4 uur's middags. Verder hebben we onderzocht of deze variatie over 
de dag verschillend was voor de drie varianten van het 4G/5G-polymorfisme. In de 
groepen met het 4G/4G en het 4G/5G-genotype was een duidelijke variatie in PAI-1 
activiteit over dag aanwezig. Deze was echter nagenoeg afwezig in de groep met het 
5G/5G-genotype (zie figuur 2). Dit zou kunnen betekenen dat personen met het 
5G/5G-genotype relatief beschermd zijn tegen een hartinfarct in de vroege ochtend. 
Deze resultaten staan beschreven in hoofdstuk 3 van het proefschrift. 
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Figuur 2. Dagvariatie in PAI-1 activiteit Figuur 3. Dagvariatie in PAI-1 activiteit 
per genotype 
4G/5G-polymorfisme en atherosclerose 
Er bestaan aanwijzingen dat PAI-1 al vroeg in het ziekteproces effecten zou kunnen 
hebben, namelijk bij het ontstaan van atherosclerose. In twee verschillende studies 
zijn we nagegaan of het 4G/4G-genotype vaker gepaard gaat met (een meer 
emstige vorm van) atherosclerose. Deze studies staan beschreven in hoofdstuk 4 en 
5. 
De mate van atherosclerose kun je op verschillende manieren meten. Zo is in een 
populatie van 208 rokende mannen de dikte van de vaatwand van de halsslagader 
gemeten (hoofdstuk 4). Hierbij is een dikke vaatwand een indicatie van ernstige 
atherosclerose. We vonden geen duidelijk verband tussen het 4G/5G-polymorfisme 
en de dikte van de vaatwand. De 4G-vorm ging niet gepaard met een dikkere 
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vaatwand. Tegen de verwachting was het percentage mannen met een dikke 
vaatwand zelfs hoger voor het 5G/5G-genotype (31% voor 5G/5G; 21% voor 4G/5G; 
14%voor4G/4G). 
In hoofstuk 5 hebben we patienten met een vernauwing van de kransslagaderen 
vergeleken met gezonde controles. Of iemand een vernauwing heeft, kan in het 
ziekenhuis worden bepaald door middel van angiografie. Dit is een onderzoek 
waarbij een katheter onder plaatselijke verdoving in de bloedvaten wordt geschoven, 
waarna contrastvloeistof wordt ingespoten. Met behulp van rontgenstralen kunnen 
de bloedvaten in beeld worden gebracht. De onderzoeksgroep bestond uit 285 
personen met een vernauwing van de kransslagader, 293 controles die ook een 
angiografie hadden ondergaan, maar geen vernauwing bleken te hebben en 198 
controles uit de algemene bevolking. We vonden geen duidelijke verbanden met het 
4G/5G-polymorfisme. Het percentage personen met het 4G/4G-genotype was wel 
het hoogst in de groep patienten, maar de verschillen met de groepen controles 
waren niet significant. 
PAI-1 activiteit, het 4G/5G-polymorfisme en het risico op hart- en vaatziekten 
In het Arnhemse Ouderen Onderzoek vonden we geen groot verschil in PAI-1 
concentraties in het bloed tussen de verschillende genotypes. De gemiddelde PAI-1 
waarde in het bloed was iets lager in de groep met het 5G/5G-genotype (1.4 lU/mL) 
dan in de andere twee groepen (beide 2.2 lU/mL). Op basis van de PAI-1 
concentratie in hun bloed werden de ouderen ingedeeld in drie groepen. We hebben 
onderzocht of ouderen in de groep met de hoogste PAI-1 concentraties aan het 
begin van het onderzoek vaker last kregen van hart- en vaatziekten dan groep met 
lage waarden. Ouderen met de hoogste PAI-1 waarden (hoger dan 3.9 lU/mL) 
hadden een hoger risico op hart- en vaatziekten dan ouderen in de groep met lage 
PAI-1 waarden (lager dan 0.93 lU/mL). De kans op sterfte ten gevolge van hart- en 
vaatziekten bleek ongeveer drie maal zo hoog te zijn voor de groep met hoge PAI-1 
waarden in vergelijking met de groep die een lage PAI-1 concentratie in het bloed 
hadden. Ook voor het optreden van hartinfarct en CVA werden verhoogde risico's 
gevonden (drie- en viermaal verhoogd). 
Van te voren verwachtten we ook een hoger risico op hart- en vaatziekten voor het 
4G/4G-genotype te zullen vinden, maar dit bleek niet het beval te zijn. Tegen onze 
verwachting in vonden we dat ouderen met het 4G/4G-genotype relatief beschermd 
waren tegen het ontstaan van een CVA (5 maal zo laag risico). Ook andere recente 
onderzoeken hebben dergelijke bevindingen laten zien. Dat personen met het 
4G/4G-genotype blijkbaar beschermd zijn tegen CVA's kan mogelijk verklaard 
worden door mechanismen die buiten de fibrinolyse liggen. 
C-reactief proteYne 
We hebben in de laatste twee hoofdstukken van het proefschrift gekeken naar CRP 
(C-reactive prote'i'ne). Dit is een eiwit dat verhoogd is als iemand een ontsteking 
heeft. De concentratie kan dan wel 1000 maal verhoogd zijn ten opzichte van 
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normaal. Heel licht verhoogde CRP-waarden blijken in diverse onderzoeken 
gerelateerd te zijn aan net risico op hart- en vaatziekten. Ook PAI-1 is verhoogd in 
de aanwezigheid van een ontsteking. In net Arnhemse Ouderen Onderzoek hebben 
we beide factoren met elkaar gecorreleerd en hieruit bleek dat ze alleen in personen 
zonder overgewicht geassocieerd waren. In hoofdstuk 8 hebben we onderzocht of 
CRP ook in het Arnhemse Ouderen Onderzoek voorspellend was voor het ontstaan 
van hart- en vaatziekten. Bij mannen bleek dit wel het geval te zijn, maar niet bij de 
vrouwen. 
DlSCUSSIE EN CONCLUSIE 
Uit het onderzoek is naar voren gekomen dat PAI-1 en het 4G/5G-polymorfisme 
geen grote invloed te hebben op atherosclerose. De relatie met acute vaatincidenten 
(zoals een hartinfarct en CVA) is nog niet duidelijk. Aan de ene kant vonden we een 
verhoogd risico voor verhoogde PAI-1 waarden, maar dit werd niet ondersteund door 
een verhoogd risico voor het 4G/4G-genotype. We vonden zelfs een beschermend 
effect van het 4G/4G-genotype voor CVA. Er is meer onderzoek nodig naar de 
mechanismen die hierbij betrokken zijn. Onze bevinding dat het dagritme in PAI-1 
verschillend is voor de verschillende genotypes kan mogelijk van klinisch belang zijn 
en moet verder worden onderzocht. 
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gekregen. Vooral je enthousiasme en je bereidheid om steeds met me mee te 
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Nu maar duimen dat hij snel gepubliceerd wordt!! 
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hartelijk bedanken voor hun belangstelling en steun in welke vorm dan ook 
gedurende de afgelopen jaren. Speciaal wil ik noemen het secretariaat (Marie en 
Eva), IT (Dirk en Ben) en Jan Burema voor statistische adviezen. 
Woensdagavond is voor mij knalpotavond. Ik vond het elke week weer heerlijk om 
voor de broodnodige ontspanning naar de Gele Knalpot te gaan en daar alles wat 
met mijn proefschrift te maken had, te vergeten. Dan realiseer je je weer: 'het komt 
wel goed!!' Met name de knalpotvakanties en het knalpotcircus waren om nooit te 
vergeten. Begeleiders en oud-begeleiders, bedankt voor jullie gezelligheid tijdens de 
'vergaderingen' in de kroeg en de diverse filmavonden, uitstapjes etcetera. 
Astrid, Use, Marcus, Monique, jullie zijn een uitstekend bewijs dat goede buren ook 
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andere vrienden en bekenden wil ik bedanken voor alle gezelligheid en steun. Ik 
hoop de komende tijd weer wat meer tijd voor jullie te hebben. 
Heit, mem, Klaas, Arianne en Bartele Sjoerd: ik weet dat ik in alle omstandigheden 
op jullie terug kan vallen en dat is van onschatbare waarde voor mij. Bartele Sjoerd, 
bedankt voor het ontwerp van de voorkant, ik ben trots op je. Klaas, jij ook bedankt 
dat je me wilde helpen met de verdere afwerking van de omslag. Heit en mem, jullie 
zijn als laatste aan de beurt. Maar: 'last but not least', want jullie steun op de 
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Hiermee ben ik aan net eind gekomen van het 'laatst geschreven, maar meest 
gelezen gedeelte' van het proeschrift. Ik ben nu dus echt klaar, al kan ik dat nog niet 
helemaal geloven. 
Nogmaals: iedereen bedankt!! 
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